
<html lang="en"     class="pb-page"  data-request-id="52eaf188-0a3f-44b7-93e8-c219ba578a94"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b01229"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia" /></meta><meta name="dc.Creator" content="Wen-Hsing  Lin" /></meta><meta name="dc.Creator" content="Su-Ying  Wu" /></meta><meta name="dc.Creator" content="Teng-Kuang  Yeh" /></meta><meta name="dc.Creator" content="Chiung-Tong  Chen" /></meta><meta name="dc.Creator" content="Jen-Shin  Song" /></meta><meta name="dc.Creator" content="Hui-Yi  Shiao" /></meta><meta name="dc.Creator" content="Ching-Chuan  Kuo" /></meta><meta name="dc.Creator" content="Tsu  Hsu" /></meta><meta name="dc.Creator" content="Cheng-Tai  Lu" /></meta><meta name="dc.Creator" content="Pei-Chen  Wang" /></meta><meta name="dc.Creator" content="Tsung-Sheng  Wu" /></meta><meta name="dc.Creator" content="Yi-Hui  Peng" /></meta><meta name="dc.Creator" content="Hui-You  Lin" /></meta><meta name="dc.Creator" content="Ching-Ping  Chen" /></meta><meta name="dc.Creator" content="Ya-Ling  Weng" /></meta><meta name="dc.Creator" content="Fang-Chun  Kung" /></meta><meta name="dc.Creator" content="Mine-Hsine  Wu" /></meta><meta name="dc.Creator" content="Yu-Chieh  Su" /></meta><meta name="dc.Creator" content="Kuo-Wei  Huang" /></meta><meta name="dc.Creator" content="Ling-Hui  Chou" /></meta><meta name="dc.Creator" content="Ching-Cheng  Hsueh" /></meta><meta name="dc.Creator" content="Kuei-Jung  Yen" /></meta><meta name="dc.Creator" content="Po-Chu  Kuo" /></meta><meta name="dc.Creator" content="Chen-Lung  Huang" /></meta><meta name="dc.Creator" content="Li-Tzong  Chen" /></meta><meta name="dc.Creator" content="Chuan  Shih" /></meta><meta name="dc.Creator" content="Hui-Jen  Tsai" /></meta><meta name="dc.Creator" content="Weir-Torn  Jiaang" /></meta><meta name="dc.Description" content="Gastrointestinal stromal tumors (GISTs) are prototypes of stem cell factor receptor (c-KIT)-driven cancer. Two receptor tyrosine kinases, c-KIT and fms-tyrosine kinase (FLT3), are frequently mutate..." /></meta><meta name="Description" content="Gastrointestinal stromal tumors (GISTs) are prototypes of stem cell factor receptor (c-KIT)-driven cancer. Two receptor tyrosine kinases, c-KIT and fms-tyrosine kinase (FLT3), are frequently mutate..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 13, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01229" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01229" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01229" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01229" /></link>
        
    
    

<title>Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01229" /></meta><meta property="og:title" content="Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0001.jpeg" /></meta><meta property="og:description" content="Gastrointestinal stromal tumors (GISTs) are prototypes of stem cell factor receptor (c-KIT)-driven cancer. Two receptor tyrosine kinases, c-KIT and fms-tyrosine kinase (FLT3), are frequently mutated in acute myeloid leukemia (AML) patients, and these mutations are associated with poor prognosis. In this study, we discovered a multitargeted tyrosine kinase inhibitor, compound 15a, with potent inhibition against single or double mutations of c-KIT developed in GISTs. Moreover, crystal structure analysis revealed the unique binding mode of 15a with c-KIT and may elucidate its high potency in inhibiting c-KIT kinase activity. Compound 15a inhibited cell proliferation and induced apoptosis by targeting c-KIT in c-KIT-mutant GIST cell lines. The antitumor effects of 15a were also demonstrated in GIST430 and GIST patient-derived xenograft models. Further studies demonstrated that 15a inhibited the proliferation of c-KIT- and FLT3-driven AML cells in vitro and in vivo. The results of this study suggest that 15a may be a potential anticancer drug for the treatment of GISTs and AML." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01229"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01229">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01229&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01229&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01229&amp;href=/doi/10.1021/acs.jmedchem.9b01229" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 11135-11150</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01070" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01252" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wen-Hsing Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wen-Hsing Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Hsing++Lin">Wen-Hsing Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Su-Ying Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Su-Ying Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Su-Ying++Wu">Su-Ying Wu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2816-6961" title="Orcid link">http://orcid.org/0000-0003-2816-6961</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Teng-Kuang Yeh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Teng-Kuang Yeh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Teng-Kuang++Yeh">Teng-Kuang Yeh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chiung-Tong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chiung-Tong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chiung-Tong++Chen">Chiung-Tong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jen-Shin Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jen-Shin Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jen-Shin++Song">Jen-Shin Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui-Yi Shiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui-Yi Shiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui-Yi++Shiao">Hui-Yi Shiao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ching-Chuan Kuo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ching-Chuan Kuo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ching-Chuan++Kuo">Ching-Chuan Kuo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsu Hsu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsu Hsu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsu++Hsu">Tsu Hsu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cheng-Tai Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng-Tai Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng-Tai++Lu">Cheng-Tai Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pei-Chen Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pei-Chen Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pei-Chen++Wang">Pei-Chen Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsung-Sheng Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsung-Sheng Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsung-Sheng++Wu">Tsung-Sheng Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi-Hui Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi-Hui Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Hui++Peng">Yi-Hui Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui-You Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui-You Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Cancer Research, National Health Research Institutes, Tainan City 704, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui-You++Lin">Hui-You Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ching-Ping Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ching-Ping Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ching-Ping++Chen">Ching-Ping Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ya-Ling Weng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ya-Ling Weng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Ling++Weng">Ya-Ling Weng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fang-Chun Kung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fang-Chun Kung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fang-Chun++Kung">Fang-Chun Kung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mine-Hsine Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mine-Hsine Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mine-Hsine++Wu">Mine-Hsine Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yu-Chieh Su</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu-Chieh Su</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Chieh++Su">Yu-Chieh Su</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kuo-Wei Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kuo-Wei Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Cancer Research, National Health Research Institutes, Tainan City 704, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kuo-Wei++Huang">Kuo-Wei Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ling-Hui Chou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ling-Hui Chou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ling-Hui++Chou">Ling-Hui Chou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ching-Cheng Hsueh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ching-Cheng Hsueh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ching-Cheng++Hsueh">Ching-Cheng Hsueh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kuei-Jung Yen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kuei-Jung Yen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kuei-Jung++Yen">Kuei-Jung Yen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Po-Chu Kuo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Po-Chu Kuo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Po-Chu++Kuo">Po-Chu Kuo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chen-Lung Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chen-Lung Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chen-Lung++Huang">Chen-Lung Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li-Tzong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li-Tzong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine,  Institute of Molecular Medicine, National Cheng Kung University, Tainan City 704, Taiwan R.O.C.</div><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan R.O.C.</div><div class="loa-info-affiliations-info">National Institute of Cancer Research, National Health Research Institutes, Tainan City 704, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li-Tzong++Chen">Li-Tzong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chuan Shih</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chuan Shih</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chuan++Shih">Chuan Shih</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui-Jen Tsai</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui-Jen Tsai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City 704, Taiwan R.O.C.</div><div class="loa-info-affiliations-info">Division of Hematology/Oncology, Kaohsiung Medical University, Kaohsiung 807, Taiwan R.O.C.</div><div class="loa-info-affiliations-info">National Institute of Cancer Research, National Health Research Institutes, Tainan City 704, Taiwan R.O.C.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#f0989a84839199b09e988299de9f8297de8487"><span class="__cf_email__" data-cfemail="80e8eaf4f3e1e9c0eee8f2e9aeeff2e7aef4f7">[email protected]</span></a>. Phone: +886-6-208-3422 Ext 65149. Fax: +886-6-208-3427 (H.-J.T).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui-Jen++Tsai">Hui-Jen Tsai</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Weir-Torn Jiaang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weir-Torn Jiaang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan R.O.C.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1562617f7c74747b72557b7d677c3b7a67723b6162"><span class="__cf_email__" data-cfemail="bccbc8d6d5ddddd2dbfcd2d4ced592d3cedb92c8cb">[email protected]</span></a>. Phone: +886-37-246-166 Ext 35712. Fax: +886-37-586-456 (W.-T.J.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weir-Torn++Jiaang">Weir-Torn Jiaang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8781-3538" title="Orcid link">http://orcid.org/0000-0001-8781-3538</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01229&amp;href=/doi/10.1021%2Facs.jmedchem.9b01229" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 11135–11150</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 13, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 July 2019</li><li><span class="item_label"><b>Published</b> online</span>13 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01229" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01229</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11135%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWen-Hsing%2BLin%252C%2BSu-Ying%2BWu%252C%2BTeng-Kuang%2BYeh%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D24%26contentID%3Dacs.jmedchem.9b01229%26title%3DIdentification%2Bof%2Ba%2BMultitargeted%2BTyrosine%2BKinase%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BGastrointestinal%2BStromal%2BTumors%2Band%2BAcute%2BMyeloid%2BLeukemia%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11150%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01229"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1160</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01229" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wen-Hsing&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Su-Ying&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Teng-Kuang&quot;,&quot;last_name&quot;:&quot;Yeh&quot;},{&quot;first_name&quot;:&quot;Chiung-Tong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jen-Shin&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Hui-Yi&quot;,&quot;last_name&quot;:&quot;Shiao&quot;},{&quot;first_name&quot;:&quot;Ching-Chuan&quot;,&quot;last_name&quot;:&quot;Kuo&quot;},{&quot;first_name&quot;:&quot;Tsu&quot;,&quot;last_name&quot;:&quot;Hsu&quot;},{&quot;first_name&quot;:&quot;Cheng-Tai&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Pei-Chen&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tsung-Sheng&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Yi-Hui&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Hui-You&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Ching-Ping&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Ya-Ling&quot;,&quot;last_name&quot;:&quot;Weng&quot;},{&quot;first_name&quot;:&quot;Fang-Chun&quot;,&quot;last_name&quot;:&quot;Kung&quot;},{&quot;first_name&quot;:&quot;Mine-Hsine&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Yu-Chieh&quot;,&quot;last_name&quot;:&quot;Su&quot;},{&quot;first_name&quot;:&quot;Kuo-Wei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Ling-Hui&quot;,&quot;last_name&quot;:&quot;Chou&quot;},{&quot;first_name&quot;:&quot;Ching-Cheng&quot;,&quot;last_name&quot;:&quot;Hsueh&quot;},{&quot;first_name&quot;:&quot;Kuei-Jung&quot;,&quot;last_name&quot;:&quot;Yen&quot;},{&quot;first_name&quot;:&quot;Po-Chu&quot;,&quot;last_name&quot;:&quot;Kuo&quot;},{&quot;first_name&quot;:&quot;Chen-Lung&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Li-Tzong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chuan&quot;,&quot;last_name&quot;:&quot;Shih&quot;},{&quot;first_name&quot;:&quot;Hui-Jen&quot;,&quot;last_name&quot;:&quot;Tsai&quot;},{&quot;first_name&quot;:&quot;Weir-Torn&quot;,&quot;last_name&quot;:&quot;Jiaang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;11135-11150&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01229&quot;},&quot;abstract&quot;:&quot;Gastrointestinal stromal tumors (GISTs) are prototypes of stem cell factor receptor (c-KIT)-driven cancer. Two receptor tyrosine kinases, c-KIT and fms-tyrosine kinase (FLT3), are frequently mutated in acute myeloid leukemia (AML) patients, and these mutations are associated with poor prognosis. In this study, we discovered a multitargeted tyrosine kinase inhibitor, compound 15a, with potent inhibition against single or double mutations of c-KIT developed in GISTs. Moreover, crystal structure analysis revealed the unique binding mode of 15a with c-KIT and may elucidate its high potency in inhibiting c-KIT kinase activity. Compound 15a inhibited cell proliferation and induced apoptosis by targeting c-KIT in c-KIT-mutant GIST cell lines. The antitumor effects of 15a were also demonstrated in GIST430 and GIST patient-derived xenograft models. Further studies demonstrated that 15a inhibited the proliferation of c-KIT- and FLT3-driven AML cells in vitro and in vivo. The results of this study suggest that 15a may b&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01229&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01229" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01229&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01229" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01229&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01229" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01229&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01229&amp;href=/doi/10.1021/acs.jmedchem.9b01229" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01229" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01229" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01229%26sid%3Dliteratum%253Aachs%26pmid%3D31721578%26genre%3Darticle%26aulast%3DLin%26date%3D2019%26atitle%3DIdentification%2Bof%2Ba%2BMultitargeted%2BTyrosine%2BKinase%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BGastrointestinal%2BStromal%2BTumors%2Band%2BAcute%2BMyeloid%2BLeukemia%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D24%26spage%3D11135%26epage%3D11150%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/jmcmar.2019.62.issue-24/20191226/jmcmar.2019.62.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Gastrointestinal stromal tumors (GISTs) are prototypes of stem cell factor receptor (c-KIT)-driven cancer. Two receptor tyrosine kinases, c-KIT and fms-tyrosine kinase (FLT3), are frequently mutated in acute myeloid leukemia (AML) patients, and these mutations are associated with poor prognosis. In this study, we discovered a multitargeted tyrosine kinase inhibitor, compound <b>15a</b>, with potent inhibition against single or double mutations of c-KIT developed in GISTs. Moreover, crystal structure analysis revealed the unique binding mode of <b>15a</b> with c-KIT and may elucidate its high potency in inhibiting c-KIT kinase activity. Compound <b>15a</b> inhibited cell proliferation and induced apoptosis by targeting c-KIT in c-KIT-mutant GIST cell lines. The antitumor effects of <b>15a</b> were also demonstrated in GIST430 and GIST patient-derived xenograft models. Further studies demonstrated that <b>15a</b> inhibited the proliferation of c-KIT- and FLT3-driven AML cells in vitro and in vivo. The results of this study suggest that <b>15a</b> may be a potential anticancer drug for the treatment of GISTs and AML.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that develop in the gastrointestinal tract. GISTs are thought to derive from the interstitial cells of Cajal.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Worldwide, epidemiological data show that the annual incidence of GISTs is approximately 10–20 cases per million people.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These tumors can occur at any site but are predominantly found in the stomach and small intestine.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Approximately 60% of patients with operable GISTs can be cured by surgery. However, about 40% of localized GISTs develop metastasis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Unresectable and/or metastatic GISTs have poor responses to conventional chemotherapy and radiation therapy. c-KIT mutations were found in most GISTs and act as a driver gene for GISTs.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Understanding the underlying cause of GISTs has led to the development and investigation of new agents targeting c-KIT. These drugs effectively inhibit the activity of mutant forms of c-KIT in tumors and significantly improve the clinical outcomes for patients with advanced GISTs.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Currently, there are three c-KIT tyrosine kinase inhibitors (TKIs) approved for treatment of advanced GISTs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The standard first-line treatment is imatinib (<b>1</b>). Treatment with <b>1</b> in advanced GISTs successfully achieved a disease control rate of 81.6% and significantly improved progression-free survival (PFS) and overall survival (OS) in a phase II clinical trial.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The results from a phase II and a phase III trial suggest that compound <b>1</b> achieves a long-term median OS of 51–57 months in patients with advanced or metastatic GISTs.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of c-KIT and FLT3 inhibitors in the clinic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although compound <b>1</b> has good response to GISTs, disease progression or recurrence still may develop by either primary or secondary resistance to <b>1</b>.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> c-KIT mutations have been found in approximately 80% of GISTs. Mutations at exon 9 and exon 11 are the most common primary mutations identified at initial diagnosis of GISTs. Approximately 7% of GISTs have PDGFRα gene mutations.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> GIST patients who are not responsive to first-line <b>1</b> treatment within 6 months are classified as primary resistant to <b>1</b>. Patients with exon 11 mutations have better response and survival to <b>1</b>, whereas those with exon 9 mutations have worse treatment outcomes.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> GIST patients with wild-type c-KIT or PDGFRα gene mutations are usually resistant to <b>1</b>. Moreover, patients who develop resistance to <b>1</b> after 6 months of treatment are classified as secondary resistance and about 50% of these patients develop a secondary mutation in either exon 13, 14, 17, or 18 of c-KIT. The majority of these secondary mutations developed in patients with primary mutations in exon 11 of c-KIT.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> For the <b>1</b>-resistant GIST patient, sunitinib (<b>2</b>), a multitargeted tyrosine kinase inhibitor, was approved as a second-line treatment for advanced GIST patients after failure of compound <b>1</b> therapy.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, regorafenib (<b>3</b>) is another multitargeted tyrosine kinase inhibitor approved in 2013 as the third-line treatment for GIST patients who were resistant or intolerant to <b>1</b> and <b>2</b>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> However, the median PFS was achieved by compounds <b>2</b> and <b>3</b> for only 6.8 and 4.8 months, respectively.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, the development and identification of novel agents for refractory GISTs are urgently required.<a onclick="showRef(event, 'ref5 ref18'); return false;" href="javascript:void(0);" class="ref ref5 ref18">(5,18)</a></div><div class="NLM_p">Acute myeloid leukemia (AML) is a hematologic malignancy with uncontrolled proliferation and impaired maturation of hematopoietic cells. A high percentage of AML patients relapse despite the apparent success of initial induction chemotherapy. The occurrence of oncogenic mutations that leads to aberrant activation and proliferation of cellular signal transduction pathways results in primary treatment failure in AML and provides insight into the refractory nature of AML.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> FMS-like tyrosine kinase-3 (FLT3) is a member of the class III membrane-bound receptor tyrosine kinase (RTK) family. In addition to FLT3, RTK class III includes c-KIT, CSF1R (FMS), PDGFRα, and PDGFRβ.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> FLT3 mutations have been identified in approximately 30% of all AML patients and these mutations are indicative of poor prognosis.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> The mutations include internal tandem duplications (ITDs) in the juxtamembrane domain of FLT3 and missense point or short-length mutations in the activation loop (AL) of the tyrosine kinase domain (TKD).<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Notably, c-KIT is mutated in a subset of AML (core-binding factor (CBF)-AML) with a range of 17–46% mutation rate.<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29">(25−29)</a> Even though CBF-AML patients usually have longer survival than other poor risk patients, CBF-AML patients with c-KIT mutation have higher risk of relapse and usually have poor survival, particularly with D816V mutation.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a></div><div class="NLM_p last">Mutations in both FLT3 and c-KIT are significantly associated with poor prognosis in patients with AML, and the development of agents that target these mutations has emerged as promising therapeutic strategies for the treatment of AML.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Currently, midostaurin (PKC-412, <b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is the only approved TKI in combination with standard intensive chemotherapy for adult patients with newly diagnosed FLT3-mutated AML. The international phase III trial results indicated that randomized patients to receive compound <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) had a higher median OS, with a hazard ratio of 0.78 compared with those receiving placebo.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> By the end of 2018, the Food and Drug Administration approved gilteritinib for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The mutation sites of c-KIT in CBF-AML mainly located on exon 8 (D419) and exon 17 (D816 and N822).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Several agents targeting c-KIT, such as compound <b>1</b> and dasatinib, have been shown to suppress the proliferation of c-KIT mutant leukemia cells in vitro.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Compound <b>1</b> failed to respond to relapsed AML patients with c-KIT mutations in earlier study.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Recently, dasatinib in combination of intensive chemotherapy was shown to induce a higher response rate for CBF-AML,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and the phase III trial is still ongoing.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Design of Multitargeted Tyrosine Kinase Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Using a structure-based design, we previously developed a novel class of 5-phenylthiazol-2-ylamine-based derivatives (structure <b>O</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as a versatile template for the development of multitargeted kinase inhibitors. This previous study led to the discovery of urea <b>5</b>, which exhibited promising in vitro and in vivo antitumor activities against FLT3-ITD-expressing MOLM-13 and MV4;11 cell lines and FLT3-ITD/D835Y-expressing 32D cell lines.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The kinome-wide selectivity profile of <b>5</b> with DiscoveRx’s KinomeScan Technology<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> demonstrated that <b>5</b> bore a low selectivity (<i>S</i> score (10) = 0.091 at a low concentration of 0.1 μM) among 395 wild-type kinases tested. Both multikinase inhibitors and single-kinase inhibitors have advantages and disadvantages, which are related to potential resistance mechanisms, pharmacokinetics, selectivity, tumor environment, and toxicity.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> However, we speculate that the off-target profile of <b>5</b> might explain its intrinsic toxicity in vivo. To trim the off-target profile, optimize target inhibition, and increase the therapeutic window with acceptable toxicity, we rationally designed a second class of heteroaryl-substituted 2-aminothiazole derivatives as multikinase inhibitors (structure <b>P</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The approach removes an important urea pharmacophore at the phenyl ring of <b>5</b> and replaces phenyl group (<b>5</b>) with a pyridine or pyrimidine group (structure <b>P</b>). Based on the chemical design, a 5-pyridin-4-yl-thiazol-2-ylamine series of compounds (<b>15</b>) was found to maintain a similar anticancer activity to that of <b>5</b>. In this study, the structure–activity relationships (SAR) of a series of structure <b>P</b> derivatives are reported. This study has led to the discovery of compound <b>15a</b>, which is a multitargeted kinase inhibitor with excellent pharmaceutical properties, good pharmacokinetics (PK) profile, and superior efficacy and tolerability in GIST and AML tumor xenograft models. These promising results demonstrate the potential of <b>15a</b> suitable for further preclinical and clinical development.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Identification of 5- pyridine-thiazol-2-ylamine derivatives as TKIs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The general synthetic route to 5-aromatic substituted thiazol-2-ylamine pyrimidines <b>12–16</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthesis began with the preparation of 5-aromatic substituted thiazol-2-ylamines <b>9</b> according to a previously published protocol with some modifications.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> 2-Aminothiazole <b>6</b> was protected with trimethylacetyl chloride using Et<sub>3</sub>N to give <i>N</i>-thiazol-2-yl-propionamide <b>7</b>. The Suzuki coupling of <b>7</b> with chloro-substituted pyridine or pyrimidine catalyzed by Pd(0) gave 5-aromatic substituted thiazol-2-ylamides <b>8</b>. Amides <b>8</b> were hydrolyzed in the presence of a concentrated acid followed by neutralization to yield free 5-aromatic substituted thiazol-2-ylamines <b>9</b>. Treatment of 5-aromatic substituted thiazol-2-ylamines <b>9</b> or the commercially available <b>10</b> with 4,6-dichloropyrimidine or 4,6-dichloro-2-methylpyrimidine in the presence of sodium hydride (NaH) and 1-methyl-2-pyrrolidinone (NMP) at 0 °C yielded 4-monosubstituted pyrimidine derivatives <b>11</b>. The treatment of these derivatives with 2° amines in DMSO at 100 °C or with 2-morpholin-4-yl-ethanol in the presence of KOH and diglyme at 160 °C yielded 4,6-disubstituted pyrimidines <b>12</b>–<b>16</b>. The synthetic routes to 4-pyridin-3-yl-thiazol-2-ylamine pyrimidine <b>19</b> and <i>N</i>-(5-pyridin-3-yl-thiazol-2-yl)benzamide <b>21</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) are shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Displacement of 6-chloro and 4-chloro substituents of 4,6-dichloropyrimidine with sodium salt of 4-pyridin-3-yl-thiazol-2-ylamine <b>17</b><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and 1-ethylpiperazine, respectively, gave 4,6-disubstituted pyrimidines <b>19</b>. Benzoyl chloride <b>20</b> with a water-solubilizing 1-methylpiperazine group was employed to acylate amine <b>9b</b> in pyridine to yield amide <b>21</b>. The freebase forms of compounds <b>12</b>–<b>16</b>, <b>19</b>, and <b>21</b> were reacted with aqueous 6 N HCl/CH<sub>3</sub>OH to yield their corresponding hydrochloride salts.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) TEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (b) 3-chloropyridine, 4-chloropyridine, or 5-chloropyrimidine, KOAc, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMAc, 150 °C, or 2-chloropyridine, CsF, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMSO, 160 °C; (c) 12 N HCl, H<sub>2</sub>O, 110 °C; (d) NaHCO<sub>3</sub>, H<sub>2</sub>O, rt to 50 °C; (e) 4,6-dichloropyrimidine or 4,6-dichloro-2-methylpyrimidine, NaH, NMP, 0 °C; (f) 2° amines, DMSO, 100 °C, or 4-(2-hydroxyethyl)morpholine, KOH, diglyme, 160 °C for <b>15f</b>; (g) 6 N HCl/CH<sub>3</sub>OH, 0 °C; (h) pyridine, 0 °C to rt.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition of Enzymes and Cell Proliferation with Thiazole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0003.gif" alt="" id="gr8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0002.gif" alt="" id="gr9" /></img><div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> In Vitro Pharmacology</h3><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the target compounds were tested against c-KIT and FLT3 (in-house kinase assays). In addition, these compounds were further evaluated against the GIST cell line GIST-T1 (expressing a heterozygous deletion in the c-KIT exon 11) and AML cell line MOLM-13 (expressing wild-type FLT3 and FLT3-ITD mutation). The first compound, <b>12</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> which lacks a urea pharmacophore of <b>5</b>, increased the inhibitory activity against c-KIT (IC<sub>50</sub> = 24 nM) but significantly lost antiproliferative potency against MOLM-13 cells (GI<sub>50</sub> = 35 nM) compared to urea <b>5</b>. Next, the effects on replacing the phenyl moiety present in <b>12</b> with pyridine groups were evaluated. The second position of pyridine attached to the fifth position of thiazole (<b>13</b>) exhibited similar inhibitory activities against wild-type c-KIT and FLT3 kinases but did result in reduced cellular potencies (GIST-T1 and MOLM-13 with GI<sub>50</sub> = 42 and 36 nM, respectively) relative to <b>5</b>. When the nitrogen atom was moved to the third position, <b>14a</b> (R<sub>2</sub> = CH<sub>3</sub>) and <b>14b</b> (R<sub>2</sub> = H) were as potent as <b>5</b> in the enzymatic assays but were significantly less active in the cellular assays with GI<sub>50</sub> values of 26–140 nM. Compound <b>15a</b> (R<sub>2</sub> = CH<sub>3</sub>), with the fourth position of pyridine attached to thiazole, exhibited similar inhibitory activities against c-KIT and FLT3 kinases compared to <b>5</b> and displayed single digit nanomolar activity against cell lines GIST-T1 (GI<sub>50</sub> = 7.1 nM) and MOLM-13 (GI<sub>50</sub> = 9.4 nM). When compared with <b>15a</b>, <b>15b</b> (R<sub>2</sub> = H) showed potent inhibitory activities against c-KIT and FLT3 (IC<sub>50</sub> < 30 nM) but no improvement in cellular potency (GI<sub>50</sub> > 10 nM).</div><div class="NLM_p">Next, we examined the effects of water-solubilizing substituents on the fourth position of the pyrimidine ring and compared the potencies of compounds <b>15c</b>–<b>15f</b> with <i>N</i>-ethylpiperazine analogue <b>15a</b>. <i>N</i>-(2-Fluoroethyl)piperazine (<b>15c</b>), <i>N</i>-(2-hydroxyethyl)piperazine (<b>15d</b>), <i>N</i>,<i>N</i>-dimethylpiperidin-4-amine (<b>15e</b>), and 4-(2-hydroxyethyl)morpholine (<b>15f</b>) did not affect the inhibitory potencies against c-KIT and FLT3 kinases. Nevertheless, <b>15e</b> bearing a <i>N</i>,<i>N</i>-dimethylpiperidin-4-amine group slightly increased the cellular activities (GIST-T1 GI<sub>50</sub> = 1.5, MOLM-13 GI<sub>50</sub> = 3.5 nM), but <b>15f</b> bearing a morpholine group tethered by a two-carbon ether apparently lost cellular potencies (GIST-T1 GI<sub>50</sub> = 27, MOLM-13 GI<sub>50</sub> = 42 nM). In this study, limited water-solubilizing groups were discussed because the effects of some water-solubilizing groups on biological activities, pharmacokinetics, and in vivo toxicities were fully clarified based on the previous results from the development of 5-phenylthiazol-2-ylamine-based inhibitors (structure <b>O</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Extensive SAR studies were carried out by adding a single methyl substituent on the pyridine ring of <b>15a</b> and replacing the pyridine moiety of <b>15a</b> with pyrimidine to yield analogues <b>15g</b> and <b>16</b>, respectively. In comparison with <b>15a</b>, 2-methylpyridine <b>15g</b> was 2-fold to 4-fold less potent against the c-KIT, FLT3, and MOLM-13 cells but maintained potency against GIST-T1 cells (GI<sub>50</sub> = 7.7 nM). Pyrimidine <b>16</b> exhibited only moderate inhibition of c-KIT (IC<sub>50</sub> = 123 nM) and FLT3 (IC<sub>50</sub> = 163 nM) with a dramatic decrease in cellular potency (GI<sub>50</sub> > 100 nM).</div><div class="NLM_p">After optimizing the 5-pyridin-4-yl-thiazol-2-yl series of pyrimidines (compounds <b>15</b>, structure P), we investigated the effects of substitutions on 2-aminothiazole and compared the potencies of compounds <b>19</b> and <b>21</b> with <b>14a</b>. A significant decrease in both enzymatic activities (IC<sub>50</sub> > 1000 nM) and cellular potencies (GI<sub>50</sub> > 1000 nM) was observed when the pyridine ring of <b>14a</b> was moved from the fifth position to the fourth position (<b>19</b>) of the thiazole ring. According to prior reports, the 2-aminothiazole moiety is conformationally well suited to form hydrogen bond interactions with the kinase hinge region of the ATP pocket,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and benzamide is a known scaffold for FLT3 kinase inhibitors.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Accordingly, we replaced the pyrimidine group with a benzamide group bearing a solubilizing substituent at the <i>para</i> position of a benzene ring, yielding benzamide <b>21</b>. This approach led to benzamide <b>21</b> as only a moderate c-KIT/FLT3 inhibitor with submicromolar activities against GIST-T1 (GI<sub>50</sub> = 647 nM) and MOLM-13 cells (GI<sub>50</sub> = 544 nM). Therefore, further modification of lead <b>21</b> was not carried out.</div><div class="NLM_p last">As for FDA-approved TKIs for GISTs or AML, compound <b>1</b> inhibits tyrosine kinases specifically BCR-ABL, c-KIT, and PDGFRα and compounds <b>2</b>–<b>4</b> are multitargeted TKIs possessing c-KIT/FLT3 dual inhibition (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <b>1</b> potently inhibited c-KIT and GIST-T1 cells with IC<sub>50</sub> and GI<sub>50</sub> values of 53 and 40 nM, respectively. Among these multitargeted TKIs (<b>2</b>–<b>4</b>), compound <b>2</b> exhibited the best enzymatic activities against c-KIT and FLT3 (IC<sub>50</sub> < 50 nM) and cellular potencies against GIST-T1 and MOLM-13 cells (GI<sub>50</sub> < 60 nM). Compounds <b>3</b> and <b>4</b> showed less potent inhibition toward MOLM-13 (GI<sub>50</sub> = 887 nM) and GIST-T1 (GI<sub>50</sub> = 235 nM) cells, respectively. Among the pyridine-substituted 2-aminothiazole analogues listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <b>15a</b> and <b>15c</b>–<b>e</b> are potent dual inhibitors of c-KIT and FLT3 with less than 10 nM antiproliferative activities in cellular assays. In preliminary studies, the pharmacokinetics, toxicities, and/or tumor-inhibiting activities between <b>15a</b> and <b>15c</b>–<b>15e</b> were compared in normal mice or SCID mouse xenografts. The results showed that <b>15a</b> caused more significant antitumor effects in GIST430 xenografts compared to <b>15c</b> and <b>15d</b>. Moreover, <b>15a</b> exhibited lower toxicity in mice compared to <b>15c</b> and <b>15e</b>, and the pharmacokinetic profile of <b>15a</b> appeared to be more favorable than that of <b>15d</b>. Therefore, compound <b>15a</b> was selected for further biological activity and in vivo efficacy studies.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Kinase Inhibition Profiles of <b>15a</b></h3><div class="NLM_p last">To better understand the enzyme inhibition by the potent compound, <b>15a</b> was first examined its kinome-wide selectivity profile with DiscoveRx’s KinomeScan Technology in a panel of 468 kinases and mutants at 100 nM (competition binding assay).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The results demonstrated that <b>15a</b> was a typical multitargeted tyrosine kinase inhibitor (<i>S</i> score (10) = 0.074 at 0.1 μM, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf" class="ext-link">Figure S1</a>). Because the competition binding assay (KinomeScan) may not fully reflect inhibitory activity, a continuous kinase enzymatic assay (HotSpot Kinase profiling, Reaction Biology Corporation) was performed to measure <b>15a</b>’s inhibition activity against selected 38 protein kinases at a concentration of 100 nM. These 38 kinases covered the major oncogenic kinases of the human protein kinome and showed higher affinity interactions with <b>15a</b> (%Ctrl <20, KinomeScan binding assay). The enzyme activity assay results showed that <b>15a</b> inhibited 22 kinases by more than 70% at 100 nM out of a panel of 38 tested kinases (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf" class="ext-link">Table S1</a>). Most importantly, the kinase profiling revealed <b>15a</b> with potent activity against clinically important wild-type and mutant kinases, including FLT3 (98%), FLT3-D835Y (99%), FLT3-ITD (99%), PDGFRα-T674I (98%), ABL1 (97%), c-Src (94%, IC<sub>50</sub> = 3 nM), TRKB (93%), TRKA (90%, IC<sub>50</sub> = 4.9 nM), PDGFRβ (88%), c-KIT (85%), PDGFRα (75%), and PDGFRα-V561D (75%).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Compound <b>15a</b> Inhibits Enzymatic Activities of a Broad Spectrum of c-KIT Mutants</h3><div class="NLM_p">There are multiple sites of c-KIT mutation in cancers, with some “hot spots” corresponding to the intracellular and extracellular juxtamembrane domains (exons 8, 9, and 11) and the activation loop of the kinase domain (exon 17), which lead to disruption of autoinhibitory mechanisms.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The ability of <b>15a</b> to potently inhibit activated c-KIT suggested that the inhibitory activity of <b>15a</b> among a variety of c-KIT mutants should be examined.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Accordingly, various single- or double-mutant isoforms of c-KIT were evaluated for their susceptibility to inhibition by <b>15a</b>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, compound <b>15a</b> more effectively inhibited a broad spectrum of c-KIT mutants bearing single mutations in the JM domain, the ATP-binding pocket, and the A-loop. In addition to single c-KIT mutants, <b>15a</b> also potently inhibited c-KIT double mutants containing primary V560G and secondary mutations at the A-loop (D816V and N822K), although reduced potency was observed in the V559D/V654A double mutant (54% inhibition at 100 nM, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Except for ATP binding site mutants and the V559D/V654A double mutant, <b>15a</b> was considerably more potent than compound <b>2</b> on the inhibition of the other mutants shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Apparently, the inhibition of these mutant forms of c-KIT by compound <b>3</b> was not comparable to <b>15a</b>, especially toward single mutants V654A, D816H, and D816V and double mutants V559D/V654A and V560G/D816V (<15% inhibition at a concentration of 100 nM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of Enzymatic Activities of c-KIT Mutants by <b>15a</b>, <b>2</b>, or <b>3</b> (by HotSpot Kinase Profiling, Reaction Biology Corporation)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="3" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">% inhibition of enzymatic activities</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="3" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><b>15a</b></th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><b>2</b> (sunitinib)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><b>3</b> (regorafenib)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="3" align="center">mutant forms of c-KIT</th><th class="colsep0 rowsep0" align="center" char=".">100 nM</th><th class="colsep0 rowsep0" align="center" char=".">10 nM</th><th class="colsep0 rowsep0" align="center" char=".">100 nM</th><th class="colsep0 rowsep0" align="center" char=".">10 nM</th><th class="colsep0 rowsep0" align="center" char=".">100 nM</th><th class="colsep0 rowsep0" align="center" char=".">10 nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">JM domain</td><td class="colsep0 rowsep0" align="left">exon 11</td><td class="colsep0 rowsep0" align="left">V560G</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">67</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">ATP binding pocket</td><td class="colsep0 rowsep0" align="left">exon 13</td><td class="colsep0 rowsep0" align="left">V654A</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 13</td><td class="colsep0 rowsep0" align="left">K642E</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">80</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 14</td><td class="colsep0 rowsep0" align="left">T670I</td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="center">A-loop</td><td class="colsep0 rowsep0" align="left">exon 17</td><td class="colsep0 rowsep0" align="left">D816H</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 17</td><td class="colsep0 rowsep0" align="left">D816V</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 17</td><td class="colsep0 rowsep0" align="left">D820E</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 17</td><td class="colsep0 rowsep0" align="left">D820Y</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">80</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 17</td><td class="colsep0 rowsep0" align="left">Y823D</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 18</td><td class="colsep0 rowsep0" align="left">A829P</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">double mutant</td><td class="colsep0 rowsep0" align="left">exon 11/13</td><td class="colsep0 rowsep0" align="left">V559D/V654A</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 11/17</td><td class="colsep0 rowsep0" align="left">V560G/D816V</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exon 11/17</td><td class="colsep0 rowsep0" align="left">V560G/N822K</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activity of <b>1</b>, <b>2</b>, <b>3</b>, and <b>15a</b> against GIST Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">primary/secondary mutation</th><th class="colsep0 rowsep0" align="center"><b>1</b> (imatinib)</th><th class="colsep0 rowsep0" align="center"><b>2</b> (sunitinib)</th><th class="colsep0 rowsep0" align="center"><b>3</b> (regorafenib)</th><th class="colsep0 rowsep0" align="center" char="."><b>15a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST882</td><td class="colsep0 rowsep0" align="left">K642E/none</td><td class="colsep0 rowsep0" align="left">195</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">285</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST430</td><td class="colsep0 rowsep0" align="left">V560-L576del/V654A</td><td class="colsep0 rowsep0" align="left">929</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">785</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST48</td><td class="colsep0 rowsep0" align="left">V560D/D820A</td><td class="colsep0 rowsep0" align="left">625</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">>2000</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values of GI<sub>50</sub> are expressed as the mean of three independent experiments and are within ±25%.</p></div></div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Crystal Structure of c-KIT Kinase in Complex with <b>15a</b></h3><div class="NLM_p">The structure of c-KIT kinase in complex with <b>15a</b> was obtained, and the statistics for data collection and refinement are summarized in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf" class="ext-link">Table S2</a>). The overall structure of <b>15a</b> bound c-KIT adopts an autoinhibited conformation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). The JM region of <b>15a</b> is ordered, and the compact hairpin loop conformation resembles that of the autoinhibited c-KIT. The N-terminal half of the hairpin loop (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) inserts directly into the interspace between the αC-helix in the N-lobe and the A-loop in the C-lobe. The insertion, together with the other solvent-exposed half (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) of the hairpin loop, stabilizes the autoinhibited state by replacing and reorienting the A-loop from an activated to an inactive conformation.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Overall structures of c-KIT in complex with <b>15a</b> (PDB code: 6KLA). (B) The interactions of c-KIT with <b>15a</b>. The juxtamembrane (JM) domain and activation loop are shown in magenta and yellow, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>15a</b> binds to c-KIT kinase in the ATP-binding site located between the N-lobe and C-lobe (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). The thiazolylamine scaffold of <b>15a</b> forms two hydrogen bonds with the backbone of Cys673 in the hinge region. In addition, the thiazolylamine group of <b>15a</b> also forms hydrophobic interactions with Leu595, Tyr672, Cys673, and Leu799. In particular, the sulfur atom of <b>15a</b> forms the sulfur-π interactions with Phe811 in the DFG motif of c-KIT kinase. The pyridine group of <b>15a</b> occupies the back pocket of the ATP-binding site by forming a hydrogen bond with the side chain of Lys623. Moreover, <b>15a</b> induces a conformational rearrangement of Phe811 to form perpendicular “edge-to-face” aromatic interactions with its pyridine group (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). In addition to Phe811, the pyridine group of <b>15a</b> also forms hydrophobic interactions with Ala621 and Leu799. The ethylpiperazine group of <b>15a</b> is solvent-exposed in the crystal structure of c-KIT, and the design of this moiety is usually for improvement of the physiochemical properties of compounds. Unlike some type II RTK inhibitors that insert deeply beyond the back pocket of the ATP-binding site,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a><b>15a</b> does not interact with the αC-helix or create any additional hydrophobic pocket that pushes the JM domain away from its autoinhibited conformation. Retaining the JM domain in an autoinhibited conformation may therefore contribute to the high potency of <b>15a</b> to inhibit c-KIT kinase activity.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Antiproliferative Effects of <b>15a</b> on c-KIT Mutant GIST Cell Lines</h3><div class="NLM_p">GIST cell lines, including c-KIT mutated GIST882, GIST48, and GIST430, were treated with <b>15a</b> and screened for the inhibitory effect of <b>15a</b> on cell proliferation via the methylene blue assay. Among the three c-KIT-mutated GIST cell lines, GIST882 carries the exon13 K642E mutation. GIST430 has a primary c-KIT exon11 in-frame deletion and a heterozygous secondary exon13 missense mutation (V654A). GIST48 has a primary homozygous exon 11 missense mutation (V560D) and a secondary heterozygous exon 17 mutation (D820A). The GI<sub>50</sub> values for GIST cell lines treated with <b>15a</b> were 5.0, 17, and 21 nM for GIST882, GIST430, and GIST48, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compared with compounds <b>1</b>–<b>3</b>, the IC<sub>50</sub> values of <b>15a</b> to suppress the cell proliferation of three c-KIT mutant GIST cell lines are much lower than those of the three available tyrosine kinase inhibitors used in clinical practice, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_p">As c-KIT is the driving oncogene of c-KIT-mutated GIST cells, we evaluated c-KIT and phosphorylated c-KIT for GIST882, GIST430, and GIST48 cells and found that phosphorylated c-KIT was significantly suppressed by <b>15a</b> time dependently, as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. GIST cells were treated with 100 nM <b>15a</b> for 24, 48, and 72 h to evaluate the inhibitory effects of <b>15a</b> on c-KIT and its downstream signals. Compound <b>15a</b> exerted marked suppressive effects on c-KIT phosphorylation in all three GIST cell lines. The downstream signals and the phosphorylation of AKT and MEK were suppressed well in GIST882 and GIST430 cells by 100 nM <b>15a</b>. In GIST48 cells, phosphorylated AKT and MEK were suppressed by 100 nM <b>15a</b> at 24 h but recovered at 48 and 72 h. This effect can be overcome by the use of <b>15a</b> at a concentration of 1000 nM, as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Since GIST-T1 cells are sensitive to compounds <b>1</b> and <b>2</b>, western blot analysis to assess the inhibitory effect of <b>15a</b> on phosphorylation of mutant c-KIT in GIST-T1 is not further tested.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>15a</b> effectively suppressed c-KIT phosphorylation and its downstream signaling pathways in GIST cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Antiproliferative Effects of <b>15a</b> on Leukemia Cell Lines</h3><div class="NLM_p">The antiproliferative activity of <b>15a</b> was assessed in a panel of leukemic and transfected BaF3 cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compound <b>15a</b> potently inhibited the proliferation of FLT3-ITD-positive AML cell lines MOLM-13 and MV4;11 with GI<sub>50</sub> values of 6.4 and 4.9 nM, respectively. In addition, Kasumi-1 cells were sensitive to <b>15a</b> with a low GI<sub>50</sub> value of 12 nM. Kasumi-1 is an AML cell line carrying a c-KIT mutation on codon 822 (N822K). In contrast, <b>15a</b> inhibited B-cell acute lymphoblastic leukemia cell line RS4;11 (expressing native FLT3), leukemic monocyte lymphoma cell line U937 (not expressing FLT3), and human chronic myeloid leukemia cell line K562 (expressing wt-BCR/ABL) at significantly higher concentrations (517–2905 nM), strongly suggesting that <b>15a</b> is a dual FLT3/c-KIT inhibitor. The growth inhibitory effects of <b>15a</b> on FLT3-driven MOLM-13 and MV4;11 cells were more potent than that of compound <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Additionally, c-KIT inhibitors <b>1</b>–<b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) showed moderate inhibition against Kasumi-1 cells with GI<sub>50</sub> values of 1002, 225, 261, and 284 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Potency Comparison of <b>4</b> and <b>15a</b> in Cellular Assays</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">cell line</th><th class="rowsep1 colsep0" colspan="2" align="center">GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">leukemia</th><th class="colsep0 rowsep0" align="center"><b>4</b> (midostaurin)</th><th class="colsep0 rowsep0" align="center" char="."><b>15a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MOLM-13</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MV4;11</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Kasumi-1<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">284</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="left">400</td><td class="colsep0 rowsep0" align="char" char=".">650</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U937</td><td class="colsep0 rowsep0" align="left">1400</td><td class="colsep0 rowsep0" align="char" char=".">2905</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K562</td><td class="colsep0 rowsep0" align="left">>20,000</td><td class="colsep0 rowsep0" align="char" char=".">517</td></tr></tbody></table><table class="table "><colgroup><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">BaF3</th><th class="colsep0 rowsep0" colspan="2" align="center">GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">parent/IL3</td><td class="colsep0 rowsep0">540</td><td class="colsep0 rowsep0">1100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">FLT3-D835Y</td><td class="colsep0 rowsep0">16</td><td class="colsep0 rowsep0">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">FLT3-ITD-D835Y</td><td class="colsep0 rowsep0">43</td><td class="colsep0 rowsep0">92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">FLT3-ITD-F691L</td><td class="colsep0 rowsep0">47</td><td class="colsep0 rowsep0">152</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Kasumi-1 GI<sub>50</sub>: <b>1</b> = 1002 nM; <b>2</b> = 225 nM; <b>3</b> = 261 nM.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Values are expressed as the mean of three independent determinations and are within ±25%.</p></div></div></div><div class="NLM_p">FLT3-ITD secondary TKD mutants, especially at residues D835 and F691, confer clinical resistance to the FLT3 inhibitors quizartinib and sorafenib.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Due to <b>15a</b>’s promising potency toward the FLT3-driven AML cell lines, the ability of <b>15a</b> to inhibit both D835Y and F691L secondary mutations of FLT3-ITD should be evaluated. In this study, we examined the cellular GI<sub>50</sub> values of <b>4</b> and <b>15a</b> against BaF3 cells expressing FLT3-D835Y (activation loop mutation), FLT3-ITD-D835Y (ITD and activation loop mutation), and FLT3-ITD-F691L (ITD and gatekeeper mutation). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, the cell proliferation-based assays indicated that the sensitivity toward <b>15a</b> differed significantly for inhibiting FLT3-D835Y (GI<sub>50</sub> = 17 nM), FLT3-ITD-D835V (GI<sub>50</sub> = 92 nM), and FLT3-ITD-F691L (GI<sub>50</sub> = 152 nM). Compound <b>15a</b> showed an equal inhibitory effect on the proliferation of BaF3 cells expressing FLT3-D835Y compared to compound <b>4</b> (GI<sub>50</sub> = 16 nM). Nevertheless, the growth inhibitory effects of <b>15a</b> on FLT3-ITD-D835Y and FLT3-ITD-F691L mutants were slightly less potent than <b>4</b>, with GI<sub>50</sub> values of 43 and 47 nM, respectively, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_p">In addition, the antiproliferative activities against other cancer cell lines were also evaluated (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf" class="ext-link">Table S3</a>). The GI<sub>50</sub> values of <b>15a</b> against 11 cancer cell lines ranged from 376 nM (Colo205) to >20,000 nM (A549 and KYSE-510). Moreover, <b>15a</b> had no inhibitory effect on Detroit 551 (normal human skin fibroblast cell), with GI<sub>50</sub> > 20,000 nM.</div><div class="NLM_p">Because the inhibitor of <b>15a</b> exhibits cytotoxicity in BaF3 cells expressing the FLT3 TKD mutant and FLT3-ITD TKD mutants (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), it was important to verify that the mechanism of cell death was directly linked to the inhibition of FLT3. Next, a western blot analysis was performed using HEK293T cells engineered to express FLT3-WT, FLT3-ITD, FLT3-D835Y, or FLT3-ITD-D835Y. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, compound <b>15a</b> potently inhibited the phosphorylation of FLT3-WT, FLT3-ITD, and FLT3-D835Y with IC<sub>50</sub> values from 0.1 to 1.0 nM. Consistently, <b>15a</b> showed moderate potency against autophosphorylation of the FLT3-ITD-D835Y mutant (IC<sub>50</sub> value of approximately 100 nM), whose inhibition level was closely correlated with an antiproliferative effect on BaF3 cells expressing FLT3-ITD-D835Y (GI<sub>50</sub> = 92 nM, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. HEK293T cells expressing FLT3-WT, FLT3-ITD, FLT3-D835Y, or FLT3-ITD/D835Y were analyzed. FLT3-transfected HEK293T cells were treated with compound <b>15a</b> at various concentrations for 1 h. Compound <b>15a</b> potently inhibits the FLT3-WT, FLT3-ITD, and FLT3-D835Y signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetics and in Vivo Efficacy Studies of <b>15a</b></h3><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> shows the pharmacokinetic properties of <b>15a</b> evaluated in male Sprague Dawley rats and ICR mice. In both species, <b>15a</b> exhibited high volumes of distribution (<i>V</i><sub>ss</sub> = 10.1 L/kg in rats and 14.7 L/kg in mice) and plasma clearances (Cl = 39.6 mL/min/kg in rats and 70.7 mL/min/kg in mice) after intravenous (IV, 2 mg/kg) administration. A single 10 mg/kg oral dose of <b>15a</b> was administered as a solution containing 22% hydroxypropyl-β-cyclodextrin in water and absorbed with a moderate half-life in rats (<i>t</i><sub>1/2</sub> = 3.9 h) and in mice (<i>t</i><sub>1/2</sub> = 4.1 h). The <i>C</i><sub>max</sub> (325 ng/mL) and AUC (1955 ng/mL·h) in mice were slightly higher than those in rats, and the oral bioavailability ranged from 36% in rats to 68% in mice. After demonstrating favorable pharmacokinetic properties and excellent cellular potency against GIST and AML cell lines, <b>15a</b> was appropriate for continued in vivo investigation to determine the antitumor activity of <b>15a</b> in a broad panel of GIST and AML xenograft models (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Profile of Compound <b>15a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="center" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">IV (dose: 2 mg/kg)</th><th class="rowsep1 colsep0" colspan="4" align="center">PO (dose: 10 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h<b>)</b></th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0-inf)</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0-inf)</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rats</td><td class="colsep0 rowsep0" align="center">5.7</td><td class="colsep0 rowsep0" align="char" char=".">39.6</td><td class="colsep0 rowsep0" align="char" char=".">10.1</td><td class="colsep0 rowsep0" align="left">804</td><td class="colsep0 rowsep0" align="center">3.9</td><td class="colsep0 rowsep0" align="left">153</td><td class="colsep0 rowsep0" align="left">1470</td><td class="colsep0 rowsep0" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mice</td><td class="colsep0 rowsep0" align="center">1.6</td><td class="colsep0 rowsep0" align="char" char=".">70.7</td><td class="colsep0 rowsep0" align="char" char=".">14.7</td><td class="colsep0 rowsep0" align="left">542</td><td class="colsep0 rowsep0" align="center">4.1</td><td class="colsep0 rowsep0" align="left">325</td><td class="colsep0 rowsep0" align="left">1955</td><td class="colsep0 rowsep0" align="left">68</td></tr></tbody></table></div></div><div class="NLM_p">First, the in vivo pharmacodynamic (PD) effect of <b>15a</b> was performed in NOD/SCID mice bearing GIST430 tumors. Three doses of <b>15a</b> (10, 20, and 40 mg/kg) were administered orally to subcutaneous GIST430 xenografts and harvested 16 h after <b>15a</b> administration. Pharmacodynamic analysis of tumors showed sustained inhibition of p-c-KIT and p-Akt in a dose-dependent response (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). These data demonstrated the long lasting effect of <b>15a</b> on c-KIT inhibition in vivo and that once-a-day oral dosing was expected to be sufficient for in vivo efficacy in the mouse model. To examine its antitumor efficacy in the GIST430 xenograft model, <b>15a</b> was administered orally at a dose of 30 mg/kg once daily (qd) on days 1–2, 5–9, and 12–16. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B, rapid tumor regression was observed during the dosing period, with three of five treated animals exhibiting complete regression (CR) by day 14. There was no tumor regrowth up to day 30, while the <b>2</b>-treated group (80 mg/kg) began to recur after dosing was halted. In an independent GIST430 xenograft model, treatment of <b>15a</b> with a low dose of 15 mg/kg also led to rapid tumor regression, but no CR was found in the low-dose group (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf" class="ext-link">Figure S2</a>). This model was resistant to <b>1</b> (approved for GIST first-line treatment) and sensitive to <b>2</b> (approved for GIST second-line treatment).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>15a</b> inhibits the growth of GIST and AML xenografts. (A) A pharmacodynamics study was conducted in the GIST430 xenograft model separately from the efficacy study. Levels of phosphorylated c-KIT (c-KIT-Tyr703) and AKT (AKT-Ser473) were determined by immunoblot. GIST430 xenografts were treated with <b>15a</b> (10, 20, and 40 mg/kg) or vehicle for 16 h. Tumors were then harvested, and protein lysates were subjected to immunoblotting for p-c-KIT, total c-KIT, p-AKT, total AKT, and β-actin. (B–F) Antitumor activity of <b>15a</b> was evaluated against (B) GIST430 xenografts, <i>n</i> = 5/group, (C) c-KIT exon 11 (delW557K558)/exon 17 (Y823D) GIST PDX, <i>n</i> = 6/group, (D) c-KIT exon 13 (K642E)/exon 17 (N822K) GIST PDX, <i>n</i> = 6/group, (E) c-KIT mutated Kasumi-1 AML xenografts, <i>n</i> = 8/group, (F) FLT3-ITD-mutated MOLM-13 AML xenografts, <i>n</i> = 4/group. Mice were treated with <b>15a</b> and reference compounds using the dosing levels indicated. The gray bars indicate the dosing schedule for <b>15a</b> and reference compounds. The tumor size is expressed as the mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the antitumor efficacy of <b>15a</b> was assessed in two GIST patient-derived xenograft (PDX) models. The first PDX model performed in NOD/SCID mice bearing the exon 11 (delW557K558)/exon 17 (Y823D) double mutant was resistant to <b>1</b> and <b>2</b>. Oral administration of <b>15a</b> showed significant antitumor effects at 15 and 30 mg/kg qd for 5 days a week for 2 weeks in the PDX model. Treatment with 15 mg/kg dosing caused tumor stasis, whereas tumor regression was observed in the 30 mg/kg dosing group during the second week of treatment followed by slow tumor regrowth starting approximately 7 days after cessation of dosing. At the end of the experiment (day 29), the mean percentage of tumor growth inhibition (TGI) was 76 and 92% in the 15 and 30 mg/kg <b>15a</b> administration groups, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). As expected, this PDX model was sensitive to <b>3</b> (30 mg/kg), which is approved for GIST third-line therapy and known to show potency against secondary c-KIT mutants in exon 17 except for D816H/V.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The second PDX model was performed in NOD/SCID mice bearing the exon 13 (K642E)/exon 17 (N822K) double mutant. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D, <b>15a</b> at doses of 15 and 30 mg/kg resulted in tumor stasis by the second week of treatment. Tumors in both groups began to recur after cessation of dosing, with mean values of 80 and 88% TGI being observed in the 15 and 30 mg/kg dosing groups, respectively, on day 29. Apparently, <b>3</b> (30 mg/kg) was not sensitive to this PDX model with a 39% TGI on day 29. In the two PDX models, <b>15a</b> is well tolerated at both effective doses.</div><div class="NLM_p last">In AML xenograft models, Kasumi-1 AML xenografts (c-KIT exon 17 N822K) in SCID mice treated with <b>15a</b> dosed orally at 10, 20, and 30 mg/kg qd on days 1–5 and 8–12. Treatment with the low dose of 10 mg/kg led to stasis of tumor growth during the administration period, and apparent tumor regression was observed in the 20 and 30 mg/kg dosing groups followed by slow tumor regrowth starting within 1 week after cessation of dosing (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E). Four animals in the 30 mg/kg group (<i>n</i> = 8) became and remained tumor free (CR) through the end of the experiment. In this model, <b>15a</b> was well tolerated at all doses. Finally, a dose-escalation study was conducted to evaluate the in vivo efficacy and toxicity of <b>15a</b> in nude mice bearing MOLM-13 tumors (FLT3-ITD+). Compound <b>15a</b> was administered orally at doses of 50 and 100 mg/kg qd on days 1–5 and 8–12. Treatment started after randomization when tumors had reached an average volume of 370 mm<sup>3</sup>. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>F, apparent tumor regression was observed for the first 5 days in the 50 and 100 mg/kg dosing groups. At 50 mg/kg, near-complete tumor regression was observed in all animals by day 15 (85% tumor regression); no tumor growth resumed after dosing was halted. At 100 mg/kg, complete disappearance of the tumor mass was observed after dosing was halted. Treatment with 100 mg/kg resulted in four of four treated animals with CR during the 13 day posttreatment observation. No mortality and significant loss of body weight (<10%) were observed in <b>15a</b>-treated animals, whereas the maximum tolerated dose of compound <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was only 25 mg/kg in nude mouse xenograft models.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A rational design approach successfully identifies a potent, orally bioavailable, and multitargeted TKI <b>15a</b>, which is expected to exhibit lower toxicity while maintaining significant in vitro potency, similar to that of <b>5</b>. Importantly, <b>15a</b> appears to have superior efficacy and tolerability in GIST and AML tumor xenograft models. In GISTs, preclinical profiling against numerous mutant forms of c-KIT demonstrates that <b>15a</b> is active against a broad spectrum of c-KIT mutants, including various secondary mutations that have been identified in <b>1</b>-resistant or <b>2</b>-resistant GISTs, exhibiting consistent potency to suppress the cell proliferation and c-KIT phosphorylation of GIST882, GIST430, and GIST48 cells. Furthermore, in vivo efficacy studies demonstrate that <b>15a</b> shows the ability of tumor regression in the GIST430 model and exon 11 (delW557K558)/exon 17 (Y823D) PDX model and the ability of suppressing tumor growth in the exon 13 (K642E)/exon 17 (N822K) PDX model. In AML, <b>15a</b> exhibits potent antiproliferative activities against the c-KIT mutant AML cell line (Kasumi-1) and FLT3-ITD AML cell lines (MOLM-13 and MV4;11). In vitro cellular assays and western blot analyses show that <b>15a</b> appears to be highly active against clinically relevant FLT3-D835Y but exhibits moderately inhibitory activity against FLT3-ITD-D835Y and FLT3-ITD-F691L. Nevertheless, the ability of higher doses of <b>15a</b> to induce long-term tumor-free status is observed in the Kasumi-1 and MOLM-13 xenograft models.</div><div class="NLM_p last">Taken together, the excellent in vitro and in vivo antitumor activities of <b>15a</b> suggest that <b>15a</b> could be a next-generation drug candidate that worthy of clinical evaluation for the treatment of GISTs and AML.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Chemistry</h3><div class="NLM_p last">All commercial chemicals and solvents are reagent grade and were used without further treatment unless otherwise noted. <sup>1</sup>H NMR spectra were obtained with a Varian Mercury-300 or a Varian Mercury-400 spectrometer. Chemical shifts were recorded in parts per million (ppm, δ) and were reported relative to the solvent peak or TMS. LC/MS data were measured on an Agilent MSD-1100 ESI-MS/MS system. High-resolution mass spectra (HRMS) were measured with a Thermo Finnigan (TSQ Quantum) electrospray ionization (ESI) mass spectrometer. Flash column chromatography was done using silica gel (Merck Kieselgel 60, no. 9385, 230–400 mesh ASTM). Reactions were monitored by TLC using Merck 60 F<sub>254</sub> silica gel glass-backed plates (5 × 10 cm); zones were detected visually under ultraviolet irradiation (254 nm) or by spraying with phosphomolybdic acid reagent (Aldrich) followed by heating at 80 °C. All starting materials and amines were commercially available unless otherwise indicated. The purity of compounds was determined by a Hitachi 2000 series HPLC system based on a reverse phase C<sub>18</sub> column (Agilent ZORBAX Eclipse XDB-C18 5 μm, 4.6 mm × 150 mm, condition A) and reverse phase phenyl column (Waters XBridge Phenly 5 μm, 4.6 mm × 150 mm, condition B) under the following gradient elution condition: mobile phase A-acetonitrile (10 to 90%, 0 to 45 min) and mobile phase B-2 mM NH<sub>4</sub>OAc aqueous solution containing 0.1% formic acid (90 to 10%, 0 to 60 min). The flow rate was 0.5 mL/min and the injection volume was 20 μL. The system was operated at 25 °C. Peaks were detected at λ = 254 nm. Purity of all the tested compounds was found to be >95% except for compound <b>15g</b> (93.5%, condition B).</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2,2-Dimethyl-<i>N</i>-thiazol-2-yl-propionamide (<b>7</b>)</h3><div class="NLM_p last">To a mixture of 2-aminothiazole (<b>6</b>, 300 mmol) and triethylamine (330 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (250 mL) at 0 °C was added trimethylacetyl chloride (310 mmol) and the mixture was stirred at room temperature under an argon atmosphere for 1 h. The mixture was washed with 6 N HCl (60 mL) and the organic layer was separated, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (20% EtOAc/hexane) to give the desired product <b>7</b> as an off-white solid (72%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.75 (s, 1H), 7.46 (d, <i>J</i> = 6.0 Hz, 1H), 7.17 (d, <i>J</i> = 6.0 Hz, 1H), 1.22 (s, 9H); MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>12</sub>N<sub>2</sub>OS, 184.07; found, 185.1 (M + H<sup>+</sup>).</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2,2-Dimethyl-<i>N</i>-(5-pyridin-2-yl-thiazol-2-yl)propionamide (<b>8a</b>)</h3><div class="NLM_p last">A mixture of 2,2-dimethyl-<i>N</i>-thiazol-2-yl-propionamide (<b>7</b>, 10 mmol), 2-chloropyridine (10 mmol), cesium fluoride (20 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.5 mmol) in dimethyl sulfoxide (20 mL) was heated at 160 °C under an argon atmosphere for 16 h. The resultant mixture was partitioned with 0.5 N HCl (150 mL) and CH<sub>2</sub>Cl<sub>2</sub> (150 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, concentrated under reduced pressure, and purified by chromatography on silica gel (3% acetone/CH<sub>2</sub>Cl<sub>2</sub>) to give the desired product <b>8a</b> as a pale brown solid (20%, precursor of <b>13</b>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.84 (s, 1H), 8.49 (d, <i>J</i> = 4.5 Hz, 1H), 8.16 (s, 1H), 7.88 (d, <i>J</i> = 7.2 Hz, 1H), 7.82–7.76 (m, 1H), 7.23 (t, <i>J</i> = 6.2 Hz, 1H), 1.24 (s, 9H); MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>15</sub>N<sub>3</sub>OS, 261.09; found, 262.1 (M + H<sup>+</sup>).</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure for the Preparation of Compounds <b>8b</b>–<b>8d</b></h3><div class="NLM_p">A mixture of 2,2-dimethyl-<i>N</i>-thiazol-2-yl-propionamide (<b>7</b>, 30 mmol), 3-chloropyridine, 4-chloropyridine or 5-chloropyrimidine (30 mmol), potassium acetate (120 mmol), and tetrakis(triphenylphosphine)palladium(0) (1.5 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (60 mL) was heated at 150 °C under an argon atmosphere for 24 h. Most of solvent was removed by distillation (120 °C /160 mm Hg) and the residue was washed with water (250 mL). The precipitate was collected by filtration, redissolved in 10% CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub> (200 mL), and filtered through a pad of celite. The filtrate was concentrated under reduced pressure and purified by chromatography on silica gel (1% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to give the desired product as an off-white solid (40–85%). Only representative compounds <b>8b</b> (precursor of <b>14</b>) and <b>8c</b> (precursor of <b>15</b>) were selected to show their NMR and mass spectra.</div><div id="sec6_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2,2-Dimethyl-<i>N</i>-(5-pyridin-3-yl-thiazol-2-yl)propionamide (<b>8b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, δ): 9.43 (s, 1H), 8.85 (s, 1H), 8.55 (d, <i>J</i> = 4.8 Hz, 1H), 7.82 (dd, <i>J</i> = 5.6, 4.4 Hz, 1H), 7.70 (d, <i>J</i> = 1.2 Hz, 1H), 7.34 (dd, <i>J</i> = 4.8, 3.2 Hz, 1H), 1.36 (s, 9H); MS (ES<sup>+</sup>) m/z calcd for C<sub>13</sub>H<sub>15</sub>N<sub>3</sub>OS, 261.09; found, 262.2 (M + H<sup>+</sup>).</div></div><div id="sec6_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2,2-Dimethyl-<i>N</i>-(5-pyridin-4-yl-thiazol-2-yl)propionamide (<b>8c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub><sup>,</sup> δ): 9.28 (bs, 1H), 8.61 (dd, <i>J</i> = 4.8, 1.6 Hz, 2H), 7.84 (s, 1H), 7.42 (dd, <i>J</i> = 4.8, 1.6 Hz, 2H), 1.38 (s, 9H); MS (ES<sup>+</sup>) m/z calcd for C<sub>13</sub>H<sub>15</sub>N<sub>3</sub>OS, 261.09; found, 262.1 (M + H<sup>+</sup>).</div></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for the Preparation of Amine Analogues <b>9</b></h3><div class="NLM_p">A mixture of <b>8</b> (5 mmol) and 12 N HCl (5 mL) in water (5 mL) was heated to reflux for 2 h. Most of solvent was removed under reduced pressure and the residue was diluted with CH<sub>3</sub>OH (15 mL). Most of solvent was removed by distillation and the residue was dried in vacuo to give <b>9</b> hydrochloride as a pale brown solid. A stirred suspension of the above solid in water (30 mL) at room temperature was adjusted to pH = 7 with sodium bicarbonate and the mixture was stirred at 50 °C for 2 h. The precipitate was collected by filtration and dried in vacuo to give the desired product as a pale brown solid <b>9</b> (85–90%). Only representative compounds <b>9b</b> (precursor of <b>14</b>) and <b>9c</b> (precursor of <b>15</b>) were selected to show their NMR and mass spectra.</div><div id="sec6_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 5-Pyridin-3-yl-thiazol-2-ylamine (<b>9b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 8.66 (d, <i>J</i> = 2.4 Hz, 1H), 8.35 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 7.81–7.78 (m, 1H), 7.54 (s, 1H), 7.35–7.31 (m, 3H); MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>7</sub>N<sub>3</sub>S, 177.04; found, 178.1 (M + H<sup>+</sup>).</div></div><div id="sec6_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 5-Pyridin-4-yl-thiazol-2-ylamine (<b>9c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 8.41 (dd, <i>J</i> = 4.8, 1.5 Hz, 2H), 7.73 (s, 1H), 7.48 (s, 2H), 7.35 (dd, <i>J</i> = 4.8, 1.5 Hz, 2H); MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>7</sub>N<sub>3</sub>S: 177.04; found, 178.1 (M + H<sup>+</sup>).</div></div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure for the Preparation of Pyrimidine Analogues <b>11</b> and <b>18</b></h3><div class="NLM_p">To a mixture of <b>9</b>, <b>10</b>, or <b>17</b> (4 mmol) and 4,6-dichloropyrimidine (8 mmol) in 1-methyl-2-pyrrolidinone (20 mL) at 0 °C was added sodium hydride (60% in oil, 10 mmol) and the mixture was stirred at 0 °C under an argon atmosphere for 1 h. The reaction was quenched with water (100 mL) at 0 °C and was adjusted to pH = 2 with 6 N HCl. The slurry was adjusted to pH = 7 with sodium bicarbonate and the precipitate was collected by filtration, washed with water (50 mL), and dried in vacuo. The residue was purified by chromatography on silica gel (20% EtOAc/CH<sub>2</sub>Cl<sub>2</sub> and then 5 to 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> gradient) to give the desired product <b>11</b> or <b>18</b> as a brown solid (45–60%). Only representative compound <b>11c</b> (precursor of <b>15</b>) was selected to show its NMR and mass spectrum.</div><div id="sec6_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (6-Chloro-2-methylpyrimidin-4-yl)-(5-pyridin-4-yl-thiazol-2-yl)amine (<b>11c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 12.15 (s, 1H), 8.53 (dd, <i>J</i> = 4.5, 1.5 Hz, 2H), 8.18 (s, 1H), 7.59 (dd, <i>J</i> = 4.5, 1.5 Hz, 2H), 6.90 (s, 1H), 2.59 (s, 3H); MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>10</sub>ClN<sub>5</sub>S, 303.03; found, 304.1 (M + H<sup>+</sup>).</div></div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure for the Preparation of Compounds <b>12</b>–<b>14</b>, <b>15a</b>–<b>15e</b>, <b>15g</b>, <b>16</b>, and <b>19</b></h3><div class="NLM_p">A mixture of compound <b>11</b> or <b>18</b> (2 mmol) and 2° amine (8 mmol) in dimethyl sulfoxide (2 mL) was heated at 100 °C for 1 h. After cooling to room temperature, the mixture was diluted with water (50 mL). The precipitate was collected by filtration, washed with water (10 mL), and dried in vacuo. The residue was purified by chromatography on aluminum oxide (0.5 to 1.5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> gradient) to give a freebase of each compound <b>12</b>–<b>14</b>, <b>15a</b>–<b>15e</b>, <b>15g</b>, or <b>19</b> as an off-white solid. To a stirred 6 N HCl (10 mL) at 0 °C was added the above solid and the solution was filtered through a 0.45 μm PVDF membrane. To the stirred filtrate was added acetone (40 mL) dropwise over the course of 1 h and the mixture was stirred for an additional 1 h at 0 °C. The precipitate was collected by filtration, washed with acetone (15 mL), and dried in vacuo to give the HCl salt of each compound <b>12</b>–<b>14</b>, <b>15a</b>–<b>15e</b>, <b>15g</b>, or <b>19</b> as a yellow solid (90–95%).</div><div id="sec6_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> [6-(4-Ethylpiperazin-1-yl)-2-methyl-pyrimidin-4-yl]-(5-phenyl-thiazol-2-yl)amine Hydrochloride (<b>12</b>)</h4><div class="NLM_p last">Mp 339.1 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.19 (bs, 1H), 7.74 (s, 1H), 7.56 (d, <i>J</i> = 7.6 Hz, 2H), 7.39–7.35 (m, 2H), 7.25 (d, <i>J</i> = 7.2 Hz, 1H), 6.03 (s, 1H), 3.60–3.40 (m, 4H), 2.40–2.30 (m, 7H), 2.32 (q, <i>J</i> = 6.8 Hz, 2H), 1.00 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 165.6, 162.8, 159.2, 157.7, 134.3, 132.7, 130.4, 129.5, 127.3, 125.7, 82.6, 52.4, 52.1, 44.0, 26.1, 12.4; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>N<sub>6</sub>S, 380.18; found, 381.4 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>20</sub>H<sub>25</sub>N<sub>6</sub>S, 381.1861; found, 381.1863; HPLC (condition A) <i>t</i><sub>R</sub> = 15.82 min, 100%, (condition B) <i>t</i><sub>R</sub> = 17.50 min, 99.9%.</div></div><div id="sec6_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> [6-(4-Ethylpiperazin-1-yl)-2-methyl-pyrimidin-4-yl]-(5-pyridin-2-yl-thiazol-2-yl)amine Hydrochloride (<b>13</b>)</h4><div class="NLM_p last">Mp 295–296 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.34 (s, 1H), 8.54 (d, <i>J</i> = 4.8 Hz, 1H), 8.32 (s, 1H), 8.01–7.96 (m, 2H), 7.40–7.34 (m, 1H), 6.31 (s, 1H), 4.37 (d, <i>J</i> = 13.2 Hz, 2H), 3.62–3.38 (m, 4H), 3.20–2.90 (m, 4H), 2.47 (s, 3H), 1.26 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (75 MHz, D<sub>2</sub>O) δ 8.6, 21.8, 42.6, 50.1, 52.3, 84.8, 123.3, 123.5, 124.2, 139.9, 142.1, 144.3, 145.2, 154.4, 157.6, 161.6, 162.7; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>S, 381.17; found, 382.2 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>S, 382.1814; found, 382.1816 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 15.44 min, 99.3%, (condition B) <i>t</i><sub>R</sub> = 18.35 min, 99.6%.</div></div><div id="sec6_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> [6-(4-Ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl]-(5-pyridin-3-yl-thiazol-2-yl)amine Hydrochloride (<b>14a</b>)</h4><div class="NLM_p last">Mp 298–299 °C.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.23 (bs, 1H), 9.15 (s, 1H), 8.68 (d, <i>J</i> = 5.2 Hz, 1H), 8.60 (d, <i>J</i> = 8.0 Hz, 1H), 8.19 (s, 1H), 7.93 (t, <i>J</i> = 6.2 Hz, 1H), 6.21 (s, 1H), 4.35 (d, <i>J</i> = 14.4 Hz, 2H), 3.55 (d, <i>J</i> = 11.6 Hz, 2H), 3.40 (t, <i>J</i> = 13.2 Hz, 2H), 3.13 (t, <i>J</i> = 5.8 Hz, 2H), 3.01 (q, <i>J</i> = 6.9 Hz, 2H), 2.50 (s, 3H), 1.28 (t, <i>J</i> = 6.6 Hz, 3H); <sup>13</sup>C NMR (75 MHz, D<sub>2</sub>O, δ): 9.6, 22.9, 43.5, 51.1, 53.3, 85.2, 125.4, 128.7, 132.1, 137.6, 138.0, 140.2, 142.8, 155.0, 159.2, 162.2, 162.4; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>S, 381.17; found, 382.2 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>S, 382.1814; found, 382.1815 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 12.15 min, 99.8%, (condition B) <i>t</i><sub>R</sub> = 22.47 min, 93.6%.</div></div><div id="sec6_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> [6-(4-Ethylpiperazin-1-yl)-pyrimidin-4-yl]-(5-pyridin-3-yl-thiazol-2-yl)amine Hydrochloride (<b>14b</b>)</h4><div class="NLM_p last">Mp 256–257 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.10 (s, 1H), 8.84–8.81 (m, 2H), 7.63 (s, 1H), 7.49–7.43 (m, 6H), 7.32 (s, 1H), 7.29 (s, 1H), 6.03 (s, 1H), 3.48 (br s, 4H), 2.40–2.30 (m, 9H), 1.01 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d<sub>6</sub></i>) δ 12.4, 26.1, 44.0, 52.1, 52.4, 82.6, 110.0, 119.2, 120.2, 125.3, 125.8, 129.1, 130.6, 133.1, 139.0, 139.1, 152.8, 157.7, 158.6, 162.9, 165.6; MS (ES<sup>+</sup>) m/z calcd for C<sub>27</sub>H<sub>29</sub>ClN<sub>8</sub>OS, 548.19; found, 549.2 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>27</sub>H<sub>30</sub>ClN<sub>8</sub>OS, 549.1952; found, 549.1948 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 25.92 min, 97.4%, (condition B) <i>t</i><sub>R</sub> = 28.18 min, 97.5%.</div></div><div id="sec6_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> [6-(4-Ethylpiperazin-1-yl)-2-methyl-pyrimidin-4-yl]-(5-pyridin-4-yl-thiazol-2-yl)amine Hydrochloride (<b>15a</b>)</h4><div class="NLM_p last">Mp 343–344 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.55 (bs, 1H), 8.72 (d, <i>J</i> = 5.6 Hz, 2H), 8.61 (s, 1H), 8.14 (d, <i>J</i> = 5.2 Hz, 2H), 6.27 (s, 1H), 4.35 (d, <i>J</i> = 13.2 Hz, 2H), 3.55 (d, <i>J</i> = 12.0 Hz, 2H), 3.45 (t, <i>J</i> = 13.0 Hz, 2H), 3.13 (t, <i>J</i> = 5.8 Hz, 2H), 3.02 (q, <i>J</i> = 10.0 Hz, 2H), 2.50 (s, 3H), 1.28 (t, <i>J</i> = 6.8 Hz, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O, δ): 8.0, 21.6, 41.8, 49.6, 51.8, 84.1, 120.7, 125.4, 140.2, 141.0, 147.6, 153.8, 158.3, 161.5, 163.2; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>S, 381.17; found, 382.2 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>S, 382.1814; found, 382.1820 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 9.77 min, 100.0%, (condition B) <i>t</i><sub>R</sub> = 10.61 min, 100.0%.</div></div><div id="sec6_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> [6-(4-Ethylpiperazin-1-yl)-pyrimidin-4-yl]-(5-pyridin-4-yl-thiazol-2-yl)amine Hydrochloride (<b>15b</b>)</h4><div class="NLM_p last">Mp 236–241 °C.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.46 (bs, 1H), 8.72 (d, <i>J</i> = 6.8 Hz, 2H), 8.62 (s, 1H), 8.50 (s, 1H), 8.14 (d, <i>J</i> = 6.4 Hz, 2H), 6.41 (s, 1H), 4.33 (d, <i>J</i> = 13.2 Hz, 2H), 3.54 (d, <i>J</i> = 11.6 Hz, 2H), 3.44 (t, <i>J</i> = 13.2 Hz, 2H), 3.20–2.96 (m, 4H), 1.27 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O, δ): 8.6, 41.9, 50.2, 52.3, 86.6, 121.5, 126.1, 140.8, 141.9, 148.2, 151.5, 153.0, 159.8, 164.0; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>21</sub>N<sub>7</sub>S, 367.16; found, 368.1 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>18</sub>H<sub>22</sub>N<sub>7</sub>S, 368.1657; found, 368.1661 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 6.70 min, 99.7%, (condition B) <i>t</i><sub>R</sub> = 9.99 min, 99.0%.</div></div><div id="sec6_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> {6-[4-(2-Fluoroethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-yl}-(5-pyridin-4-yl-thiazol-2-yl)amine hydrochloride (<b>15c</b>)</h4><div class="NLM_p last">Mp 281–283 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.89 (bs, 1H), 8.73 (d, <i>J</i> = 6.3 Hz, 2H), 8.62 (s, 1H), 8.15 (d, <i>J</i> = 5.7 Hz, 2H), 6.26 (s, 1H), 4.95 (d, <i>J</i> = 47.4 Hz, 2H), 4.38 (s, 2H, overlapping with water peak), 3.70–3.35 (m, 6H), 3.18 (bs, 2H), 2.50 (s, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O, δ): 22.3, 42.1, 51.2, 56.6 (d, <i>J</i> = 19 Hz), 77.8 (d, <i>J</i> = 166 Hz), 84.6, 121.4, 125.9, 140.8, 141.5, 148.4, 154.3, 159.5, 162.4, 164.0; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>FN<sub>7</sub>S, 399.16; found, 400.1 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>23</sub>FN<sub>7</sub>S, 400.1720; found, 400.1719 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 8.99 min, 99.7%, (condition B) <i>t</i><sub>R</sub> = 11.44 min, 99.1%.</div></div><div id="sec6_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-{4-[2-Methyl-6-(5-pyridin-4-yl-thiazol-2-ylamino)pyrimidin-4-yl]-piperazin-1-yl}ethanol Hydrochloride (<b>15d</b>)</h4><div class="NLM_p last">Mp 287–288 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.03 (s, 1H), 8.73 (d, <i>J</i> = 7.2 Hz, 2H), 8.63 (s, 1H), 8.15 (d, <i>J</i> = 7.2 Hz, 2H), 6.26 (s, 1H), 4.34 (d, <i>J</i> = 12.4 Hz, 2H), 3.82 (t, <i>J</i> = 5.2 Hz, 2H), 3.62 (d, <i>J</i> = 12.0 Hz, 2H), 3.43 (t, <i>J</i> = 12.4 Hz, 2H), 3.30–3.09 (m, 4H), 2.49 (s, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O, δ): 22.2, 42.1, 50.9, 54.8, 58.1, 84.7, 121.3, 126.0, 140.8, 141.6, 148.3, 154.3, 159.0, 162.2, 163.8; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>OS: 397.17; found, 398.1 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>OS, 398.1763; found, 398.1767 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 7.92 min, 100.0%, (condition B) <i>t</i><sub>R</sub> = 10.50 min, 100.0%.</div></div><div id="sec6_7_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> [6-(4-Dimethylaminopiperidin-1-yl)-2-methylpyrimidin-4-yl]-(5-pyridin-4-yl-thiazol-2-yl)amine Hydrochloride (<b>15e</b>)</h4><div class="NLM_p last">Mp 323–324 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.07 (s, 1H), 8.73 (d, <i>J</i> = 6.9 Hz, 2H), 8.62 (s, 1H), 8.15 (d, <i>J</i> = 6.9 Hz, 2H), 6.25 (s, 1H), 4.43 (d, <i>J</i> = 12.9 Hz, 2H), 3.44 (quin, <i>J</i> = 5.2 Hz, 1H), 2.94 (t, <i>J</i> = 12.5 Hz, 2H), 2.69 (d, <i>J</i> = 4.5 Hz, 6H), 2.49 (s, 3H), 2.15 (d, <i>J</i> = 10.5 Hz, 2H), 1.60 (q, <i>J</i> = 11.0 Hz, 2H); <sup>13</sup>C NMR (75 MHz, D<sub>2</sub>O, δ): 21.7, 25.5, 39.8, 44.4, 62.1, 84.6, 121.2, 126.3, 140.8, 142.0, 148.3, 154.8, 156.3, 161.6, 163.5; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>7</sub>S: 395.19; found: 396.1 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>20</sub>H<sub>26</sub>N<sub>7</sub>S: 396.1970; found, 396.1976 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 9.19 min, 98.7%, (condition B) <i>t</i><sub>R</sub> = 11.43 min, 97.6%.</div></div><div id="sec6_7_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> [2-Methyl-6-(2-morpholin-4-yl-ethoxy)pyrimidin-4-yl]-(5-pyridin-4-yl-thiazol-2-yl)amine Hydrochloride (<b>15f</b>)</h4><div class="NLM_p">To a mixture of <b>11c</b> (1 mmol) and 4-(2-hydroxyethyl)morpholine (4 mmol) in diglyme (1 mL) at 100 °C was added potassium hydroxide (10 mmol) and the mixture was stirred at 160 °C under an argon atmosphere for 10 min. The reaction was quenched with water (20 mL) at 0 °C and was adjusted to pH = 2 with 6 N HCl. The slurry was adjusted to pH = 7 with sodium bicarbonate and the precipitate was collected by filtration, washed with water (10 mL), and dried in vacuo. The residue was purified by chromatography on aluminum oxide (0.5 to 1.5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> gradient) to give a freebase of <b>15f</b> as an off-white solid. To a suspension of the solid in MeOH (10 mL) at 0 °C was added 6 N HCl (1 mL) with stirring. Most of solvent was removed under reduced pressure and the residue was treated with EtOH (10 mL). The precipitate was collected by filtration, washed with acetone (10 mL), and dried in vacuo to give the desired product as a yellow solid (48%).</div><div class="NLM_p last">Mp 302–303 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.61 (s, 1H), 8.74 (d, <i>J</i> = 5.2 Hz, 2H), 8.64 (s, 1H), 8.17 (d, <i>J</i> = 5.2 Hz, 2H), 6.37 (s, 1H), 4.72 (s, 2H), 4.00–3.80 (m, 4H), 3.64–3.42 (m, 4H), 3.16 (bs, 2H), 2.59 (s, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O, δ): 22.6, 52.2, 55.3, 62.7, 63.5, 86.8, 120.8, 126.4, 140.6, 141.3, 148.1, 157.9, 162.6, 164.9, 165.9; MS (ES<sup>+</sup>) m/z calcd for C<sub>19</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S, 398.15; found, 399.2 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub>S, 399.1603; found, 399.1609 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 8.04 min, 99.9%, (condition B) <i>t</i><sub>R</sub> = 10.52 min, 99.7%.</div></div><div id="sec6_7_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> [6-(4-Ethylpiperazin-1-yl)-2-methyl-pyrimidin-4-yl]-[5-(2-methyl-pyridin-4-yl)thiazol-2-yl]amine Hydrochloride (<b>15g</b>)</h4><div class="NLM_p last">Mp 299–301 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.54 (s, 1H), 8.54 (s, 1H), 8.52 (d, <i>J</i> = 3.2 Hz, 1H), 7.99 (s, 1H), 7.95 (d, <i>J</i> = 6.0 Hz, 1H), 6.25 (s, 1H), 4.35 (s, 2H), 3.53 (d, <i>J</i> = 10.8 Hz, 2H), 3.43 (m, 2H), 3.11 (m, 2H), 3.00 (m, 2H), 2.68 (s, 3H), 2.47 (m, 3H), 1.26 (m, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O, δ): 8.8, 18.9, 25.1, 40.9, 49.5, 50.6, 84.2, 109.6, 118.4, 120.9, 125.2, 140.2, 143.7, 147.9, 152.8, 156.7, 161.2, 163.4, 164.9; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>S, 395.19; found, 396.2 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>S, 396.1970; found, 396.1975 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 9.35 min, 96.9%, (condition B) <i>t</i><sub>R</sub> = 11.79 min, 93.5%.</div></div><div id="sec6_7_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> [6-(4-Ethylpiperazin-1-yl)-2-methyl-pyrimidin-4-yl]-(5-pyrimidin-5-yl-thiazol-2-yl)amine Hydrochloride (<b>16</b>)</h4><div class="NLM_p last">Mp 354–355 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 11.35 (bs, 1H), 9.20–9.03 (m, 3H), 8.09 (s, 1H), 6.28 (s, 1H), 4.40 (s, 2H), 3.56 (d, <i>J</i> = 12.4 Hz, 2H), 3.44 (d, <i>J</i> = 7.4 Hz, 2H), 3.13 (bs, 2H), 3.02 (d, <i>J</i> = 8.0 Hz, 2H), 1.28 (bs, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O-<i>d</i><sub>6</sub>, δ): 8.6, 21.7, 42.3, 50.2, 52.3, 83.9, 123.4, 126.2, 134.8, 152.8, 153.3, 155.1, 158.9, 160.9, 161.3; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>S, 382.17; found, 383.3 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>S, 383.1766; found, 383.1764 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 13.07 min, 99.4%, (condition B) <i>t</i><sub>R</sub> = 15.52 min, 98.7%.</div></div><div id="sec6_7_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> [6-(4-Ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl]-(4-pyridin-3-yl-thiazol-2-yl)amine Hydrochlorid (<b>19</b>)</h4><div class="NLM_p last">Mp 72–74 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6,</sub> δ): 11.80 (bs, 1H), 11.54 (bs, 1H), 9.28 (s, 1H), 8.94 (d, <i>J</i> = 8.4 Hz, 1H), 8.84 (d, <i>J</i> = 5.2 Hz, 1H), 8.15–8.07 (m, 2H), 6.31 (bs, 2H), 4.35 (d, <i>J</i> = 14.0 Hz, 2H), 3.55 (d, <i>J</i> = 12.0 Hz, 2H), 3.45 (t, <i>J</i> = 13.0 Hz, 2H), 3.15–3.07 (m, 2H), 3.00 (q, <i>J</i> = 10.0 Hz, 2H), 2.49 (s, 3H), 1.27 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O, δ): 8.7, 22.0, 42.5, 50.1, 52.3, 83.4, 114.4, 127.6, 132.4, 137.8, 139.7, 142.1, 142.3, 153.1, 158.1, 160.2, 160.6; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>7</sub>S: 381.17; found, 382.1 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>S, 382.1814; found, 382.1798 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 12.76 min, 98.3%, (condition B) <i>t</i><sub>R</sub> = 13.95 min, 98.4%.</div></div><div id="sec6_7_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(4-Methylpiperazin-1-ylmethyl)-N-(5-pyridin-3-yl-thiazol-2-yl)benzamide Hydrochloride (<b>21</b>)</h4><div class="NLM_p">To a solution of <b>9b</b> (2 mmol) in pyridine (5 mL) at 0 °C was added 4-(4-methyl-piperazin-1-ylmethyl)benzoyl chloride (<b>20</b>, 3 mmol) and the mixture was stirred at room temperature under an argon atmosphere for 1 h. Most of solvent was removed under reduced pressure and the residue was washed with 1 N NaHCO<sub>3</sub> (10 mL). The precipitate was collected by filtration and purified by chromatography on silica gel (5 to 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> gradient) to give a freebase of <b>21</b> an off-white solid. To a suspension of the solid in MeOH (20 mL) at 0 °C was added 6 N HCl (2 mL) with stirring. Most of solvent was removed under reduced pressure and the residue was treated with EtOH (15 mL). The precipitate was collected by filtration, washed with acetone (15 mL), and dried in vacuo to give the desired product as a yellow solid (75%).</div><div class="NLM_p last">Mp 266–267 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ): 12.02 (bs, 1H), 9.20 (s, 1H), 8.73 (d, <i>J</i> = 5.2 Hz, 1H), 8.65 (d, <i>J</i> = 8.4 Hz, 1H), 8.36 (s, 1H), 8.20 (d, <i>J</i> = 8.4 Hz, 2H), 7.94 (q, <i>J</i> = 4.5 Hz, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 2H), 4.50 (bs, 2H), 3.70–3.35 (m, 8H), 2.81 (bs, 3H); MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>OS, 393.16; found, 394.1 (M + H<sup>+</sup>); HRMS (ESI) calcd for C<sub>21</sub>H<sub>24</sub>N<sub>5</sub>OS, 394.1702; found, 394.1701 (M + H<sup>+</sup>); HPLC (condition A) <i>t</i><sub>R</sub> = 11.78 min, 98.3%, (condition B) <i>t</i><sub>R</sub> = 14.96 min, 99.7%.</div></div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Biochemical Kinase Assays</h3><div class="NLM_p last">The recombinant His-c-KIT (residues T544 to end) was expressed in an Sf9 insect cell. The kinase assay was carried out in 96-well plates at 30 °C for 150 min in a final volume of 10 μL including the following components: 250 ng of c-KIT proteins, 40 mM Tris-HCl, pH 7.4, 2 mM MnCl<sub>2</sub>, 2 mM DTT, 20 mM MgCl<sub>2</sub>, 0.1 mg/mL bovine serum albumin, 40 μM poly(Glu,Tyr) 4:1, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 20 μM ATP. Following incubation, 5 μL of ADP-Glo reagent (Promega) was added and the mixture was incubated at 25 °C for 40 min. Ten microliters of KDR reagent was added and the mixture was incubated 25 °C for 30 min. Fifteen microliters of buffer and mixture was added. A 30 μL aliquot of each reaction mixture was transferred to a black microtiter plate and the luminescence was measured on a Wallac Vector 1420 multilabel counter. The recombinant GST-FLT3 (residues Y567 to S993) containing a kinase domain was expressed in Sf9 insect cells transfected the baculovirus containing a pBac-PAK8-GST-FLT3-KD plasmid. The FLT3 WT Kinase-Glo assays were carried out in 96-well plates at 30 °C for 4 h and tested the compound in a final volume of 50 μL including the following components: 75 ng of GST-FLT3 proteins, 25 mM HEPES, pH 7.4, 4 mM MnCl<sub>2</sub>, 10 mM MgCl<sub>2</sub>, 2 mM DTT, 0.02% Triton X-100, 0.1 mg/mL bovine serum albumin, 25 μM Her2 peptide substrate, 0.5 mM Na<sub>3</sub>VO<sub>4</sub>, and 1 μM ATP. Following incubation, 50 μL of Kinase-Glo Plus reagent (Promega, Madison, WI, USA) was added and the mixture was incubated at 25 °C for 20 min. A 70 μL aliquot of each reaction mixture was transferred to a black microtiter plate and the luminescence was measured on a Wallac Vector 1420 multilabel counter (PerkinElmer, Shelton, CT, USA).</div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> HotSpot Kinase Profiling Assays</h3><div class="NLM_p last">In vitro kinase profiling of c-KIT mutants and 38 kinases was performed at Reaction Biology Corporation. The assay conditions and protocol are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Kinase Expression, Purification, and Crystallization</h3><div class="NLM_p">The c-KIT kinase domain (residues 547–935), with the kinase insertion domain (residues 694–753) being deleted and replaced by a 6-nucleotide fragment encoding Thr-Ser, was cloned into a pBacPAK8 vector to generate recombinant baculovirus for protein expression. A 6x-histidine tag followed by a thrombin cleavage site was also added in-frame to the N-terminal of cloned c-KIT. Recombinant c-KIT was expressed in Sf9 insect cells and the cell pellets were suspended in Tris buffer (25 mM Tris-HCl, pH 7.6, 250 mM NaCl, and 0.5 mM TCEP) and lysed by sonication. The supernatant was loaded onto a HisTrap HP column (GE Life Sciences) and c-KIT containing the His tag was eluted by a liner imidazole gradient. The buffer was then exchanged to thrombin cleavage buffer (20 mM Tris-HCl, pH 8.4, 150 mM NaCl, and 2.5 mM CaCl<sub>2</sub>) and cleaved by thrombin at 4 °C overnight. After removal of the His tag, the buffer of recombinant c-KIT proteins was exchanged to 25 mM Tris-HCl, pH 7.6, 250 mM NaCl, and 5 mM DTT.</div><div class="NLM_p last">Recombinant c-KIT kinase was co-crystallized with <b>15a</b> by a hanging drop method. c-KIT proteins (7.0 mg/mL) were preincubated with 0.7 mM <b>15a</b> on ice and mixed with equal volume of reservoir solution (20% PEG3350 and 100 mM sodium citrate tribasic dihydrate, pH 5.6) and 2% benzamidine hydrochloride as an additive. Crystals were grown at 18 °C and immersed quickly in the reservoir solutions with additional cryoprotectants containing 8% ethylene glycol before being flash-frozen in liquid nitrogen. The X-ray diffraction data sets were collected at the beamline TPS05A (NSRRC, Taiwan) and processed with the HKL2000 program. The initial phases of c-KIT kinase domain structures were obtained by molecular replacement using the PHENIX package. The previously reported c-KIT structure (PDB code 1 T46) was used as a template. Structure refinement was performed using PHENIX and model building was carried out by COOT.</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Cell Lines and Cell Culture</h3><div class="NLM_p">GIST882, GIST430, and GIST48 cells were gifts from Dr. Jonathan A. Fletcher (Harvard Medical School, US). They were all cultured in incubators maintained at 37 °C and 5% CO<sub>2</sub>. GIST882 cells were cultured in RPMI-1640 supplemented with 20% fetal bovine serum (FBS). GIST48 cells were cultured with F10 supplemented with 20% FBS, 0.5% Mito, serum extender (BD Bioscience, 355006), and 1% pituitary extract bovine (BD Bioscience 354123). GIST430 cells were cultured in IMDM supplemented with 20% FBS.</div><div class="NLM_p last">MV4;11, Kasumi-1, RS4;11, U937, K562, BaF3, and HEK293T cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The MOLM-13 cell line was purchased from the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany). The GIST-T1 cell line was obtained from Cosmo Bio Co., Ltd (Tokyo, Japan). The GIST-T1, MOLM-13, MV4:11, RSV4;11, U937, K562, BaF3, BaF3/FLT3-ITD-F691L, and BaF3/FLT3-ITD-D835Y cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 10 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C and 5% CO<sub>2</sub>. The Kasumi-1 cells were cultured in RPMI 1640 medium supplemented with 20% fetal bovine serum (FBS), 1 mM Hepes, 1 mM sodium pyruvate, 10 U/mL penicillin, and 100 μg/mL streptomycin. The HEK293T and FLT3-transfected HEK293T cells were cultured in DMEM (Invitrogen, USA) medium with 10% FBS fetal bovine serum.</div></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> MTS Cell Viability Assay</h3><div class="NLM_p">GIST882, GIST430, or GIST48 cells (4 × 10<sup>4</sup>) were treated with different dosage of <b>15a</b>, imatinib, sunitinib, or regorafenib. The treated GIST882 cells were incubated for 144 h and GIST48 and GIST430 cells were incubated for 120 h at 37 °C in 5% CO<sub>2</sub>. Cell proliferation was determined by incubating the cells with methylene blue (Clontech, CA, USA) for 1 h. The absorbance was measured at 450 nm using a SpectraMax M5 microplate reader (Molecular Devices, USA).</div><div class="NLM_p last">The cell viability assay was performed by seeding 1 × 10<sup>4</sup> cells (MOLM-13, MV4:11, Kasumi-1, RS4;11, U937, K562, BaF3, BaF3/FLT3-D835Y, BaF3/FLT3-ITD-D835Y, and BaF3/FLT3-ITD-F691L) per well in a 96-well culture plate. GIST-T1 cells were seeded in a 96-well culture plate at density of 8 × 10<sup>3</sup> cells/100 μL. After 16 h, cells were then treated with vehicle or various concentrations of the compound in medium for 72 h. The viable cells were quantitated using the CellTiter 96 AQueous MTS method (Promega, Madison, WI, USA) according to the manufacturer’s recommended protocol. The results were determined by measuring the absorbance at 490 nm using a plate reader (Victor2; PerkinElmer, Shelton, CT, USA). The IC<sub>50</sub> value was defined as the amount of compound that caused 50% reduction in cell viability in comparison with DMSO-treated (vehicle) control and was calculated using Prism version 6 software (GraphPad, San Diego, CA, USA).</div></div><div id="sec6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Western Blot Analysis</h3><div class="NLM_p">GIST882, GIST430, or GIST48 cells were treated with 1 or 100 nM <b>15a</b> at the prespecified time points to evaluate the time effect. Cell lysates were extracted with the CelLytic M mammalian cell lysis/extraction solution purchased from Sigma (St. Louis, MO, USA). The cell lysates were resolved in SDS-PAGE gel and transferred to PVDF membranes (Bio-Rad, CA, USA). Nonspecific binding was blocked using 5% BSA/PBST for 1 h, washed four times with 0.1% Tween-20/PBS, and followed by incubating with designed primary antibodies overnight at 4 °C. The immunocomplexes were detected by probing with antimouse or antirabbit IgG conjugated with horseradish peroxidase and visualized using the Enhanced Chemiluminescence detection kit (PerkinElmer Western Lightning Plus-ECL; MA, USA). The primary antibodies, p-Akt, p-MEK, and p-MAPK were purchased from Cell Signaling Technology (Danvers, USA). Antibodies against GAPDH were purchased from Santa Cruz (TX, USA). Antibody against p-c-KIT was purchased from Invitrogen (Frederick, USA). c-KIT was purchased from DAKO (Carpinteria, USA).</div><div class="NLM_p last">Transfected HEK293T cells were lysed in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 1 mM PMSF, and 1 mM DTT). Protein lysates were resolved by SDS-PAGE and transferred onto a poly(vinylidene difluoride) (PVDF) membrane (Millipore, Bedford, MA, USA). The membranes were immunoblotted with appropriate antibodies and detected using the SuperSignal reagent (Pierce, Rockford, IL, USA) followed by exposure to an X-ray film. The anti-pFLT3-Tyr591 (no. 3461, Cell Signaling Technology) antibody was purchased for western blotting analysis.</div></div><div id="sec6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Pharmacokinetics</h3><div class="NLM_p last">Male ICR mice (25–35 g) and male Sprague Dawley rats (300–400 g) were obtained from BioLASCO (Taiwan Co., Ltd, Ilan, Taiwan). The animal studies were performed according to NHRI institutional animal care and committee-approved procedures. Rats were surgically prepared with a jugular-vein cannula 1 day before dosing. Rats and mice were fasted overnight (for approximately 18–20 h) before dosing. Water was available ad libitum throughout the experiment. Food was provided at 4 h after dosing. A single 2.0 and 10 mg/kg dose of compound, as a PEG400/DMA (80/20, v/v) solution, was separately administered to rats and mice. The groups consisted of three rats each route and a total of 33 and 27 mice for intravenously (IV) and oral gavage (PO), respectively. Each rat received 2 or 10 mL of the dosing solution/kg of body weight and each mouse was given 100 and 200 μL of dosing solution by intravenous injection and by gavage, respectively. At 0 (before dosing), 2, 5 (IV only), 15, and 30 min and at 1, 2, 4, 6, 8, 16 (mice only), and 24 h after dosing, a blood sample (0.15 mL) was collected from each rat through the jugular-vein cannula and ∼500 μL was collected from groups of three mice at each time point by cardiac puncture and stored in ice (0–4 °C). Immediately after collecting the blood sample, 150 mL of physiological saline (containing 30 Units of heparin per ml) was injected into the rat through the jugular-vein cannula. Plasma was separated from the blood by centrifugation (14,000<i>g</i> for 15 min at 4 °C in a Beckman Model AllegraTM 6R centrifuge) and stored in a freezer (−20 °C). All samples were analyzed for the parent drug by LC–MS/MS. Data were acquired through selected reaction ion monitoring. Plasma concentration data were analyzed with a noncompartmental method.</div></div><div id="sec6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Pharmacodynamic Studies</h3><div class="NLM_p last">PD studies were performed separately from the efficacy studies. GIST430-bearing NOD/SCID male mice were prepared by the same method as the efficacy study. Animals were randomized when average tumor volume reached to >100 mm<sup>3</sup>, followed by oral dosing of <b>15a</b> or vehicle. Tumors were collected at 16 h after administration. Tumors were excised, weighed, and stored at −80 °C. A portion of the tumor tissue was rinsed with phosphate-buffered saline buffer and then homogenized in RIPA buffer (no. 9806, Cell Signaling Technology) with protease/phosphatase inhibitors (B14001/B15001, Biotool, Houston, TX, USA). After the protein concentrations were quantified by Pierce bicinchoninic acid (BCA) assay kit (no. 23227, Thermo Scientific, Rockfold, IL, USA), 30 μg of protein lysate was subjected to SDS–polyacrylamide gel electrophoresis, followed by immunoblotting with antibodies (anti-c-KIT (no. 3308, Cell Signaling Technology), anti-p-c-KIT-Tyr703 (no. 3073, Cell Signaling Technology), and anti-β-actin (MA5-15739, Thermo Fisher)), and then detected using the SuperSignal reagent (Pierce, Rockford, IL, USA), followed by exposure to an X-ray film and quantification of the changes of c-KIT phosphorylation.</div></div><div id="sec6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Animal Studies</h3><div class="NLM_p">The animal use protocol was approved by National Health Research Institutes (protocol no: NHRI-IACUC-106076-A). NOD/SCID male mice were obtained from the National Laboratory Animal Center, Tainan, Taiwan. NOD/SCID female mice were purchased from Jackson Laboratories, Bar Habor, ME, USA. SCID male mice and athymic nude male mice were purchased from BioLASCO, Ilan, Taiwan. Compound <b>15a</b>, sunitinib (Selleckchem), and regorafenib (Ark Pharm, Inc.) were formulated in 20% (2-hydroxypropyl)-β-cyclodextrin (Sigma). For the GIST430 xenograft model, GIST430 cells (2 × 10<sup>7</sup>/mouse) were injected subcutaneously into NOD/SCID (6 to 8 weeks old) male mice. For the GIST exon 11/17 (GS5108 model) and exon 13/17 (GS5107 model) PDX studies, GS5108 cells (1 × 10<sup>5</sup>/mouse) and GS5107 cells (9.1 × 10<sup>4</sup>/mouse) were injected subcutaneously into NOD/SCID (6 to 8 weeks old) female mice. Both the PDX models were performed at Crown Biosciences. For the mouse xenograft model using leukemia cell lines, Kasumi-1 and MOLM-13 cells (1 × 10<sup>6</sup>/mouse) were injected subcutaneously into SCID and athymic nude (6 to 8 weeks old) male mice, respectively. Animals were randomized when average tumor volume reached approximately 210 mm<sup>3</sup> (<i>n</i> = 5) for GIST430 tumors, approximately 180 mm<sup>3</sup> (<i>n</i> = 6) for GS5108 tumors, approximately 230 mm<sup>3</sup> (<i>n</i> = 6) for GS5107 tumors, approximately 250 mm<sup>3</sup> (<i>n</i> = 8) for Kasumi-1 tumors, and approximately 370 mm<sup>3</sup> (<i>n</i> = 4) for MOLM-13 tumors, followed by oral dosing of compounds at the indicated dose levels, and schedules are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><div class="NLM_p last">Tumor size was measured with a digital caliper, and the tumor volume in mm<sup>3</sup> was calculated by the formula: volume = (length × width<sup>2</sup>)/2. All mice were monitored daily for signs of toxicity. Body weight and tumor size were measured twice or three times a week. Daily observations of health changes are possible during the experimental time. At the end of the studies, animals will then be euthanized by carbon dioxide inhalation followed by cervical dislocation.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01229" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60312" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60312" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01229?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01229</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Material and methods of HotSpot kinase profiling assays and antiproliferation assays; Figure S1, the TREEspot interaction maps and selectivity score of <b>15a</b>; Table S1, kinase inhibition profile of compound <b>15a</b>; Table S2, statistics of X-ray diffraction data and structure refinement for the c-KIT complex; Table S3, cell viability of cancer cell lines and normal cell line treated with <b>15a</b>; Figure S2, comparison of the antitumor effect of <b>15a</b> (15 mg/kg) and <b>2</b> (40 mg/kg) on GIST430 xenograft mouse model; <sup>1</sup>H and <sup>13</sup>C NMR spectrum of <b>15a</b> and HPLC reports for the purity check of compounds <b>15a</b>–<b>g</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Additional information for <b>14a</b>, <b>14b</b>, and <b>15a</b>–<b>5g</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf">jm9b01229_si_001.pdf (1.79 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_002.csv">jm9b01229_si_002.csv (3.47 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">6KLA (c-KIT/<b>15a</b>).</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01229" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-Jen Tsai</span> - <span class="hlFld-Affiliation affiliation">Division of Hematology/Oncology, Department of Internal
Medicine,
National Cheng Kung University Hospital, College of Medicine, 
     and , National Cheng Kung
University, Tainan City 704, Taiwan R.O.C.</span>; 
    <span class="hlFld-Affiliation affiliation">Division
of Hematology/Oncology, 
     and , Kaohsiung Medical University, Kaohsiung 807, Taiwan R.O.C.</span>; 
    <span class="hlFld-Affiliation affiliation">National
Institute of Cancer Research, National Health
Research Institutes, Tainan
City 704, Taiwan R.O.C.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7d1517090e1c143d13150f1453120f1a53090a"><span class="__cf_email__" data-cfemail="dfb7b5abacbeb69fb1b7adb6f1b0adb8f1aba8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weir-Torn Jiaang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8781-3538" title="Orcid link">http://orcid.org/0000-0001-8781-3538</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0f787b65666e6e61684f61677d6621607d68217b78"><span class="__cf_email__" data-cfemail="9ee9eaf4f7fffff0f9def0f6ecf7b0f1ecf9b0eae9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Hsing Lin</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Su-Ying Wu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2816-6961" title="Orcid link">http://orcid.org/0000-0003-2816-6961</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teng-Kuang Yeh</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiung-Tong Chen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jen-Shin Song</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-Yi Shiao</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ching-Chuan Kuo</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsu Hsu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng-Tai Lu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pei-Chen Wang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsung-Sheng Wu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Hui Peng</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-You Lin</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Cancer Research, National Health
Research Institutes, Tainan
City 704, Taiwan R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ching-Ping Chen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Ling Weng</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fang-Chun Kung</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mine-Hsine Wu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Chieh Su</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kuo-Wei Huang</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Cancer Research, National Health
Research Institutes, Tainan
City 704, Taiwan R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling-Hui Chou</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ching-Cheng Hsueh</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kuei-Jung Yen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Po-Chu Kuo</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen-Lung Huang</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Tzong Chen</span> - <span class="hlFld-Affiliation affiliation">Division of Hematology/Oncology, Department of Internal
Medicine,
National Cheng Kung University Hospital, College of Medicine, 
    Institute of
Molecular Medicine, 
     and , National Cheng Kung
University, Tainan City 704, Taiwan R.O.C.</span>; 
    <span class="hlFld-Affiliation affiliation">Division of Gastroenterology, Department
of Internal Medicine, Kaohsiung Medical University Hospital, 
     and , Kaohsiung Medical University, Kaohsiung 807, Taiwan R.O.C.</span>; 
    <span class="hlFld-Affiliation affiliation">National
Institute of Cancer Research, National Health
Research Institutes, Tainan
City 704, Taiwan R.O.C.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chuan Shih</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan
R.O.C.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.-H.L., S.-Y.W., and T.-K.Y. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the staff of beamlines TPS05A, BL15A1, and BL13B1 at the National Synchrotron Radiation Research Center (NSRRC), Taiwan, and SP44XU at the Spring-8, Japan, for technical assistance. The National Health Research Institutes, Ministry of Economic Affairs and National Science Council of Taiwan (MOST 103-2325-B-400-013) financially supported the study.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">c-KIT</td><td class="NLM_def"><p class="first last">stem cell factor receptor</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-like tyrosine kinase-3</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression-free survival</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">mOS</td><td class="NLM_def"><p class="first last">median overall survival</p></td></tr><tr><td class="NLM_term">CSF1R (FMS)</td><td class="NLM_def"><p class="first last">colony stimulating factor receptor</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">ITDs</td><td class="NLM_def"><p class="first last">internal tandem duplications</p></td></tr><tr><td class="NLM_term">AL</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">TKD</td><td class="NLM_def"><p class="first last">tyrosine kinase domain</p></td></tr><tr><td class="NLM_term">CBF</td><td class="NLM_def"><p class="first last">core-binding factor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">qd</td><td class="NLM_def"><p class="first last">once daily</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">complete regression</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04031" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04031" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">983</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)60106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2FS0140-6736%2813%2960106-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23623056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=973-983&author=H.+Joensuuauthor=P.+Hohenbergerauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2FS0140-6736%2813%2960106-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu, Heikki; Hohenberger, Peter; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">9896</span>),
    <span class="NLM_cas:pages">973-983</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that arise in the gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in the abdomen.  They can occur at any age, the median age being 60-65 years, and typically cause bleeding, anemia, and pain.  GISTs have variable malignant potential, ranging from small lesions with a benign behavior to fatal sarcomas.  Most tumors stain pos. for the mast/stem cell growth factor receptor KIT and anoctamin 1 and harbor a kinase-activating mutation in either KIT or PDGFRA.  Tumors without such mutations could have alterations in genes of the succinate dehydrogenase complex or in BRAF, or rarely RAS family genes.  About 60% of patients are cured by surgery.  Adjuvant treatment with imatinib is recommended for patients with a substantial risk of recurrence, if the tumor has an imatinib-sensitive mutation.  Tyrosine kinase inhibitors substantially improve survival in advanced disease, but secondary drug resistance is common.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnoEP2zf4WbVg90H21EOLACvtfcHk0lj591bgQoEChQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D&md5=11113c24bdb425aac4341372dea2e9bc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960106-3%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26spage%3D973%26epage%3D983%26doi%3D10.1016%2FS0140-6736%2813%2960106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miettinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasota, J.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span>. <i>Virchows Arch.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>438</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1007/s004280000338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1007%2Fs004280000338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=11213830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2001&pages=1-12&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%E2%80%93definition%2C+clinical%2C+histological%2C+immunohistochemical%2C+and+molecular+genetic+features+and+differential+diagnosis&doi=10.1007%2Fs004280000338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span></div><div class="casAuthors">Miettinen, Markku; Lasota, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 81 refs.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.  They are defined here as KIT (CD117, stem cell factor receptor)-pos. mesenchymal spindle cell or epithelioid neoplasms primary in the GI tract, omentum, and mesentery.  GISTs typically present in older individuals and are most common in the stomach (60-70%), followed by small intestine (20-25%), colon and rectum (5%), and esophagus (<5%).  Benign tumors outnumber the malignant ones by a wide margin.  Approx. 70% of GISTs are pos. for CD34, 20-30% are pos. for smooth muscle actin (SMA), 10% are pos. for S100 protein and <5% are pos. for desmin.  The expression of CD34 and SMA is often reciprocal.  GISTs commonly have activating mutations in exon 11 (or rarely exon 9 and exon 13) of the KIT gene that encodes a tyrosine kinase receptor for the growth factor named stem cell factor or mast cell growth factor.  Ligand-independent activation of KIT appears to be a strong candidate for mol. pathogenesis of GISTs, and it may be a target for future treatment for such tumors.  Other genetic changes in GISTs discovered using comparative genomic hybridization include losses in 14q and 22q in both benign and malignant GISTs and occurrence in various gains predominantly in malignant GISTs.  GISTs have phenotypic similarities with the interstitial cells of Cajal and, therefore, a histogenetic origin from these cells has been suggested.  An alternative possibility, origin of pluripotential stem cells, is also possible; this is supported by the same origin of Cajal cells and smooth muscle and by the common SMA expression in GISTs.  GISTs differ clin. and pathogenetically from true leiomyosarcomas (very rare in the GI tract) and leiomyomas.  The latter occur in the GI tract, predominantly in the esophagus (intramural tumors) and the colon and rectum (muscularis mucosae tumors).  They also differ from schwannomas that are benign S100-pos. spindle cell tumors usually presenting in the stomach.  GI autonomic nerve tumors (GANTs) are probably a subset of GIST.  Other mesenchymal tumors that have to be sepd. from GISTs include inflammatory myofibroblastic tumors in children, desmoid, and dedifferentiated liposarcoma.  Angiosarcomas and metastatic melanomas, both of which are often KIT-pos., should not be confused with GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeixqNq3cd-7Vg90H21EOLACvtfcHk0ljsyLsA-ceHpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D&md5=d2600b6aa118b36339ace603c1c9b87f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs004280000338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004280000338%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%25E2%2580%2593definition%252C%2520clinical%252C%2520histological%252C%2520immunohistochemical%252C%2520and%2520molecular%2520genetic%2520features%2520and%2520differential%2520diagnosis%26jtitle%3DVirchows%2520Arch.%26date%3D2001%26volume%3D438%26spage%3D1%26epage%3D12%26doi%3D10.1007%2Fs004280000338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad
Tunio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad%0ATunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0ljsyLsA-ceHpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarlomo-Rikala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tervahartiala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+kinase+inhibitor+STI571+in+a+patient+with+a+metastatic+gastrointestinal+stromal+tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2eaetTKJkIL55bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poveda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Muro, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Guerrero, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubedo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valverde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Broto, J.</span></span> <span> </span><span class="NLM_article-title">GEIS guidelines for gastrointestinal sarcomas (GIST)</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.ctrv.2016.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=28351781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A280%3ADC%252BC1cvitVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2017&pages=107-119&author=A.+Povedaauthor=X.+G.+Del+Muroauthor=J.+A.+L%C3%B3pez-Guerreroauthor=R.+Cubedoauthor=V.+Mart%C3%ADnezauthor=I.+Romeroauthor=C.+Serranoauthor=C.+Valverdeauthor=J.+Mart%C3%ADn-Broto&title=GEIS+guidelines+for+gastrointestinal+sarcomas+%28GIST%29&doi=10.1016%2Fj.ctrv.2016.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">GEIS guidelines for gastrointestinal sarcomas (GIST)</span></div><div class="casAuthors">Poveda Andres; Garcia Del Muro Xavier; Lopez-Guerrero Jose Antonio; Cubedo Ricardo; Martinez Virginia; Romero Ignacio; Serrano Cesar; Valverde Claudia; Martin-Broto Javier</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-119</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract.  They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes(1).  On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum.  GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists...) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours.  Following its introduction, median survival of patients with advanced or metastatic GIST increased from 18 to more than 60months.  Sunitinib and Regorafenib are two targeted agents with worldwide approval for second- and third-line treatment, respectively, in metastatic GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMuzx4_Tbipsjl5L8hwNX0fW6udTcc2eaetTKJkIL55bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvitVKrtg%253D%253D&md5=aed94085e7bdbb5c0d5b69039d49e8e2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DPoveda%26aufirst%3DA.%26aulast%3DDel%2BMuro%26aufirst%3DX.%2BG.%26aulast%3DL%25C3%25B3pez-Guerrero%26aufirst%3DJ.%2BA.%26aulast%3DCubedo%26aufirst%3DR.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DV.%26aulast%3DRomero%26aufirst%3DI.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DValverde%26aufirst%3DC.%26aulast%3DMart%25C3%25ADn-Broto%26aufirst%3DJ.%26atitle%3DGEIS%2520guidelines%2520for%2520gastrointestinal%2520sarcomas%2520%2528GIST%2529%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2017%26volume%3D55%26spage%3D107%26epage%3D119%26doi%3D10.1016%2Fj.ctrv.2016.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den%0AAbbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+M.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors&doi=10.1056%2FNEJMoa020461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0lhcmiPnaU9aFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480%26doi%3D10.1056%2FNEJMoa020461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span> <span> </span><span class="NLM_article-title">Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.13.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2007.13.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18235121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=620-625&author=C.+D.+Blankeauthor=G.+D.+Demetriauthor=M.+von+Mehrenauthor=M.+C.+Heinrichauthor=B.+Eisenbergauthor=J.+A.+Fletcherauthor=C.+L.+Corlessauthor=C.+D.+M.+Fletcherauthor=P.+J.+Robertsauthor=D.+Heinzauthor=E.+Wehreauthor=Z.+Nikolovaauthor=H.+Joensuu&title=Long-term+results+from+a+randomized+phase+II+trial+of+standard-versus+higher-dose+imatinib+mesylate+for+patients+with+unresectable+or+metastatic+gastrointestinal+stromal+tumors+expressing+KIT&doi=10.1200%2FJCO.2007.13.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT</span></div><div class="casAuthors">Blanke, Charles D.; Demetri, George D.; von Mehren, Margaret; Heinrich, Michael C.; Eisenberg, Burton; Fletcher, Jonathan A.; Corless, Christopher I.; Fletcher, Christopher D. M.; Roberts, Peter J.; Heinz, Daniela; Wehre, Elisabeth; Nikolova, Zariana; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown.  A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels.  We conducted a long-term anal. of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status.  Patients and Methods: Patients with advanced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to receive imatinib 400 vs. 600 mg/d.  Data were prospectively collected on KIT mutational status, total tumor area, and other potential prognostic factors.  Patients were followed for a median of 63 mo.  Results: One hundred forty-seven patients were enrolled: 73 were in arm A (imatinib 400 mg/d), and 74 were in arm B (imatinib 600 mg/d).  Response rates, median progression-free survival, and median overall survival were essentially identical on both arms, and median survival was 57 mo for all patients.  Forty-one patients overall (28%) remained on the drug long-term.  Female sex, the presence of an exon 11 mutation, and normal albumin and neutrophil levels were independently assocd. with better survival.  Conclusion: Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyVblFUfMWELVg90H21EOLACvtfcHk0lhIK0K2cL1z0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D&md5=c46d47e909e201a380a236246a2af159</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.4403%26sid%3Dliteratum%253Aachs%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinz%26aufirst%3DD.%26aulast%3DWehre%26aufirst%3DE.%26aulast%3DNikolova%26aufirst%3DZ.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DLong-term%2520results%2520from%2520a%2520randomized%2520phase%2520II%2520trial%2520of%2520standard-versus%2520higher-dose%2520imatinib%2520mesylate%2520for%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520gastrointestinal%2520stromal%2520tumors%2520expressing%2520KIT%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D620%26epage%3D625%26doi%3D10.1200%2FJCO.2007.13.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramwell, V. H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, E. C.</span></span> <span> </span><span class="NLM_article-title">Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.13.4452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2007.13.4452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18235122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1alsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=626-632&author=C.+D.+Blankeauthor=C.+Rankinauthor=G.+D.+Demetriauthor=C.+W.+Ryanauthor=M.+von+Mehrenauthor=R.+S.+Benjaminauthor=A.+K.+Raymondauthor=V.+H.+C.+Bramwellauthor=L.+H.+Bakerauthor=R.+G.+Makiauthor=M.+Tanakaauthor=J.+R.+Hechtauthor=M.+C.+Heinrichauthor=C.+D.+M.+Fletcherauthor=J.+J.+Crowleyauthor=E.+C.+Borden&title=Phase+III+Randomized%2C+Intergroup+Trial+Assessing+Imatinib+Mesylate+At+Two+Dose+Levels+in+Patients+With+Unresectable+or+Metastatic+Gastrointestinal+Stromal+Tumors+Expressing+the+Kit+Receptor+Tyrosine+Kinase%3A+S0033&doi=10.1200%2FJCO.2007.13.4452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033</span></div><div class="casAuthors">Blanke, Charles D.; Rankin, Cathryn; Demetri, George D.; Ryan, Christopher W.; von Mehren, Margaret; Benjamin, Robert S.; Raymond, A. Kevin; Bramwell, Vivien H. C.; Baker, Laurence H.; Maki, Robert G.; Tanaka, Michael; Hecht, J. Randolph; Heinrich, Michael C.; Fletcher, Christopher D. M.; Crowley, John J.; Borden, Ernest C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">626-632</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a std. dose (400 mg daily) vs. a high dose (400 mg twice daily).  Patients and Methods: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clin. trial.  At registration, patients were randomly assigned to either std. or high-dose imatinib, with close interval follow-up.  If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the std.-dose arm could reregister to the trial and receive the high-dose imatinib regimen.  Results: Seven hundred forty-six patients with advanced GIST from-148 centers across the United States and Canada were enrolled onto this trial in 9 mo.  With a median follow-up of 4.5 years, median progression-free survival was 18 mo for patients on the std.-dose arm, and 20 mo for those receiving high-dose imatinib.  Median overall survival was 55 and 51 mo, resp.  There were no statistically significant differences in objective response rates, progression-free survival, or overall survival.  After progression on std.-dose imatinib, 33% of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease.  There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm.  Conclusion: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment.  It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6phAEmNKA7Vg90H21EOLACvtfcHk0lhIK0K2cL1z0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1alsLs%253D&md5=ab64d4536338ce48e613ff17290f9f14</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.4452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.4452%26sid%3Dliteratum%253Aachs%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DRankin%26aufirst%3DC.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DRaymond%26aufirst%3DA.%2BK.%26aulast%3DBramwell%26aufirst%3DV.%2BH.%2BC.%26aulast%3DBaker%26aufirst%3DL.%2BH.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DHecht%26aufirst%3DJ.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DCrowley%26aufirst%3DJ.%2BJ.%26aulast%3DBorden%26aufirst%3DE.%2BC.%26atitle%3DPhase%2520III%2520Randomized%252C%2520Intergroup%2520Trial%2520Assessing%2520Imatinib%2520Mesylate%2520At%2520Two%2520Dose%2520Levels%2520in%2520Patients%2520With%2520Unresectable%2520or%2520Metastatic%2520Gastrointestinal%2520Stromal%2520Tumors%2520Expressing%2520the%2520Kit%2520Receptor%2520Tyrosine%2520Kinase%253A%2520S0033%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D626%26epage%3D632%26doi%3D10.1200%2FJCO.2007.13.4452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gounder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1007/s00280-010-1526-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1007%2Fs00280-010-1526-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1aisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=25-43&author=M.+M.+Gounderauthor=R.+G.+Maki&title=Molecular+basis+for+primary+and+secondary+tyrosine+kinase+inhibitor+resistance+in+gastrointestinal+stromal+tumor&doi=10.1007%2Fs00280-010-1526-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor</span></div><div class="casAuthors">Gounder, Mrinal M.; Maki, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">25-43</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Small mol. kinase inhibitors have irrevocably altered cancer treatment.  March 2010 marks the 10th anniversary of using imatinib in gastrointestinal stromal tumors (GIST), a cardinal example of the utility of such targeted therapy in a solid tumor.  Before imatinib, metastatic GIST was frustrating to treat due to its resistance to std. cytotoxic chemotherapy.  Median survival for patients with metastatic GIST improved from 19 to 60 mo with imatinib.  In treating patients with GIST, two patterns of tyrosine kinase inhibitor resistance have been obsd.  In the first, ∼9-14% of patients have progression within 3 mo of starting imatinib.  These patients are classified as having primary or early resistance.  Median progression-free survival (PFS) on imatinib is approx. 24 mo; patients with later progression are classified as having secondary or acquired resistance.  Primary studies and a meta-anal. of studies of imatinib in GIST patients have identified prognostic features that contribute to treatment failure.  One of the strongest predictors for success of therapy is KIT or PDGFRA mutational status.  Patients with KIT exon 11 mutant GIST have better response rates, PFS, and overall survival compared to other mutations.  A great deal has been learned in the last decade about sensitivity and resistance of GIST to imatinib; however, many unanswered questions remain about secondary resistance mechanisms and clin. management in the third- and fourth-line setting.  This review will discuss the role of dose effects, and early and late resistance to imatinib and their clin. implications.  Patients intolerant to imatinib (5%) and those who progress on imatinib are treated with sunitinib.  The mechanism of resistance to sunitinib is unknown at this time but is also appears related to growth of clones with secondary mutations in KIT.  Third- and fourth-line treatments of GIST and with future treatment strategies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCg0Z0wMSrHLVg90H21EOLACvtfcHk0liG47igDQOs7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1aisg%253D%253D&md5=cacc77383bbbca1c503a03074f1ac5e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1526-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1526-3%26sid%3Dliteratum%253Aachs%26aulast%3DGounder%26aufirst%3DM.%2BM.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26atitle%3DMolecular%2520basis%2520for%2520primary%2520and%2520secondary%2520tyrosine%2520kinase%2520inhibitor%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D25%26epage%3D43%26doi%3D10.1007%2Fs00280-010-1526-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumours: origin and molecular oncology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1038/nrc3143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fnrc3143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22089421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=865-878&author=C.+L.+Corlessauthor=C.+M.+Barnettauthor=M.+C.+Heinrich&title=Gastrointestinal+stromal+tumours%3A+origin+and+molecular+oncology&doi=10.1038%2Fnrc3143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumours: origin and molecular oncology</span></div><div class="casAuthors">Corless, Christopher L.; Barnett, Christine M.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">865-878</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are a paradigm for the development of personalized treatment for cancer patients.  The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumors set the stage for more accurate diagnosis and the development of kinase inhibitor therapy.  Subsequent studies of genotype and phenotype have led to a mol. classification of GIST and to treatment optimization on the basis of mol. subtype.  The study of drug-resistant tumors has advanced our understanding of kinase biol., enabling the development of novel kinase inhibitors.  Further improvements in GIST treatment may require targeting GIST stem cell populations and/or addnl. genomic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY7ze-9Y_FbVg90H21EOLACvtfcHk0liG47igDQOs7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I&md5=345c2287f7cdf8775b2a05114ccf5563</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3143%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBarnett%26aufirst%3DC.%2BM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DGastrointestinal%2520stromal%2520tumours%253A%2520origin%2520and%2520molecular%2520oncology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D865%26epage%3D878%26doi%3D10.1038%2Fnrc3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Call, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walentas, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherzer, N.</span></span> <span> </span><span class="NLM_article-title">Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">90</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-12-90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1186%2F1471-2407-12-90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22429770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos12msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=90&author=J.+Callauthor=C.+D.+Walentasauthor=J.+C.+Eickhoffauthor=N.+Scherzer&title=Survival+of+gastrointestinal+stromal+tumor+patients+in+the+imatinib+era%3A+life+raft+group+observational+registry&doi=10.1186%2F1471-2407-12-90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry</span></div><div class="casAuthors">Call, Jerry; Walentas, Christopher D.; Eickhoff, Jens C.; Scherzer, Norman</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Gastrointestinal stromal tumors (GIST), one of the most common mesenchymal tumors of the gastrointestinal tract, prior to routine immunohistochem. staining and the introduction of tyrosine kinase inhibitors, were often mistaken for neoplasms of smooth muscle origin such as leiomyomas, leiomyosarcomas or leiomyoblastomas.  Since the advent of imatinib, GIST has been further delineated into adult- (KIT or PDGFRα mutations) and pediatric- (typified by wild-type GIST/succinate dehydrogenase deficiencies) types.  Using varying gender ratios at age of diagnosis we sought to elucidate prognostic factors for each sub-type and their impact on overall survival.  Methods: This is a long-term retrospective anal. of a large observational study of an international open cohort of patients from a GIST research and patient advocacy's lifetime registry.  Demog. and disease-specific data were voluntarily supplied by its members from May 2000-Oct. 2010; the primary outcome was overall survival.  Assocns. between survival and prognostic factors were evaluated by univariate Cox proportional hazard analyses, with backward selection at P < 0.05 used to identify independent factors.  Results: Inflections in gender ratios by age at diagnosis in years delineated two distinct groups: above and below age 35 at diagnosis.  Closer anal. confirmed the above 35 age group as previously reported for adult-type GIST, typified by mixed primary tumor sites and gender, KIT or PDGFRα mutations and shorter survival times.  The pediatric group (< age 18 at diagnosis) was also as previously reported with predominantly stomach tumors, females, wild-type GIST or SDH mutations, and extended survival.  "Young adults" however formed a third group aged 18-35 at diagnosis and were a clear mix of these two previously reported distinct sub-types.  Conclusions: Pediatric- and adult-type GIST have been previously characterized in clin. settings and these observations confirm significant prognostic factors for each from a diverse real-world cohort.  Addnl., these findings suggest that extra diligence be taken with "young adults" (aged 18-35 at diagnosis) as pediatric-type GIST may present well beyond adolescence, particularly as these distinct sub-types have different causes, and consequently respond differently to treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKjgXc16iy87Vg90H21EOLACvtfcHk0lhvHYIeQkUprw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos12msbc%253D&md5=1b11f5d1caa2c42ee2c1c5767c3ddc58</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-12-90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-12-90%26sid%3Dliteratum%253Aachs%26aulast%3DCall%26aufirst%3DJ.%26aulast%3DWalentas%26aufirst%3DC.%2BD.%26aulast%3DEickhoff%26aufirst%3DJ.%2BC.%26aulast%3DScherzer%26aufirst%3DN.%26atitle%3DSurvival%2520of%2520gastrointestinal%2520stromal%2520tumor%2520patients%2520in%2520the%2520imatinib%2520era%253A%2520life%2520raft%2520group%2520observational%2520registry%26jtitle%3DBMC%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D90%26doi%3D10.1186%2F1471-2407-12-90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owzar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramwell, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertagnolli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5360</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.17.4284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2008.17.4284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18955451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5360-5367&author=M.+C.+Heinrichauthor=K.+Owzarauthor=C.+L.+Corlessauthor=D.+Hollisauthor=E.+C.+Bordenauthor=C.+D.+M.+Fletcherauthor=C.+W.+Ryanauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=C.+Rankinauthor=R.+S.+Benjaminauthor=V.+H.+Bramwellauthor=G.+D.+Demetriauthor=M.+M.+Bertagnolliauthor=J.+A.+Fletcher&title=Correlation+of+Kinase+Genotype+and+Clinical+Outcome+in+the+North+American+Intergroup+Phase+III+Trial+of+Imatinib+Mesylate+for+Treatment+of+Advanced+Gastrointestinal+Stromal+Tumor%3A+CALGB+150105+Study+by+Cancer+and+Leukemia+Group+B+and+Southwest+Oncology+Group&doi=10.1200%2FJCO.2008.17.4284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group</span></div><div class="casAuthors">Heinrich, Michael C.; Owzar, Kouros; Corless, Christopher L.; Hollis, Donna; Borden, Ernest C.; Fletcher, Christopher D. M.; Ryan, Christopher W.; von Mehren, Margaret; Blanke, Charles D.; Rankin, Cathryn; Benjamin, Robert S.; Bramwell, Vivien H.; Demetri, George D.; Bertagnolli, Monica M.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5360-5367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Imatinib mesylate is std. treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally.  In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing.  We examd. the relationship between kinase genotype and treatment outcome for 428 patients enrolled on the North American phase III study SWOG S0033/CALGB 150105 and treated with either 400 mg or 800 mg daily doses of imatinib.  The presence of KIT exon 11-mutant genotype (n = 283) correlated with improved treatment outcome when compared with KIT exon 9-mutant (n = 32) and wild-type (WT; n = 67) genotypes for objective response (complete response [CR]/partial response [PR], 71.7% v 44.4% [P = .007]; and 44.6% [P = .0002], resp.); time to tumor progression (TTP; median 24.7 mo v 16.7 and 12.8 mo, resp.); and overall survival (OS; median 60.0 mo v 38.4 and 49.0 mo, resp.).  The survival outcomes for patients with exon 9-mutant, exon 11-mutant or WT GIST were not affected by imatinib dose.  However, there was evidence of improved response rates for patients with exon 9-mutant tumors treated with imatinib 800 mg vs. 400 mg (CR/PR, 67% v 17%; P = .02).  Patients who had CD117-neg. GIST had similar TTP but inferior OS compared with patients who had CD117-pos. disease, which suggests that patients who have CD117-neg. GIST may benefit from imatinib treatment.  In addn., we identified novel but rare mutations of the KIT extracellular domain (exons 8 and 9).  We confirmed the favorable impact of KIT exon 11 genotype when compared with KIT exon 9 and wild-type genotype for patients with advanced GIST who are treated with imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEsXG_BaegR7Vg90H21EOLACvtfcHk0lhvHYIeQkUprw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D&md5=e172b60b8246817b8dd79fa23794f2fc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.4284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.4284%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DOwzar%26aufirst%3DK.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHollis%26aufirst%3DD.%26aulast%3DBorden%26aufirst%3DE.%2BC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DRankin%26aufirst%3DC.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DBramwell%26aufirst%3DV.%2BH.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBertagnolli%26aufirst%3DM.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCorrelation%2520of%2520Kinase%2520Genotype%2520and%2520Clinical%2520Outcome%2520in%2520the%2520North%2520American%2520Intergroup%2520Phase%2520III%2520Trial%2520of%2520Imatinib%2520Mesylate%2520for%2520Treatment%2520of%2520Advanced%2520Gastrointestinal%2520Stromal%2520Tumor%253A%2520CALGB%2520150105%2520Study%2520by%2520Cancer%2520and%2520Leukemia%2520Group%2520B%2520and%2520Southwest%2520Oncology%2520Group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5360%26epage%3D5367%26doi%3D10.1200%2FJCO.2008.17.4284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreevey, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4342</span>– <span class="NLM_lpage">4349</span>, <span class="refDoi"> DOI: 10.1200/JCO.2003.04.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.-J.+Chenauthor=A.+D.+Van+den%0AAbbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor&doi=10.1200%2FJCO.2003.04.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0lgJr2_jFVb95w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.-J.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349%26doi%3D10.1200%2FJCO.2003.04.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Gastrointestinal
Stromal Tumor Meta-Analysis Group (MetaGIST)</span> <span> </span><span class="NLM_article-title">Comparison of Two Doses of Imatinib for the Treatment
of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis
of 1,640 Patients</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.1200/JCO.2009.24.2099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2009.24.2099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=20124181" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1247-1253&author=Gastrointestinal%0AStromal+Tumor+Meta-Analysis+Group+%28MetaGIST%29&title=Comparison+of+Two+Doses+of+Imatinib+for+the+Treatment%0Aof+Unresectable+or+Metastatic+Gastrointestinal+Stromal+Tumors%3A+A+Meta-Analysis%0Aof+1%2C640+Patients&doi=10.1200%2FJCO.2009.24.2099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.24.2099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.24.2099%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DComparison%2520of%2520Two%2520Doses%2520of%2520Imatinib%2520for%2520the%2520Treatment%250Aof%2520Unresectable%2520or%2520Metastatic%2520Gastrointestinal%2520Stromal%2520Tumors%253A%2520A%2520Meta-Analysis%250Aof%25201%252C640%2520Patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1247%26epage%3D1253%26doi%3D10.1200%2FJCO.2009.24.2099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koryotowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leversha, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMatteo, R. P.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4190</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0liuCt2j8eeU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5352</span>– <span class="NLM_lpage">5359</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.15.7461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2007.15.7461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18955458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5352-5359&author=M.+C.+Heinrichauthor=R.+G.+Makiauthor=C.+L.+Corlessauthor=C.+R.+Antonescuauthor=A.+Harlowauthor=D.+Griffithauthor=A.+Townauthor=A.+McKinleyauthor=W.+B.+Ouauthor=J.+A.+Fletcherauthor=C.+D.+M.+Fletcherauthor=X.+Huangauthor=D.+P.+Cohenauthor=C.+M.+Baumauthor=G.+D.+Demetri&title=Primary+and+secondary+kinase+genotypes+correlate+with+the+biological+and+clinical+activity+of+sunitinib+in+imatinib-resistant+gastrointestinal+stromal+tumor&doi=10.1200%2FJCO.2007.15.7461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Maki, Robert G.; Corless, Christopher L.; Antonescu, Cristina R.; Harlow, Amy; Griffith, Diana; Town, Ajia; McKinley, Arin; Ou, Wen-Bin; Fletcher, Jonathan A.; Fletcher, Christopher D. M.; Huang, Xin; Cohen, Darrel P.; Baum, Charles M.; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5352-5359</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor α (PDGFRA) kinases, which are imatinib targets.  Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with GIST after they experience imatinib failure.  We evaluated the impact of primary and secondary kinase genotype on sunitinib activity.  Tumor responses were assessed radiol. in a phase I/II trial of sunitinib in 97 patients with metastatic, imatinib-resistant/intolerant GIST.  KIT/PDGFRA mutational status was detd. for 78 patients by using tumor specimens obtained before and after prior imatinib therapy.  Kinase mutants were biochem. profiled for sunitinib and imatinib sensitivity.  Clin. benefit (partial response or stable disease for ≥ 6 mo) with sunitinib was obsd. for the three most common primary GIST genotypes: KIT exon 9 (58%), KIT exon 11 (34%), and wild-type KIT/PDGFRA (56%).  Progression-free survival (PFS) was significantly longer for patients with primary KIT exon 9 mutations (P = .0005) or with a wild-type genotype (P = .0356) than for those with KIT exon 11 mutations.  The same pattern was obsd. for overall survival (OS).  PFS and OS were longer for patients with secondary KIT exon 13 or 14 mutations (which involve the KIT-ATP binding pocket) than for those with exon 17 or 18 mutations (which involve the KIT activation loop).  Biochem. profiling studies confirmed the clin. results.  The clin. activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-Yvw1bbDYrVg90H21EOLACvtfcHk0liuCt2j8eeU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D&md5=b84e19da0589f0ba6b12d8ed6b0da2c6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.15.7461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.15.7461%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DHarlow%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DMcKinley%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCohen%26aufirst%3DD.%2BP.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DPrimary%2520and%2520secondary%2520kinase%2520genotypes%2520correlate%2520with%2520the%2520biological%2520and%2520clinical%2520activity%2520of%2520sunitinib%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5352%26epage%3D5359%26doi%3D10.1200%2FJCO.2007.15.7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterom, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackstein, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69446-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2FS0140-6736%2806%2969446-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=17046465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Efficacy+and+safety+of+sunitinib+in+patients+with+advanced+gastrointestinal+stromal+tumour+after+failure+of+imatinib%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2806%2969446-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span></div><div class="casAuthors">Demetri, George D.; van Oosterom, Allan T.; Garrett, Christopher R.; Blackstein, Martin E.; Shah, Manisha H.; Verweij, Jaap; McArthur, Grant; Judson, Ian R.; Heinrich, Michael C.; Morgan, Jeffrey A.; Desai, Jayesh; Fletcher, Christopher D.; George, Suzanne; Bello, Carlo L.; Huang, Xin; Baum, Charles M.; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9544</span>),
    <span class="NLM_cas:pages">1329-1338</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumor are available.  We did a randomized, double-blind, placebo-controlled, multicenter, international trial to assess tolerability and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients with advanced gastrointestinal stromal tumor who were resistant to or intolerant of previous treatment with imatinib.  Blinded sunitinib or placebo was given orally once daily at a 50-mg starting dose in 6-wk cycles with 4 wk on and 2 wk off treatment.  The primary endpoint was time to tumor progression.  Intention-to-treat, modified intention-to-treat, and per-protocol analyses were done.  This study is registered at ClinicalTrials.gov, no. NCT00075218.  Three hundred and twelve patients were randomized in a 2:1 ratio to receive sunitinib (n = 207) or placebo (n=105); the trial was unblinded early when a planned interim anal. showed significantly longer time to tumor progression with sunitinib.  Median time to tumor progression was 27.3 wk (95% CI 16.0-32.1) in patients receiving sunitinib and 6.4 wk (4.4-10.0) in those on placebo (hazard ratio 0.33; p < 0.0001).  Therapy was reasonably well tolerated; the most common treatment-related adverse events were fatigue, diarrhea, skin discoloration, and nausea.  We noted significant clin. benefit, including disease control and superior survival, with sunitinib compared with placebo in patients with advanced gastrointestinal stromal tumor after failure and discontinuation of imatinib.  Tolerability was acceptable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6YRQ18H894LVg90H21EOLACvtfcHk0ljwHzvp7SGjhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL&md5=b21e01faede44c98f645be945c2638c0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969446-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969446-4%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2806%2969446-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badalamenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappeler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuss, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group">GRID study investigators</span> <span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23177515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Sch%C3%B6ffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casaliauthor=GRID+study+investigators&title=Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28GRID%29%3A+an+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Demetri, George D.; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, Piotr; Gelderblom, Hans; Hohenberger, Peter; Leahy, Michael; von Mehren, Margaret; Joensuu, Heikki; Badalamenti, Giuseppe; Blackstein, Martin; Le Cesne, Axel; Schoffski, Patrick; Maki, Robert G.; Bauer, Sebastian; Nguyen, Binh Bui; Xu, Jianming; Nishida, Toshirou; Chung, John; Kappeler, Christian; Kuss, Iris; Laurent, Dirk; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9863</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Until now, only imatinib and sunitinib have proven clin. benefit in patients with gastrointestinal stromal tumors (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression.  We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.We did this phase 3 trial at 57 hospitals in 17 countries.  Patients with histol. confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geog. region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 wk of each 4 wk cycle.  The study sponsor, participants, and investigators were masked to treatment assignment.  The primary endpoint was progression-free survival (PFS).  At disease progression, patients assigned placebo could crossover to open-label regorafenib.  Analyses were by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT01271712.From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66).  Data cutoff was Jan 26, 2012.  Median PFS per independent blinded central review was 4·8 mo (IQR 1·4-9·2) for regorafenib and 0·9 mo (0·9-1·8) for placebo (hazard ratio [HR] 0·27, 95% CI 0·19-0·39; p<0·0001).  After progression, 56 patients (85%) assigned placebo crossed over to regorafenib.  Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned placebo.  The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%).The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on std. treatments.  As far as we are aware, this is the first clin. trial to show benefit from a kinase inhibitor in this highly refractory population of patients.Bayer HealthCare Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2GIfYXBPyLVg90H21EOLACvtfcHk0lg9YMcCBYvUdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL&md5=f8ee42424a9b3bd7558b1a2f1461af33</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528GRID%2529%253A%2520an%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. M.</span></span> <span> </span><span class="NLM_article-title">Drug therapy for acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-01-0178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2005-01-0178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15870183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVejsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=1154-1163&author=M.+S.+Tallmanauthor=D.+G.+Gillilandauthor=J.+M.+Rowe&title=Drug+therapy+for+acute+myeloid+leukemia&doi=10.1182%2Fblood-2005-01-0178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Drug therapy for acute myeloid leukemia</span></div><div class="casAuthors">Tallman, Martin S.; Gilliland, D. Gary; Rowe, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1154-1163</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Although improvement in outcomes has occurred in younger adults with acute myeloid leukemia (AML) during the past 4 decades, progress in older adults has been much less conspicuous, if at all.  Approx. 50% to 75% of adults with AML achieve complete remission (CR) with cytarabine and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.  However, only approx. 20% to 30% of the patients enjoy long-term disease survival.  Various post-remission strategies have been explored to eliminate minimal residual disease.  The optimal dose, schedule, and no. of cycles of post-remission chemotherapy for most patients are not known.  A variety of prognostic factors can predict outcome and include the karyotype of the leukemic cells and the presence of transmembrane transporter proteins, which extrude certain chemotherapy agents from the cell and confer multidrug resistance and mutations in or over expressions of specific genes such as WT1, CEBPA, BAX and the ratio of BCL2 to BAX, BAALC, EVI1, KIT, and FLT3.  Most recently, insights into the mol. pathogenesis of AML have led to the development of more specific targeted agents and have ushered in an exciting new era of antileukemia therapy.  Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors, farnesyl transferase inhibitors, histone deacetylase and proteasome inhibitors, antiangiogenesis agents, Fms-like tyrosine kinase 3 (FLT3) inhibitors, and apoptosis inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzCcZj26mc7Vg90H21EOLACvtfcHk0lgVTEhqwFfHVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVejsLg%253D&md5=47612c984ffbba03ddbb344d59e9a7f9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-01-0178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-01-0178%26sid%3Dliteratum%253Aachs%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26atitle%3DDrug%2520therapy%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D1154%26epage%3D1163%26doi%3D10.1182%2Fblood-2005-01-0178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0lgVTEhqwFfHVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0lj8xP_SU5FT_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitruck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreitmeier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4372</span>– <span class="NLM_lpage">4380</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-05-1440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2002-05-1440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12393388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsFCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=4372-4380&author=S.+Fr%C3%B6hlingauthor=R.+F.+Schlenkauthor=J.+Breitruckauthor=A.+Bennerauthor=S.+Kreitmeierauthor=K.+Tobisauthor=H.+D%C3%B6hnerauthor=K.+D%C3%B6hner&title=Prognostic+significance+of+activating+FLT3+mutations+in+younger+adults+%2816+to+60+years%29+with+acute+myeloid+leukemia+and+normal+cytogenetics%3A+a+study+of+the+AML+Study+Group+Ulm&doi=10.1182%2Fblood-2002-05-1440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group Ulm</span></div><div class="casAuthors">Frohling, Stefan; Schlenk, Richard F.; Breitruck, Jochen; Benner, Axel; Kreitmeier, Sylvia; Tobis, Karen; Dohner, Hartmut; Dohner, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4372-4380</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To assess the prognostic relevance of activating mutations of the FLT3 gene in homogeneously treated adults 16 to 60 yr of age with acute myeloid leukemia (AML) and normal cytogenetics, pretreatment samples from 224 patients entered into 2 consecutive multicenter treatment trials were analyzed for FLT3 internal tandem duplications (ITDs) and Asp835 mutations.  Treatment included intensive double-induction therapy and postremission therapy with high cumulative doses of high-dose cytarabine.  ITDs were detected in 32% of the patients and were related to de novo AML and to high white blood cell (WBC) counts, percentages of peripheral blood (PB) and bone marrow (BM) blasts, and serum lactate dehydrogenase levels.  Asp835 mutations were present in 14% of the patients and were assocd. with WBC counts and percentages of PB and BM blasts that were higher than those of patients without FLT3 mutations.  With a median follow-up of 34 mo, remission duration and overall survival (OS) were significantly shorter for patients with Asp835 mutations or an ITD than for those without FLT3 mutations.  These results were attributable mainly to the neg. prognostic effect of FLT3 ITDs.  On multivariate anal., mutant FLT3 was an independent marker affecting remission duration and OS (hazard ratio, 2.35 and 2.11, resp.).  Fluorescence in situ hybridization did not detect monoallelic FLT3 deletions in ITD-pos. patients.  FLT3 mutations identify a subset of young AML patients with normal cytogenetics who do not benefit from intensive chemotherapy, including double-induction and postremission therapy with high-dose cytarabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5OxLOop4i7rVg90H21EOLACvtfcHk0lj8xP_SU5FT_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsFCqsL4%253D&md5=5720f6a42a67b4481b331219ad8e30ca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-05-1440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-05-1440%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DBreitruck%26aufirst%3DJ.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DKreitmeier%26aufirst%3DS.%26aulast%3DTobis%26aufirst%3DK.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26atitle%3DPrognostic%2520significance%2520of%2520activating%2520FLT3%2520mutations%2520in%2520younger%2520adults%2520%252816%2520to%252060%2520years%2529%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520normal%2520cytogenetics%253A%2520a%2520study%2520of%2520the%2520AML%2520Study%2520Group%2520Ulm%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D4372%26epage%3D4380%26doi%3D10.1182%2Fblood-2002-05-1440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kikushige, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niiro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagafuji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, K.</span></span> <span> </span><span class="NLM_article-title">Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">7358</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.180.11.7358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.4049%2Fjimmunol.180.11.7358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18490735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=7358-7367&author=Y.+Kikushigeauthor=G.+Yoshimotoauthor=T.+Miyamotoauthor=T.+Iinoauthor=Y.+Moriauthor=H.+Iwasakiauthor=H.+Niiroauthor=K.+Takenakaauthor=K.+Nagafujiauthor=M.+Haradaauthor=F.+Ishikawaauthor=K.+Akashi&title=Human+Flt3+is+expressed+at+the+hematopoietic+stem+cell+and+the+granulocyte%2Fmacrophage+progenitor+stages+to+maintain+cell+survival&doi=10.4049%2Fjimmunol.180.11.7358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival</span></div><div class="casAuthors">Kikushige, Yoshikane; Yoshimoto, Goichi; Miyamoto, Toshihiro; Iino, Tadafumi; Mori, Yasuo; Iwasaki, Hiromi; Niiro, Hiroaki; Takenaka, Katsuto; Nagafuji, Koji; Harada, Mine; Ishikawa, Fumihiko; Akashi, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7358-7367</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">FLT3/FLK2, a member of the receptor tyrosine kinase family, plays a crit. role in maintenance of hematopoietic homeostasis, and the constitutively active form of the FLT3 mutation is one of the most common genetic abnormalities in acute myelogenous leukemia.  In murine hematopoiesis, Flt3 is not expressed in self-renewing hematopoietic stem cells, but its expression is restricted to the multipotent and the lymphoid progenitor stages at which cells are incapable of self-renewal.  The authors extensively analyzed the expression of Flt3 in human (h) hematopoiesis.  Strikingly, in both the bone marrow and the cord blood, the human hematopoietic stem cell population capable of long-term reconstitution in xenogeneic hosts uniformly expressed Flt3.  Furthermore, human Flt3 is expressed not only in early lymphoid progenitors, but also in progenitors continuously along the granulocyte/macrophage pathway, including the common myeloid progenitor and the granulocyte/macrophage progenitor.  The authors further found that human Flt3 signaling prevents stem and progenitors from spontaneous apoptotic cell death at least through up-regulating Mcl-1, an indispensable survival factor for hematopoiesis.  Thus, the distribution of Flt3 expression is considerably different in human and mouse hematopoiesis, and human FLT3 signaling might play an important role in cell survival, esp. at stem and progenitor cells that are crit. cellular targets for acute myelogenous leukemia transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKXcrR-KQExrVg90H21EOLACvtfcHk0lj4Y93HYptNDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D&md5=3ff9bbe7a42c4ce0a87017014f7c3c2b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.180.11.7358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.180.11.7358%26sid%3Dliteratum%253Aachs%26aulast%3DKikushige%26aufirst%3DY.%26aulast%3DYoshimoto%26aufirst%3DG.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DIino%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DTakenaka%26aufirst%3DK.%26aulast%3DNagafuji%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DF.%26aulast%3DAkashi%26aufirst%3DK.%26atitle%3DHuman%2520Flt3%2520is%2520expressed%2520at%2520the%2520hematopoietic%2520stem%2520cell%2520and%2520the%2520granulocyte%252Fmacrophage%2520progenitor%2520stages%2520to%2520maintain%2520cell%2520survival%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D7358%26epage%3D7367%26doi%3D10.4049%2Fjimmunol.180.11.7358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Duhier, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodeve, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Care, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peake, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. T.</span></span> <span> </span><span class="NLM_article-title">Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2141.2001.02850.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1046%2Fj.1365-2141.2001.02850.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=11442493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2001&pages=983-988&author=F.+M.+Abu-Duhierauthor=A.+C.+Goodeveauthor=G.+A.+Wilsonauthor=R.+S.+Careauthor=I.+R.+Peakeauthor=J.+T.+Reilly&title=Identification+of+novel+FLT-3+Asp835+mutations+in+adult+acute+myeloid+leukaemia&doi=10.1046%2Fj.1365-2141.2001.02850.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia</span></div><div class="casAuthors">Abu-Duhier, F. M.; Goodeve, A. C.; Wilson, G. A.; Care, R. S.; Peake, I. R.; Reilly, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">983-988</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Genomic DNA from 97 cases of adult de novo acute myeloid leukemia (AML) was screened using polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) for FLT3 exon 20 mutations.  Initial sequencing of four cases, representing the spectrum of CSGE abnormalities, revealed changes affecting codon Asp835 in three cases and also an intron 20 A to G change.  In order to identify all possible Asp835 alterations, as well as the frequency of the intronic change nucleotide 2541+57 A→G, the patient PCR products were digested with EcoRV and NlaIII resp.  Seven cases (7.2%) possessed a mutation affecting Asp835; these were identified, following DNA sequencing, as Asp835Tyr (n = 5), Asp835His (n = 1) and Asp835del (n = 1).  Alterations affecting Asp835 were not found in 80 normal control DNA samples.  In contrast, the nucleotide 2541+57 A→G change was shown to be a polymorphism, with an allelic frequency of 0.24 for the G and 0.76 for the A allele.  This study reports, for the first time, point mutations in the human FLT3 gene that, because of their homol. with other class III receptor tyrosine kinase mutations, probably result in constitutive activation of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyMMv-RBFxCbVg90H21EOLACvtfcHk0lj4Y93HYptNDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D&md5=7989d20d19f76954dbeaf2fde89d8add</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2141.2001.02850.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2141.2001.02850.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Duhier%26aufirst%3DF.%2BM.%26aulast%3DGoodeve%26aufirst%3DA.%2BC.%26aulast%3DWilson%26aufirst%3DG.%2BA.%26aulast%3DCare%26aufirst%3DR.%2BS.%26aulast%3DPeake%26aufirst%3DI.%2BR.%26aulast%3DReilly%26aufirst%3DJ.%2BT.%26atitle%3DIdentification%2520of%2520novel%2520FLT-3%2520Asp835%2520mutations%2520in%2520adult%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2001%26volume%3D113%26spage%3D983%26epage%3D988%26doi%3D10.1046%2Fj.1365-2141.2001.02850.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boissel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brethon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvrignon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesnel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruchel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preudhomme, C.</span></span> <span> </span><span class="NLM_article-title">Acute Leukemia French Association (ALFA) and the Leucémies Aiguës Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">965</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fsj.leu.2404188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=16598313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVymtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=965-970&author=N.+Boisselauthor=H.+Leroyauthor=B.+Brethonauthor=N.+Philippeauthor=S.+de+Bottonauthor=A.+Auvrignonauthor=E.+Raffouxauthor=T.+Leblancauthor=X.+Thomasauthor=O.+Hermineauthor=B.+Quesnelauthor=A.+Baruchelauthor=G.+Levergerauthor=H.+Dombretauthor=C.+Preudhomme&title=Acute+Leukemia+French+Association+%28ALFA%29+and+the+Leuc%C3%A9mies+Aigu%C3%ABs+My%C3%A9loblastiques+de+l%E2%80%99Enfant+%28LAME%29+Cooperative+Groups.+Incidence+and+prognostic+impact+of+c-kit%2C+FLT3%2C+and+Ras+gene+mutations+in+core+binding+factor+acute+myeloid+leukemia+%28CBF-AML%29&doi=10.1038%2Fsj.leu.2404188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)</span></div><div class="casAuthors">Boissel, N.; Leroy, H.; Brethon, B.; Philippe, N.; de Botton, S.; Auvrignon, A.; Raffoux, E.; Leblanc, T.; Thomas, X.; Hermine, O.; Quesnel, B.; Baruchel, A.; Leverger, G.; Dombret, H.; Preudhomme, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">965-970</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In core binding factors (CBF) acute myeloid leukemia (AML), the disruption of CBFα/β genes impairs normal hematopoietic differentiation and is supposed to cooperate with addnl. mutations promoting proliferation.  The incidence and the prognosis of receptor tyrosine kinase (RTK) c-Kit and FLT3 mutations and Ras mutations were evaluated in 103 pediatric and adult patients with CBF-AML. c-Kit mutations were present in 17% patients. c-Kit exon 8 mutations were more frequent in inv(16) than in t(8;21) subset (20 vs. 6%).  Only one patient had FLT3-ITD but FLT3-D835 was as frequent as reported in AML population (7%).  Ras mutations were significantly more frequent in inv(16) than in t(8;21) subset (36 vs. 8%, P=0.001).  RTK mutations were assocd. with a higher white blood cell count (WBC) (36 vs. 21 G/L, P=0.05).  FLT3 mutations were significantly assocd. with a shorter EFS and survival (P<0.0001 and P=0.0002) owing to an excess of early events. c-Kit mutations were assocd. with a shorter EFS and RFS (P=0.002 and P=0.003) in t(8;21) but not inv(16) patients.  As previously obsd., Ras mutations did not affect prognosis.  Screening for RTK mutations may help to identify patients with a more adverse outcome and thus susceptible to benefit from intensified protocols or RTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS1ibFNaWpL7Vg90H21EOLACvtfcHk0lh0FYJWbXEycw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVymtL8%253D&md5=3157803f6302d4f4fcca7c3d0ceda228</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404188%26sid%3Dliteratum%253Aachs%26aulast%3DBoissel%26aufirst%3DN.%26aulast%3DLeroy%26aufirst%3DH.%26aulast%3DBrethon%26aufirst%3DB.%26aulast%3DPhilippe%26aufirst%3DN.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DAuvrignon%26aufirst%3DA.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DLeblanc%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DQuesnel%26aufirst%3DB.%26aulast%3DBaruchel%26aufirst%3DA.%26aulast%3DLeverger%26aufirst%3DG.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DPreudhomme%26aufirst%3DC.%26atitle%3DAcute%2520Leukemia%2520French%2520Association%2520%2528ALFA%2529%2520and%2520the%2520Leuc%25C3%25A9mies%2520Aigu%25C3%25ABs%2520My%25C3%25A9loblastiques%2520de%2520l%25E2%2580%2599Enfant%2520%2528LAME%2529%2520Cooperative%2520Groups.%2520Incidence%2520and%2520prognostic%2520impact%2520of%2520c-kit%252C%2520FLT3%252C%2520and%2520Ras%2520gene%2520mutations%2520in%2520core%2520binding%2520factor%2520acute%2520myeloid%2520leukemia%2520%2528CBF-AML%2529%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D965%26epage%3D970%26doi%3D10.1038%2Fsj.leu.2404188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzaniga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colapietro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elice, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadali, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larizza, L.</span></span> <span> </span><span class="NLM_article-title">KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15339674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2jsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2004&pages=920-925&author=A.+Beghiniauthor=C.+B.+Ripamontiauthor=R.+Cairoliauthor=G.+Cazzanigaauthor=P.+Colapietroauthor=F.+Eliceauthor=G.+Nadaliauthor=G.+Grilloauthor=O.+A.+Haasauthor=A.+Biondiauthor=E.+Morraauthor=L.+Larizza&title=KIT+activating+mutations%3A+incidence+in+adult+and+pediatric+acute+myeloid+leukemia%2C+and+identification+of+an+internal+tandem+duplication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication</span></div><div class="casAuthors">Beghini, Alessandro; Ripamonti, Carla B.; Cairoli, Roberto; Cazzaniga, Giovanni; Colapietro, Patrizia; Elice, Francesca; Nadali, Gianpaolo; Grillo, Giovanni; Haas, Oskar A.; Biondi, Andrea; Morra, Enrica; Larizza, Lidia</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">920-925</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Mutations of KIT receptor tyrosine kinase are involved in the constitutive activation and development of human hematol. malignancies.  Gain-of-function mutations in the second intracellular kinase domain (TK2) and in the juxtamembrane domain are described in patients with core binding factor acute myeloid leukemia (CBFL) and are assocd. with leukocytosis.  We evaluated the incidence of KIT mutation in 52 adult patients with de novo CBFL and in 49 FLT3/ITD-neg. childhood patients with de novo acute myeloid leukemia (AML), excluding cases of acute promyelocytic leukemia.  In order to analyze the role of KIT in CBFL we examd. the KIT mutations in 52 adult CBFL, including 15 previously reported patients, and in 49 non-APL childhood AML patients using sensitive detection methods.  We correlated our findings with the presence of trisomy 4 and investigated the relationship of the extra chromosome 4 with KIT mutations.  Several kinds of gain-of-function KIT mutations were found in 24 of the 52 (46.1%) adult CBFL cases and 6 of the 49 (12.2%) non-APL childhood AML patients.  KIT mutations were detected in 4 of the 8 adult patients and one childhood AML case bearing trisomy of chromosome 4 as either the sole cytogenetic aberration or a karyotypic aberration addnl. to t(8;21).  In three of the trisomy 4 cases we demonstrated that trisomy 4 leads to duplication of the KIT mutated allele.  These results underline that the KIT gene is activated in AML characterized by distinct cytogenetic and mol. genetic patterns and represents the most frequently mutated target in adult CBFL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ-Z_ofoCbQ7Vg90H21EOLACvtfcHk0lh0FYJWbXEycw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2jsLo%253D&md5=822eece5386084d15bbcf57c37a0575e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DRipamonti%26aufirst%3DC.%2BB.%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DCazzaniga%26aufirst%3DG.%26aulast%3DColapietro%26aufirst%3DP.%26aulast%3DElice%26aufirst%3DF.%26aulast%3DNadali%26aufirst%3DG.%26aulast%3DGrillo%26aufirst%3DG.%26aulast%3DHaas%26aufirst%3DO.%2BA.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DMorra%26aufirst%3DE.%26aulast%3DLarizza%26aufirst%3DL.%26atitle%3DKIT%2520activating%2520mutations%253A%2520incidence%2520in%2520adult%2520and%2520pediatric%2520acute%2520myeloid%2520leukemia%252C%2520and%2520identification%2520of%2520an%2520internal%2520tandem%2520duplication%26jtitle%3DHaematologica%26date%3D2004%26volume%3D89%26spage%3D920%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span> <span> </span><span class="NLM_article-title">Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">5593</span>– <span class="NLM_lpage">5603</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-03-343988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2011-03-343988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=21881046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=5593-5603&author=Y.+Shenauthor=Y.-M.+Zhuauthor=X.+Fanauthor=J.-Y.+Shiauthor=Q.-R.+Wangauthor=X.-J.+Yanauthor=Z.-H.+Guauthor=Y.-Y.+Wangauthor=B.+Chenauthor=C.-L.+Jiangauthor=H.+Yanauthor=F.-F.+Chenauthor=H.-M.+Chenauthor=Z.+Chenauthor=J.+Jinauthor=S.-J.+Chen&title=Gene+mutation+patterns+and+their+prognostic+impact+in+a+cohort+of+1185+patients+with+acute+myeloid+leukemia&doi=10.1182%2Fblood-2011-03-343988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia</span></div><div class="casAuthors">Shen, Yang; Zhu, Yong-Mei; Fan, Xing; Shi, Jing-Yi; Wang, Win-Rong; Yan, Xiao-Jing; Gu, Zhao-Hui; Wang, Yan-Yan; Chen, Bing; Jiang, Chun-Lei; Yan, Han; Chen, Fei-Fei; Chen, Hai-Min; Chen, Zhu; Jin, Jie; Chen, Sai-Juan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5593-5603</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML) patients, we examd. the gene status for both fusion products such as AML1 (CBFα)-ETO, CBFβ-MYH11, PML-RARα, and MLL rearrangement as a result of chromosomal translocations and mutations in genes including FLT3, C-KIT, N-RAS, NPM1, CEBPA, WT1, ASXL1, DNMT3A, MLL, IDH1, IDH2, and TET2 in 1185 AML patients.  Clin. anal. was mainly carried out among 605 cases without recognizable karyotype abnormalities except for 11q23.  Of these 605 patients, 452 (74.7%) were found to have at least 1 mutation, and the relationship of gene mutations with clin. outcome was investigated.  We revealed a correlation pattern among NPM1, DNMT3A, FLT3, IDH1, IDH2, CEBPA, and TET2 mutations.  Multivariate anal. identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event-free survival (EFS), whereas biallelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in both the whole group and among younger patients < 60 years of age.  The use of mol. markers allowed us to subdivide the series of 605 patients into distinct prognostic groups with potential clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUMhCyQzG2g7Vg90H21EOLACvtfcHk0lhdLeMIEWFFqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqtrzO&md5=bb8076c36e63b1d63a3fba3fe42894c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-03-343988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-03-343988%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.-M.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.-Y.%26aulast%3DWang%26aufirst%3DQ.-R.%26aulast%3DYan%26aufirst%3DX.-J.%26aulast%3DGu%26aufirst%3DZ.-H.%26aulast%3DWang%26aufirst%3DY.-Y.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DC.-L.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DF.-F.%26aulast%3DChen%26aufirst%3DH.-M.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.-J.%26atitle%3DGene%2520mutation%2520patterns%2520and%2520their%2520prognostic%2520impact%2520in%2520a%2520cohort%2520of%25201185%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D5593%26epage%3D5603%26doi%3D10.1182%2Fblood-2011-03-343988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadali, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elice, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colapietro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichelatti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunghi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodeghiero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzolo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larizza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span> <span> </span><span class="NLM_article-title">Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3463</span>– <span class="NLM_lpage">3468</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-09-3640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2005-09-3640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=16384925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Git7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3463-3468&author=R.+Cairoliauthor=A.+Beghiniauthor=G.+Grilloauthor=G.+Nadaliauthor=F.+Eliceauthor=C.+B.+Ripamontiauthor=P.+Colapietroauthor=M.+Nichelattiauthor=L.+Pezzettiauthor=M.+Lunghiauthor=A.+Cuneoauthor=A.+Violaauthor=F.+Ferraraauthor=M.+Lazzarinoauthor=F.+Rodeghieroauthor=G.+Pizzoloauthor=L.+Larizzaauthor=E.+Morra&title=Prognostic+impact+of+c-KIT+mutations+in+core+binding+factor+leukemias%3A+an+Italian+retrospective+study&doi=10.1182%2Fblood-2005-09-3640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study</span></div><div class="casAuthors">Cairoli, Roberto; Beghini, Alessandro; Grillo, Giovanni; Nadali, Gianpaolo; Elice, Francesca; Ripamonti, Carla Barbara; Colapietro, Patrizia; Nichelatti, Michele; Pezzetti, Laura; Lunghi, Monia; Cuneo, Antonio; Viola, Assunta; Ferrara, Felicetto; Lazzarino, Mario; Rodeghiero, Francesco; Pizzolo, Giovanni; Larizza, Lidia; Morra, Enrica</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3463-3468</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain, exon 8, and internal tandem duplication (ITD) mutations of c-KIT, were obsd. in about 46% of core binding factor leukemia (CBFL) patients.  To evaluate their prognostic significance, 67 adult patients with CBFL were analyzed to ascertain the c-KIT mutation status.  In acute myeloid leukemia (AML) with t(8;21), the presence of c-KIT TKD mutation at codon 816 (TKD816) was assocd. with a high white blood cell count at diagnosis (median, 29.60 × 109/L) and a higher incidence (33%) of extramedullary leukemia (EML) during the course of the disease.  Data also showed that the TKD816 mutated patients (n = 12) had a significantly higher incidence of relapse and a lower overall survival (OS) at 24 mo, compared with the 17 c-KIT unmutated (c-KIT-) patients (90% vs 35.3%, P = .002; 25% vs 76.5%, P = .006, resp.).  No difference in relapse incidence (P = .126) and OS (P = .474) was obsd. between the c-KIT mutated other than TKD816 (n = 7) and the c-KIT patients.  These findings indicate that c-KIT TKD816 mutation has a neg. impact on the outcome of AML with t(8;21).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-PTedhnPNrVg90H21EOLACvtfcHk0lhy-QjmPZVH8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Git7Y%253D&md5=8ebedd57cca52e77db305f45d6eab23a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-09-3640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-09-3640%26sid%3Dliteratum%253Aachs%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DGrillo%26aufirst%3DG.%26aulast%3DNadali%26aufirst%3DG.%26aulast%3DElice%26aufirst%3DF.%26aulast%3DRipamonti%26aufirst%3DC.%2BB.%26aulast%3DColapietro%26aufirst%3DP.%26aulast%3DNichelatti%26aufirst%3DM.%26aulast%3DPezzetti%26aufirst%3DL.%26aulast%3DLunghi%26aufirst%3DM.%26aulast%3DCuneo%26aufirst%3DA.%26aulast%3DViola%26aufirst%3DA.%26aulast%3DFerrara%26aufirst%3DF.%26aulast%3DLazzarino%26aufirst%3DM.%26aulast%3DRodeghiero%26aufirst%3DF.%26aulast%3DPizzolo%26aufirst%3DG.%26aulast%3DLarizza%26aufirst%3DL.%26aulast%3DMorra%26aufirst%3DE.%26atitle%3DPrognostic%2520impact%2520of%2520c-KIT%2520mutations%2520in%2520core%2520binding%2520factor%2520leukemias%253A%2520an%2520Italian%2520retrospective%2520study%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3463%26epage%3D3468%26doi%3D10.1182%2Fblood-2005-09-3640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H. D.</span></span> <span> </span><span class="NLM_article-title">KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1007/s00277-012-1580-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1007%2Fs00277-012-1580-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23053179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2013&pages=163-171&author=H.-J.+Kimauthor=H.+K.+Ahnauthor=C.+W.+Jungauthor=J.+H.+Moonauthor=C.-H.+Parkauthor=K.-O.+Leeauthor=S.-H.+Kimauthor=Y.-K.+Kimauthor=H.-J.+Kimauthor=S.+K.+Sohnauthor=S.+H.+Kimauthor=W.+S.+Leeauthor=K.+H.+Kimauthor=Y.-C.+Munauthor=H.+Kimauthor=J.+Parkauthor=W.+S.+Minauthor=H.-J.+Kimauthor=D.+H.+D.+Kim&title=KIT+D816+mutation+associates+with+adverse+outcomes+in+core+binding+factor+acute+myeloid+leukemia%2C+especially+in+the+subgroup+with+RUNX1%2FRUNX1T1+rearrangement&doi=10.1007%2Fs00277-012-1580-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement</span></div><div class="casAuthors">Kim, Hee-Jin; Ahn, Hee Kyung; Jung, Chul Won; Moon, Joon Ho; Park, Chang-Hun; Lee, Ki-O.; Kim, Sun-Hee; Kim, Yeo-Kyeoung; Kim, Hyeoung-Joon; Sohn, Sang Kyun; Kim, Sung Hyun; Lee, Won Sik; Kim, Kyoung Ha; Mun, Yeung-Chul; Kim, Hawk; Park, Jinny; Min, Woo-Sung; Kim, Hee-Je; Kim, Dong Hwan Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-171</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Core binding factor (CBF)-pos. acute myeloid leukemia (AML) presents a favorable prognosis, except for patients with KIT mutation, esp. D816 mutation.  The current retrospective study attempted to validate a prognostic role of KIT mutation in 121 Korean patients with CBF AML.  The study patients consisted of 121 patients with CBF AML (82 patients with RUNX1/RUNX1T1 [67.8 %] and 39 patients with CBFB/MYH11 [32.2 %]) recruited from eight institutions in Korea.  All patients received idarubicin plus cytarabine or behenoyl cytosine arabinoside 3 + 7 induction chemotherapy.  The KIT gene mutation status was detd. by direct sequencing analyses.  A KIT mutation was detected in 32 cases (26.4 %) in our series of patients.  The KIT mutation was most frequent in exon 17 (n = 18, 14.9 %; n = 16 with D816 mutation), followed by exon 8 (n = 10, 8.3 %).  The presence of KIT D816 mutation was assocd. with adverse outcomes for the event-free survival (p = 0.03) and for the overall survival (p = 0.02).  The unfavorable impact of D816 mutation was more prominent when the anal. was confined to the RUNX1/RUNX1T1 subtype.  The KIT mutation was detected in 26.4 % of Korean patients with CBF AML.  The KIT D816 mutation demonstrated an unfavorable prognostic implication, particularly in the RUNX1/RUNX1T1 subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj8NJvDprBILVg90H21EOLACvtfcHk0lhvMICtAjnKWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslyksQ%253D%253D&md5=d7f9c9f6672d6e1d9c3851366ae793df</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs00277-012-1580-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-012-1580-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DAhn%26aufirst%3DH.%2BK.%26aulast%3DJung%26aufirst%3DC.%2BW.%26aulast%3DMoon%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DC.-H.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DY.-K.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DSohn%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DMun%26aufirst%3DY.-C.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DMin%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DD.%2BH.%2BD.%26atitle%3DKIT%2520D816%2520mutation%2520associates%2520with%2520adverse%2520outcomes%2520in%2520core%2520binding%2520factor%2520acute%2520myeloid%2520leukemia%252C%2520especially%2520in%2520the%2520subgroup%2520with%2520RUNX1%252FRUNX1T1%2520rearrangement%26jtitle%3DAnn.%2520Hematol.%26date%3D2013%26volume%3D92%26spage%3D163%26epage%3D171%26doi%3D10.1007%2Fs00277-012-1580-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span> <span> </span><span class="NLM_article-title">BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT–driven myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2323</span>– <span class="NLM_lpage">2333</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-1006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1158%2F1535-7163.MCT-15-1006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=27512117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2323-2333&author=L.-T.+Chenauthor=C.-T.+Chenauthor=W.-T.+Jiaangauthor=T.-Y.+Chenauthor=J.-H.+Butterfieldauthor=N.-Y.+Shihauthor=J.+T.-A.+Hsuauthor=H.-Y.+Linauthor=S.-F.+Linauthor=H.-J.+Tsai&title=BPR1J373%2C+an+oral+multiple+tyrosine+kinase+inhibitor%2C+targets+c-KIT+for+the+treatment+of+c-KIT%E2%80%93driven+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-15-1006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia</span></div><div class="casAuthors">Chen, Li-Tzong; Chen, Chiung-Tong; Jiaang, Weir-Torn; Chen, Tsai-Yun; Butterfield, Joseph H.; Shih, Neng-Yao; Hsu, John Tsu-An; Lin, Hui-You; Lin, Sheng-Fung; Tsai, Hui-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2323-2333</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myelogenous leukemia (AML) carrying t(8;21)(q22;q22) or inv(16)/t(16;16)(p13;q22) is classified as core binding factor (CBF)-AML and accounts for approx. 15% of AML.  C-KIT mutation can be detected in 17%∼46% of CBF-AML and is assocd. with poor prognosis.  C-KIT mutation is a crucial hit and cooperates with AML1-ETO resulting from t(8;21)(q22;q22) to cause overt AML.  Tyrosine kinase inhibitors (TKI) targeting c-KIT, such as imatinib, has been used successfully to treat c-KIT driven gastrointestinal stromal tumors.  However, the effect of TKI on c-KIT-driven leukemia, including CBF-AML and systemic mastocytosis (SM), has not been satisfactory.  BPR1J373 is a 5-phenylthiazol-2-ylamine-pyriminide deriv. targeting multiple tyrosine kinases.  It was shown to inhibit cell proliferation and induce apoptosis in AML cells with constitutively activated c-KIT via inhibiting c-KIT phosphorylation and its downstream signals.  The compd. induced apoptosis by the mitochondrial intrinsic pathway through upregulation of proapoptotic proteins Bax and Bak and caspase 8 and 9 activation in c-KIT mutant Kasumi-1 cells.  Furthermore, it induced cell-cycle arrest via targeting aurora kinase B in c-KIT wild-type KG-1 cells.  The antitumor response of BPR1J373 was also shown in s.c. grafted SCID mice.  BPR1J373 was shown to effectively suppress c-KIT phosphorylation of D816V mutation by treating c-KIT-null COS-1 cells transfected with c-KIT D816V mutant plasmid.  In conclusion, BPR1J373 inhibits cell proliferation of c-KIT-driven AML cells via induction of apoptosis and cell-cycle arrest.  It is also effective for multiple drug-resistant c-KIT D816V mutation.  BPR1J373 deserves further development for clin. use in c-KIT-driven myeloid leukemia.  Mol Cancer Ther; 15(10); 2323-33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4zD_iK24M3rVg90H21EOLACvtfcHk0lhvMICtAjnKWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbvF&md5=6cdc91f7966670a03c7d9aedf0443a75</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-1006%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.-T.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DJiaang%26aufirst%3DW.-T.%26aulast%3DChen%26aufirst%3DT.-Y.%26aulast%3DButterfield%26aufirst%3DJ.-H.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLin%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DS.-F.%26aulast%3DTsai%26aufirst%3DH.-J.%26atitle%3DBPR1J373%252C%2520an%2520oral%2520multiple%2520tyrosine%2520kinase%2520inhibitor%252C%2520targets%2520c-KIT%2520for%2520the%2520treatment%2520of%2520c-KIT%25E2%2580%2593driven%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2323%26epage%3D2333%26doi%3D10.1158%2F1535-7163.MCT-15-1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes</span>. <i>Arch. Iran. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=20039765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2isr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=21-25&author=F.+Zakerauthor=M.+Mohammadzadehauthor=M.+Mohammadi&title=Detection+of+KIT+and+FLT3+mutations+in+acute+myeloid+leukemia+with+different+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes</span></div><div class="casAuthors">Zaker, Farhad; Mohammadzadeh, Mohammad; Mohammadi, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Iranian Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-25</span>CODEN:
                <span class="NLM_cas:coden">AIMRD2</span>;
        ISSN:<span class="NLM_cas:issn">1029-2977</span>.
    
            (<span class="NLM_cas:orgname">Academy of Medical Sciences of the I. R. Iran</span>)
        </div><div class="casAbstract">Background: Mutations in KIT and fms-like tyrosine kinase 3 genes lead to uncontrolled proliferation of leukemic cells with a poor prognosis.  Since, data concerning the incidence and assocns. with patients characteristics vary amongst different studies, the aim of the present study is to identify and quantify the frequency of mutations in Iranian patients suffering from acute myeloid leukemia.  Methods: Internal tandem duplication and D835 mutations in the fms-like tyrosine kinase 3 gene of acute myeloid leukemia patients were studied through polymerase chain reaction and polymerase chain reaction-RFLP anal.  Amplified products for a point mutation in D816 for KIT have also been identified through the polymerase chain reaction-RFLP technique.  The mutations in exon 8 of KIT were detected by using the PCR and the Conformational Sensitive Gel Electrophoresis techniques, and amplified products have been confirmed by sequencing techniques.  Results: Internal tandem duplication and D835 mutations in the fms-like tyrosine kinase 3 gene occurred in 18% and 6% of AML patients, resp.  Frequencies of mutation were 1.4% and 4.7% in exon 8 and D816 of the KIT gene in acute myeloid leukemia patients.  These results were substantially different for various subclasses of French-American-British classification.  Conclusion: This study revealed that approx. 30% of acute myeloid leukemia patients have either KIT or fms-like tyrosine kinase 3 genetic mutations.  The presence of fms-like tyrosine kinase 3 was significantly assocd. with M3 morphol. and mutations of KIT were significantly assocd. with M2 and M4 subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEOqJdH-gspLVg90H21EOLACvtfcHk0lihLX0wjuZtag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2isr%252FO&md5=26d1cbeb3a8b12d53ab621e2586914a3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaker%26aufirst%3DF.%26aulast%3DMohammadzadeh%26aufirst%3DM.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DDetection%2520of%2520KIT%2520and%2520FLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520with%2520different%2520subtypes%26jtitle%3DArch.%2520Iran.%2520Med.%26date%3D2010%26volume%3D13%26spage%3D21%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrekar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiede, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Coco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandwein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederwieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span> <span> </span><span class="NLM_article-title">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1614359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJMoa1614359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=28644114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=454-464&author=R.+M.+Stoneauthor=S.+J.+Mandrekarauthor=B.+L.+Sanfordauthor=K.+Laumannauthor=S.+Geyerauthor=C.+D.+Bloomfieldauthor=C.+L.+Thiedeauthor=T.+W.+Priorauthor=K.+D%C3%B6hnerauthor=G.+Marcucciauthor=F.+Lo-Cocoauthor=R.+B.+Klisovicauthor=A.+Weiauthor=J.+Sierraauthor=M.+A.+Sanzauthor=J.+M.+Brandweinauthor=T.+de+Witteauthor=D.+Niederwieserauthor=F.+R.+Appelbaumauthor=B.+C.+Medeirosauthor=M.+S.+Tallmanauthor=J.+Krauterauthor=R.+F.+Schlenkauthor=A.+Ganserauthor=H.+Serveauthor=G.+Ehningerauthor=S.+Amadoriauthor=R.+A.+Larsonauthor=H.+D%C3%B6hner&title=Midostaurin+plus+chemotherapy+for+acute+myeloid+leukemia+with+a+FLT3+mutation&doi=10.1056%2FNEJMoa1614359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span></div><div class="casAuthors">Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S.; Bloomfield, C. D.; Thiede, C.; Prior, T. W.; Dohner, K.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; Wei, A.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T.; Niederwieser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Krauter, J.; Schlenk, R. F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R. A.; Dohner, H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-464</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes.  We conducted a phase 3 trial to det. whether the addn. of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to std. chemotherapy would prolong overall survival in this population.  Methods: We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 mutations.  Patients were randomly assigned to receive std. chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or placebo.  Randomization was stratified according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal tandem duplication (ITD) mutation with either a high ratio (>0.7) or a low ratio (0.05 to 0.7) of mutant to wild-type alleles (ITD [high] and ITD [low], resp.).  Allogeneic transplantation was allowed.  The primary end point was overall survival.  Results: A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 357 to the placebo group.  The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, and TKD in 162 patients.  The treatment groups were well balanced with respect to age, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin group vs. 59.4% in the placebo group were women, P = 0.04).  Overall survival was significantly longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P = 0.009), as was event-free survival (hazard ratio for event or death, 0.78; one-sided P = 0.002).  In both the primary anal. and an anal. in which data for patients who underwent transplantation were censored, the benefit of midostaurin was consistent across all FLT3 subtypes.  The rate of severe adverse events was similar in the two groups.  Conclusions: The addn. of the multitargeted kinase inhibitor midostaurin to std. chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IT8JULCk7bVg90H21EOLACvtfcHk0lgJoXWKt-qKLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK&md5=9b0b003122a307b4d92f05826745cb8c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1614359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1614359%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DMandrekar%26aufirst%3DS.%2BJ.%26aulast%3DSanford%26aufirst%3DB.%2BL.%26aulast%3DLaumann%26aufirst%3DK.%26aulast%3DGeyer%26aufirst%3DS.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DThiede%26aufirst%3DC.%2BL.%26aulast%3DPrior%26aufirst%3DT.%2BW.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DSierra%26aufirst%3DJ.%26aulast%3DSanz%26aufirst%3DM.%2BA.%26aulast%3DBrandwein%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26atitle%3DMidostaurin%2520plus%2520chemotherapy%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520a%2520FLT3%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D454%26epage%3D464%26doi%3D10.1056%2FNEJMoa1614359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbiano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podoltsev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosono, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasabou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1728</span>– <span class="NLM_lpage">1740</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1902688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJMoa1902688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=31665578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1728-1740&author=A.+E.+Perlauthor=G.+Martinelliauthor=J.+E.+Cortesauthor=A.+Neubauerauthor=E.+Bermanauthor=S.+Paoliniauthor=P.+Montesinosauthor=M.+R.+Baerauthor=R.+A.+Larsonauthor=C.+Ustunauthor=F.+Fabbianoauthor=H.+P.+Erbaauthor=A.+Di+Stasiauthor=R.+Stuartauthor=R.+Olinauthor=M.+Kasnerauthor=F.+Ciceriauthor=W.+C.+Chouauthor=N.+Podoltsevauthor=C.+Recherauthor=H.+Yokoyamaauthor=N.+Hosonoauthor=S.+S.+Yoonauthor=J.+H.+Leeauthor=T.+Pardeeauthor=A.+T.+Fathiauthor=C.+Liuauthor=N.+Hasabouauthor=X.+Liuauthor=E.+Bahceciauthor=M.+J.+Levis&title=Gilteritinib+or+Chemotherapy+for+Relapsed+or+Refractory+FLT3-Mutated+AML&doi=10.1056%2FNEJMoa1902688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML</span></div><div class="casAuthors">Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; Fabbiano, F.; Erba, H. P.; Stasi, A. Di; Stuart, R.; Olin, R.; Kasner, M.; Ciceri, F.; Chou, W.-C.; Podoltsev, N.; Recher, C.; Yokoyama, H.; Hosono, N.; Yoon, S.-S.; Lee, J.-H.; Pardee, T.; Fathi, A. T.; Liu, C.; Hasabou, N.; Liu, X.; Bahceci, E.; Levis, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1728-1740</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy.  Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refractory FLT3-mutated AML. methods In a phase 3 trial, we randomly assigned adults with relapsed or refractory FLT3-mutated AML in a 2:1 ratio to receive either gilteritinib (at a dose of 120 mg per day) or salvage chemotherapy.  The two primary end points were overall survival and the percentage of patients who had complete remission with full or partial hematol. recovery.  Secondary end points included event-free survival (freedom from treatment failure [i.e., relapse or lack of remission] or death) and the percentage of patients who had complete remission. results Of 371 eligible patients, 247 were randomly assigned to the gilteritinib group and 124 to the salvage chemotherapy group.  The median overall survival in the gilteritinib group was significantly longer than that in the chemotherapy group (9.3 mo vs. 5.6 mo; hazard ratio for death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P<0.001).  The median event-free survival was 2.8 mo in the gilteritinib group and 0.7 mo in the chemotherapy group (hazard ratio for treatment failure or death, 0.79; 95% CI, 0.58 to 1.09).  The percentage of patients who had complete remission with full or partial hematol. recovery was 34.0% in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, resp. (risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4).  In an anal. that was adjusted for therapy duration, adverse events of grade 3 or higher and serious adverse events occurred less frequently in the gilteritinib group than in the chemotherapy group; the most common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia (45.9%), anemia (40.7%), and thrombocytopenia (22.8%). conclusions Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrkmbPcDc_2rVg90H21EOLACvtfcHk0lidOtKNUhKrqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktr3J&md5=6ea458f41ee4d275f423bf9749d920ce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1902688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1902688%26sid%3Dliteratum%253Aachs%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DBerman%26aufirst%3DE.%26aulast%3DPaolini%26aufirst%3DS.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DUstun%26aufirst%3DC.%26aulast%3DFabbiano%26aufirst%3DF.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DR.%26aulast%3DOlin%26aufirst%3DR.%26aulast%3DKasner%26aufirst%3DM.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DChou%26aufirst%3DW.%2BC.%26aulast%3DPodoltsev%26aufirst%3DN.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DYokoyama%26aufirst%3DH.%26aulast%3DHosono%26aufirst%3DN.%26aulast%3DYoon%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DPardee%26aufirst%3DT.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DHasabou%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DGilteritinib%2520or%2520Chemotherapy%2520for%2520Relapsed%2520or%2520Refractory%2520FLT3-Mutated%2520AML%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D1728%26epage%3D1740%26doi%3D10.1056%2FNEJMoa1902688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashman, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of c-KIT in cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1517/13543784.2013.740010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1517%2F13543784.2013.740010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23127174" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=103-115&author=L.+K.+Ashmanauthor=R.+Griffith&title=Therapeutic+targeting+of+c-KIT+in+cancer&doi=10.1517%2F13543784.2013.740010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.740010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.740010%26sid%3Dliteratum%253Aachs%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DGriffith%26aufirst%3DR.%26atitle%3DTherapeutic%2520targeting%2520of%2520c-KIT%2520in%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D22%26spage%3D103%26epage%3D115%26doi%3D10.1517%2F13543784.2013.740010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cammenga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergholz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocking, C.</span></span> <span> </span><span class="NLM_article-title">Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3961</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-02-0583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2005-02-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=16081693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12ktr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3958-3961&author=J.+Cammengaauthor=S.+Hornauthor=U.+Bergholzauthor=G.+Sommerauthor=G.+Sommerauthor=P.+Besmerauthor=W.+Fiedlerauthor=C.+Stocking&title=Extracellular+KIT+receptor+mutants%2C+commonly+found+in+core+binding+factor+AML%2C+are+constitutively+active+and+respond+to+imatinib+mesylate&doi=10.1182%2Fblood-2005-02-0583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate</span></div><div class="casAuthors">Cammenga, Joerg; Horn, Stefan; Bergholz, Ulla; Sommer, Gunhild; Besmer, Peter; Fiedler, Walter; Stocking, Carol</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3958-3961</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Multiple genetic alterations are required to induce acute myelogenous leukemia (AML).  Mutations in the extracellular domain of the KIT receptor are almost exclusively found in patients with AML carrying translocations or inversions affecting members of the core binding factor (CBF) gene family and correlate with a high risk of relapse.  We demonstrate that these complex insertion and deletion mutations lead to constitutive activation of the KIT receptor, which induces factor-independent growth of interleukin-3 (IL-3)-dependent cells.  Mutation of the evolutionary conserved amino acid D419 within the extracellular domain was sufficient to constitutively activate the KIT receptor, although high expression levels were required.  Dose-dependent growth inhibition and apoptosis were obsd. using either the protein tyrosine kinase inhibitor imatinib mesylate (STI571, Gleevec) or by blocking the phosphoinositide-3-kinase (PI3K)-AKT pathway.  Our data show that the addn. of kinase inhibitors to conventional chemotherapy might be a new therapeutic option for CBF-AML expressing mutant KIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMvzuHAcCqt7Vg90H21EOLACvtfcHk0ljSM2l83kSOHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12ktr3N&md5=d326a7e9c09e5345a09b4acbd12bc862</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0583%26sid%3Dliteratum%253Aachs%26aulast%3DCammenga%26aufirst%3DJ.%26aulast%3DHorn%26aufirst%3DS.%26aulast%3DBergholz%26aufirst%3DU.%26aulast%3DSommer%26aufirst%3DG.%26aulast%3DSommer%26aufirst%3DG.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DStocking%26aufirst%3DC.%26atitle%3DExtracellular%2520KIT%2520receptor%2520mutants%252C%2520commonly%2520found%2520in%2520core%2520binding%2520factor%2520AML%252C%2520are%2520constitutively%2520active%2520and%2520respond%2520to%2520imatinib%2520mesylate%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3958%26epage%3D3961%26doi%3D10.1182%2Fblood-2005-02-0583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mpakou, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontsioti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papageorgiou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottaridi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girkas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakitsos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitriadis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dervenoulas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappa, V.</span></span> <span> </span><span class="NLM_article-title">Dasatinib inhibits proliferation and induces apoptosis in the Kasumi-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2012.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.leukres.2012.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23149070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GksLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=175-182&author=V.+E.+Mpakouauthor=F.+Kontsiotiauthor=S.+Papageorgiouauthor=A.+Spathisauthor=C.+Kottaridiauthor=K.+Girkasauthor=P.+Karakitsosauthor=G.+Dimitriadisauthor=I.+Dervenoulasauthor=V.+Pappa&title=Dasatinib+inhibits+proliferation+and+induces+apoptosis+in+the+Kasumi-1+cell+line+bearing+the+t%288%3B21%29%28q22%3Bq22%29+and+the+N822K+c-kit+mutation&doi=10.1016%2Fj.leukres.2012.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation</span></div><div class="casAuthors">Mpakou, Vassiliki E.; Kontsioti, Frieda; Papageorgiou, Sotiris; Spathis, Aris; Kottaridi, Christine; Girkas, Kostas; Karakitsos, Petros; Dimitriadis, George; Dervenoulas, Ioannis; Pappa, Vasiliki</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating mutations of the c-kit gene are frequently found in CBF (core binding factor) leukemias.  We evaluated the effect of tyrosine kinase inhibitor dasatinib in leukemic cell lines bearing or not c-kit mutations.  Our data demonstrate that in the AML Kasumi-1 cell line, bearing the N822K c-kit mutation, dasatinib is a potent suppressor of c-kit and Src kinase activity and inhibits the phosphorylation of their downstream target AKT, possibly through the Src-mediated VEGF/VEGFR receptor type 2 pathway.  Dasatinib also effectively blocks proliferation and induces apoptosis through caspase-3 activation in Kasumi-1 cells.  These data further encourage the integration of dasatinib in the treatment of CBF AML with c-kit mutations in the context of clin. trials, which are eagerly anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWv_FEismgWbVg90H21EOLACvtfcHk0ljSM2l83kSOHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GksLvE&md5=397f482ae8e13bda68734eb99112e582</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DMpakou%26aufirst%3DV.%2BE.%26aulast%3DKontsioti%26aufirst%3DF.%26aulast%3DPapageorgiou%26aufirst%3DS.%26aulast%3DSpathis%26aufirst%3DA.%26aulast%3DKottaridi%26aufirst%3DC.%26aulast%3DGirkas%26aufirst%3DK.%26aulast%3DKarakitsos%26aufirst%3DP.%26aulast%3DDimitriadis%26aufirst%3DG.%26aulast%3DDervenoulas%26aufirst%3DI.%26aulast%3DPappa%26aufirst%3DV.%26atitle%3DDasatinib%2520inhibits%2520proliferation%2520and%2520induces%2520apoptosis%2520in%2520the%2520Kasumi-1%2520cell%2520line%2520bearing%2520the%2520t%25288%253B21%2529%2528q22%253Bq22%2529%2520and%2520the%2520N822K%2520c-kit%2520mutation%26jtitle%3DLeuk.%2520Res.%26date%3D2013%26volume%3D37%26spage%3D175%26epage%3D182%26doi%3D10.1016%2Fj.leukres.2012.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larizza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span> <span> </span><span class="NLM_article-title">Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations a report of three cases</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2004.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.leukres.2004.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15725473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslWlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2005&pages=397-400&author=R.+Cairoliauthor=A.+Beghiniauthor=E.+Morelloauthor=G.+Grilloauthor=M.+Montilloauthor=L.+Larizzaauthor=E.+Morra&title=Imatinib+mesylate+in+the+treatment+of+core+binding+factor+leukemias+with+KIT+mutations+a+report+of+three+cases&doi=10.1016%2Fj.leukres.2004.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases</span></div><div class="casAuthors">Cairoli, Roberto; Beghini, Alessandro; Morello, Enrico; Grillo, Giovanni; Montillo, Marco; Larizza, Lidia; Morra, Enrica</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-400</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aim of this study is to investigate the capability of Imatinib to induce an anti-leukemic effect in Core Binding Factor (CBF)-leukemia patients presenting either with extracellular juxtamembrane or kinase KIT mutations.  On the basis of a screening anal. for KIT mutations, two patients with a kinase mutation and one with extracellular juxtamembrane mutation, in first or subsequent leukemic relapse, received 400 mg Imatinib twice daily for 30 days.  After Imatinib discontinuation, bone marrow cells were re-tested to assess the KIT mutational status and the chromosomal set.  In our experience, none of the treated patients had a response by std. criteria; in particular, we did not observe any activity against acute myeloid leukemia (AML) assocd. with KIT kinase mutations.  However, in the patient with extracellular juxtamembrane mutation, Imatinib seems to have some clin. beneficial effect and, most important, is able to abrogate the leukemic subclone carrying the mutation.  Whether Imatinib, in combination with other agents, may play a role in the treatment of AML with more sensitive extracellular juxtamembrane KIT mutation remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXbvOZfx-WF7Vg90H21EOLACvtfcHk0lgf9UzWxNt6Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslWlsrk%253D&md5=2cd30e11361aa06b7c2499fd950b5fb4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2004.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2004.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DG.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DLarizza%26aufirst%3DL.%26aulast%3DMorra%26aufirst%3DE.%26atitle%3DImatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520core%2520binding%2520factor%2520leukemias%2520with%2520KIT%2520mutations%2520a%2520report%2520of%2520three%2520cases%26jtitle%3DLeuk.%2520Res.%26date%3D2005%26volume%3D29%26spage%3D397%26epage%3D400%26doi%3D10.1016%2Fj.leukres.2004.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kündgen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwänen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfreundschuh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringhoffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girschikofsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinicke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göhring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span> <span> </span><span class="NLM_article-title">Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1621</span>– <span class="NLM_lpage">1630</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0129-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fs41375-018-0129-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=29720733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOnu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1621-1630&author=P.+Paschkaauthor=R.+F.+Schlenkauthor=D.+Weberauthor=A.+Bennerauthor=L.+Bullingerauthor=M.+Heuserauthor=V.+I.+Gaidzikauthor=F.+Tholauthor=M.+Agrawalauthor=V.+Teleanuauthor=M.+L%C3%BCbbertauthor=W.+Fiedlerauthor=M.+Radsakauthor=J.+Krauterauthor=H.+A.+Horstauthor=R.+Greilauthor=K.+Mayerauthor=A.+K%C3%BCndgenauthor=U.+Martensauthor=G.+Heilauthor=H.+R.+Salihauthor=B.+Hertensteinauthor=C.+Schw%C3%A4nenauthor=G.+Wulfauthor=E.+Langeauthor=M.+Pfreundschuhauthor=M.+Ringhofferauthor=M.+Girschikofskyauthor=T.+Heinickeauthor=D.+Kraemerauthor=G.+G%C3%B6hringauthor=A.+Ganserauthor=K.+D%C3%B6hnerauthor=H.+D%C3%B6hner&title=Adding+dasatinib+to+intensive+treatment+in+core-binding+factor+acute+myeloid+leukemia-results+of+the+AMLSG+11-08+trial&doi=10.1038%2Fs41375-018-0129-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial</span></div><div class="casAuthors">Paschka, Peter; Schlenk, Richard F.; Weber, Daniela; Benner, Axel; Bullinger, Lars; Heuser, Michael; Gaidzik, Verena I.; Thol, Felicitas; Agrawal, Mridul; Teleanu, Veronica; Luebbert, Michael; Fiedler, Walter; Radsak, Markus; Krauter, Juergen; Horst, Heinz-A.; Greil, Richard; Mayer, Karin; Kuendgen, Andrea; Martens, Uwe; Heil, Gerhard; Salih, Helmut R.; Hertenstein, Bernd; Schwaenen, Carsten; Wulf, Gerald; Lange, Elisabeth; Pfreundschuh, Michael; Ringhoffer, Mark; Girschikofsky, Michael; Heinicke, Thomas; Kraemer, Doris; Goehring, Gudrun; Ganser, Arnold; Doehner, Konstanze; Doehner, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1621-1630</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation chemotherapy and administered as single agent for 1-yr maintenance in first-line treatment of adult patients with core-binding factor (CBF) acute myeloid leukemia (AML).  The primary combined end point in this study was safety and feasibility, and included the rates of early (ED) and hypoplastic (HD) deaths, pleural/pericardial effusion 3°/4° and liver toxicity 3°/4°, and the rate of refractory disease.  Secondary end points were cumulative incidence of relapse (CIR) and death in complete remission (CID), and overall survival (OS).  Eighty-nine pts [median age 49.5 years, range: 19-73 years; t(8;21), n = 37; inv (16), n = 52] were included.  No unexpected excess in toxicity was obsd.  The rates of ED/HD and CR/CRi were 4.5% (4/89) and 94% (84/89), resp.  The 4-yr estd. CIR, CID, and OS were 33.1% [95%-CI (confidence interval), 22.7-43.4%], 6.0% (95% CI, 0.9-11.2%), and 74.7% (95% CI, 66.1-84.5%), resp.  On the basis of the acceptable toxicity profile and favorable outcome in the AMLSG 11-08 trial, a confirmatory randomized phase III trial with dasatinib in adults with CBF-AML is ongoing (ClinicalTrials.gov Identifier: NCT02013648).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXBMxJwo61LVg90H21EOLACvtfcHk0ljggFdxz-C9Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOnu7fL&md5=54051eb915d0ff0257f9958ba04c1c23</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0129-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0129-6%26sid%3Dliteratum%253Aachs%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DWeber%26aufirst%3DD.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DMayer%26aufirst%3DK.%26aulast%3DK%25C3%25BCndgen%26aufirst%3DA.%26aulast%3DMartens%26aufirst%3DU.%26aulast%3DHeil%26aufirst%3DG.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DHertenstein%26aufirst%3DB.%26aulast%3DSchw%25C3%25A4nen%26aufirst%3DC.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DLange%26aufirst%3DE.%26aulast%3DPfreundschuh%26aufirst%3DM.%26aulast%3DRinghoffer%26aufirst%3DM.%26aulast%3DGirschikofsky%26aufirst%3DM.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DKraemer%26aufirst%3DD.%26aulast%3DG%25C3%25B6hring%26aufirst%3DG.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26atitle%3DAdding%2520dasatinib%2520to%2520intensive%2520treatment%2520in%2520core-binding%2520factor%2520acute%2520myeloid%2520leukemia-results%2520of%2520the%2520AMLSG%252011-08%2520trial%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1621%26epage%3D1630%26doi%3D10.1038%2Fs41375-018-0129-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.ejmech.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=26081023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=151-161&author=C.-T.+Chenauthor=J.+T.-A.+Hsuauthor=W.-H.+Linauthor=C.-T.+Luauthor=S.-C.+Yenauthor=T.+Hsuauthor=Y.-L.+Huangauthor=J.-S.+Songauthor=C.-H.+Chenauthor=L.-H.+Chouauthor=K.-J.+Yenauthor=C.-P.+Chenauthor=P.-C.+Kuoauthor=C.-L.+Huangauthor=H.-E.+Liuauthor=Y.-S.+Chaoauthor=T.-K.+Yehauthor=W.-T.+Jiaang&title=Identification+of+a+potent+5-phenyl-thiazol-2-ylamine-based+inhibitor+of+FLT3+with+activity+against+drug+resistance-conferring+point+mutations&doi=10.1016%2Fj.ejmech.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span></div><div class="casAuthors">Chen, Chiung-Tong; Hsu, John T.-A.; Lin, Wen-Hsing; Lu, Cheng-Tai; Yen, Shih-Chieh; Hsu, Tsu; Huang, Yu-Ling; Song, Jen-Shin; Chen, Chun-Hwa; Chou, Ling-Hui; Yen, Kuei-Jung; Chen, Ching-Ping; Kuo, Po-Chu; Huang, Chen-Lung; Liu, H. Eugene; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML).  However, clin. data have been not encouraging due to incomplete inhibition of FLT3 or the emergence of resistant mutations treated with these older agents.  The authors previously developed a series of 3-phenyl-1H-5-pyrazolylamine derivs. as highly potent and selective FLT3 inhibitors with good in vivo efficacy using an i.v. (IV) route.  However, the poor bioavailability of these pyrazole compds. limits the development of these promising antileukemic compds. for clin. use.  Herein, the authors describe a novel class of 5-phenyl-thiazol-2-ylamine compds. that are multitargeted FLT3 inhibitors.  From this class of compds., compd. I was very potent against AML cell lines and exhibited excellent oral efficacy in AML xenograft models.  In addn., further studies demonstrated that compd. I exhibited potent in vitro and in vivo activities against clin. relevant AC220 (3)-resistant kinase domain mutants of FLT3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KrlNgs-LL7Vg90H21EOLACvtfcHk0ljggFdxz-C9Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI&md5=d51f2152965d841a378c3c38dbcde6c7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DYen%26aufirst%3DS.-C.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.-L.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChou%26aufirst%3DL.-H.%26aulast%3DYen%26aufirst%3DK.-J.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DKuo%26aufirst%3DP.-C.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DLiu%26aufirst%3DH.-E.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DJiaang%26aufirst%3DW.-T.%26atitle%3DIdentification%2520of%2520a%2520potent%25205-phenyl-thiazol-2-ylamine-based%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520drug%2520resistance-conferring%2520point%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D100%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.ejmech.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0ljggFdxz-C9Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broekman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: Multi-targeted or single-targeted?</span>. <i>World J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.5306/wjco.v2.i2.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.5306%2Fwjco.v2.i2.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=21603317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=80-93&author=F.+Broekmanauthor=E.+Giovannettiauthor=G.+J.+Peters&title=Tyrosine+kinase+inhibitors%3A+Multi-targeted+or+single-targeted%3F&doi=10.5306%2Fwjco.v2.i2.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: Multi-targeted or single-targeted?</span></div><div class="casAuthors">Broekman Fleur; Giovannetti Elisa; Peters Godefridus J</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since in most tumors multiple signaling pathways are involved, many of the inhibitors in clinical development are designed to affect a wide range of targeted kinases.  The most important tyrosine kinase families in the development of tyrosine kinase inhibitors are the ABL, SCR, platelet derived growth factor, vascular endothelial growth factor receptor and epidermal growth factor receptor families.  Both multi-kinase inhibitors and single-kinase inhibitors have advantages and disadvantages, which are related to potential resistance mechanisms, pharmacokinetics, selectivity and tumor environment.  In different malignancies various tyrosine kinases are mutated or overexpressed and several resistance mechanisms exist.  Pharmacokinetics is influenced by interindividual differences and differs for two single targeted inhibitors or between patients treated by the same tyrosine kinase inhibitor.  Different tyrosine kinase inhibitors have various mechanisms to achieve selectivity, while differences in gene expression exist between tumor and stromal cells.  Considering these aspects, one type of inhibitor can generally not be preferred above the other, but will depend on the specific genetic constitution of the patient and the tumor, allowing personalized therapy.  The most effective way of cancer treatment by using tyrosine kinase inhibitors is to consider each patient/tumor individually and to determine the strategy that specifically targets the consequences of altered (epi)genetics of the tumor.  This strategy might result in treatment by a single multi kinase inhibitor for one patient, but in treatment by a couple of single kinase inhibitors for other patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUsa5qqJaBY_csfMJQC1ZdfW6udTcc2eY-Tmi1nVXP0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D&md5=683eaad679244b5efc5813d1ffaaaf57</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v2.i2.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v2.i2.80%26sid%3Dliteratum%253Aachs%26aulast%3DBroekman%26aufirst%3DF.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520Multi-targeted%2520or%2520single-targeted%253F%26jtitle%3DWorld%2520J.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D2%26spage%3D80%26epage%3D93%26doi%3D10.5306%2Fwjco.v2.i2.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span>; <span class="NLM_string-name">Churcher, I.</span>; <span class="NLM_string-name">Hunt, P. A.</span>; <span class="NLM_string-name">Steadman, V. A.</span></span> <span> </span><span class="NLM_article-title">Aminothiazole Derivatives as Inhibitors of MARK</span>. Patent WO <span class="NLM_patent">2007141571</span>, December 13, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Bettati&author=I.+Churcher&author=P.+A.+Hunt&author=V.+A.+Steadman&title=Aminothiazole+Derivatives+as+Inhibitors+of+MARK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBettati%26aufirst%3DM.%26atitle%3DAminothiazole%2520Derivatives%2520as%2520Inhibitors%2520of%2520MARK%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mjambili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.bmcl.2013.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=24373723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=560-564&author=F.+Mjambiliauthor=M.+Njorogeauthor=K.+Naranauthor=C.+De+Kockauthor=P.+J.+Smithauthor=V.+Mizrahiauthor=D.+Warnerauthor=K.+Chibale&title=Synthesis+and+biological+evaluation+of+2-aminothiazole+derivatives+as+antimycobacterial+and+antiplasmodial+agents&doi=10.1016%2Fj.bmcl.2013.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents</span></div><div class="casAuthors">Mjambili, Faith; Njoroge, Mathew; Naran, Krupa; De Kock, Carmen; Smith, Peter J.; Mizrahi, Valerie; Warner, Digby; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">560-564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of compds. I [R = 4-O2NC6H4, 4-ClC6H4, 2-thienyl, etc.] derived from the 2-amino-4-(2-pyridyl)thiazole scaffold was synthesized and tested for in vitro antimycobacterial activity against the Mycobacterium tuberculosis H37Rv strain, antiplasmodial activity against the chloroquine sensitive NF54 Plasmodium falciparum strain and cytotoxicity on a mammalian cell line.  Optimal antimycobacterial activity was found with compds. with a 2-pyridyl ring at position 4 of the thiazole scaffold, a substituted Ph ring at the 2-amino position, and an amide linker between the scaffold and the substituted Ph.  The antiplasmodial activity was best with compds. that had the Ph ring substituted with hydrophobic electron withdrawing groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9Hw3LGvVwi7Vg90H21EOLACvtfcHk0li3K1DrywmOmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSn&md5=85051bd02817d8033f0c23fb6c9d59f9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DMjambili%26aufirst%3DF.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DNaran%26aufirst%3DK.%26aulast%3DDe%2BKock%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DWarner%26aufirst%3DD.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-aminothiazole%2520derivatives%2520as%2520antimycobacterial%2520and%2520antiplasmodial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D560%26epage%3D564%26doi%3D10.1016%2Fj.bmcl.2013.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artusi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennuni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calgani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Identification of aminoimidazole and aminothiazole derivatives as Src family kinase inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2027</span>– <span class="NLM_lpage">2041</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1002%2Fcmdc.201500428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=26514807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCksrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2027-2041&author=C.+M.+Franciniauthor=A.+L.+Fallacaraauthor=R.+Artusiauthor=L.+Mennuniauthor=A.+Calganiauthor=A.+Angelucciauthor=S.+Schenoneauthor=M.+Botta&title=Identification+of+aminoimidazole+and+aminothiazole+derivatives+as+Src+family+kinase+inhibitors&doi=10.1002%2Fcmdc.201500428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors</span></div><div class="casAuthors">Francini, Cinzia Maria; Fallacara, Anna Lucia; Artusi, Roberto; Mennuni, Laura; Calgani, Alessia; Angelucci, Adriano; Schenone, Silvia; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2027-2041</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Src family kinases (SFKs) are a family of non-receptor tyrosine kinases (TKs) implicated in the regulation of many cellular processes.  The aberrant activity of these TKs has been assocd. with the growth and progression of cancer.  In particular, c-Src is overexpressed or hyperactivated in a variety of solid tumors and is most likely a strong promoting factor for the development of metastasis.  Herein, the synthesis of new 4-aminoimidazole and 2-aminothiazole derivs. and their in vitro biol. evaluation are described for their potential use as SFK inhibitors.  Initially, 2-aminothiazole analogs of dasatinib and 4-aminoimidazole derivs. were synthesized and tested against the SFKs Src, Fyn, Lyn, and Yes.  Five hits were identified as the most promising compds., with Ki values in the range of 90-480 nM.  A combination of mol. docking, homol. modeling, and mol. dynamics were then used to investigate the possible binding mode of such compds. within the ATP binding site of the SFKs.  Finally, the antiproliferative activities of the best candidates were evaluated against SH-SY5Y and K562 cell lines.  Compd. 3 b [2-(4-{2-methyl-6-[(5-phenylthiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)ethanol] was found to be the most active inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd1goyBW68MbVg90H21EOLACvtfcHk0li3K1DrywmOmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCksrbP&md5=0e48b0e39f0796f0598776baf60b1421</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500428%26sid%3Dliteratum%253Aachs%26aulast%3DFrancini%26aufirst%3DC.%2BM.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DArtusi%26aufirst%3DR.%26aulast%3DMennuni%26aufirst%3DL.%26aulast%3DCalgani%26aufirst%3DA.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520aminoimidazole%2520and%2520aminothiazole%2520derivatives%2520as%2520Src%2520family%2520kinase%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D2027%26epage%3D2041%26doi%3D10.1002%2Fcmdc.201500428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, F.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of conformational control inhibitors switching off the activated c-KIT and targeting a broad range of clinically relevant c-KIT mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3940</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01845</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01845" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=3940-3957&author=T.-S.+Wuauthor=W.-H.+Linauthor=H.-J.+Tsaiauthor=C.-C.+Hsuehauthor=T.+Hsuauthor=P.-C.+Wangauthor=H.-Y.+Linauthor=Y.-H.+Pengauthor=C.-T.+Luauthor=L.-C.+Leeauthor=C.-H.+Tuauthor=F.-C.+Kungauthor=H.-Y.+Shiaoauthor=T.-K.+Yehauthor=J.-S.+Songauthor=J.-Y.+Changauthor=Y.-C.+Suauthor=L.-T.+Chenauthor=C.-T.+Chenauthor=W.-T.+Jiaangauthor=S.-Y.+Wu&title=Discovery+of+conformational+control+inhibitors+switching+off+the+activated+c-KIT+and+targeting+a+broad+range+of+clinically+relevant+c-KIT+mutants&doi=10.1021%2Facs.jmedchem.8b01845"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01845%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.-S.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DHsueh%26aufirst%3DC.-C.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.-C.%26aulast%3DLin%26aufirst%3DH.-Y.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DLee%26aufirst%3DL.-C.%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DKung%26aufirst%3DF.-C.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DSu%26aufirst%3DY.-C.%26aulast%3DChen%26aufirst%3DL.-T.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DJiaang%26aufirst%3DW.-T.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DDiscovery%2520of%2520conformational%2520control%2520inhibitors%2520switching%2520off%2520the%2520activated%2520c-KIT%2520and%2520targeting%2520a%2520broad%2520range%2520of%2520clinically%2520relevant%2520c-KIT%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D62%26spage%3D3940%26epage%3D3957%26doi%3D10.1021%2Facs.jmedchem.8b01845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2856</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.bmc.2013.03.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23618709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2856-2867&author=W.-H.+Linauthor=J.+T.-A.+Hsuauthor=S.-Y.+Hsiehauthor=C.-T.+Chenauthor=J.-S.+Songauthor=S.-C.+Yenauthor=T.+Hsuauthor=C.-T.+Luauthor=C.-H.+Chenauthor=L.-H.+Chouauthor=Y.-N.+Yangauthor=C.-H.+Chiuauthor=C.-P.+Chenauthor=Y.-J.+Tsengauthor=K.-J.+Yenauthor=C.-F.+Yehauthor=Y.-S.+Chaoauthor=T.-K.+Yehauthor=W.-T.+Jiaang&title=Discovery+of+3-phenyl-1H-5-pyrazolylamine+derivatives+containing+a+urea+pharmacophore+as+potent+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmc.2013.03.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Lin, Wen-Hsing; Hsu, John T.-A.; Hsieh, Shu-Yi; Chen, Chiung-Tong; Song, Jen-Shin; Yen, Shih-Chieh; Hsu, Tsu; Lu, Cheng-Tai; Chen, Chun-Hwa; Chou, Ling-Hui; Yang, Yung-Ning; Chiu, Ching-Hui; Chen, Ching-Ping; Tseng, Ya-Ju; Yen, Kuei-Jung; Yeh, Ching-Fang; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2856-2867</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preclin. investigations and early clin. trials suggest that FLT3 inhibitors are a viable therapy for acute myeloid leukemia.  However, early clin. data have been underwhelming due to incomplete inhibition of FLT3.  The authors have developed 3-phenyl-1H-5-pyrazolylamine as an efficient template for kinase inhibitors.  Structure-activity relationships led to the discovery of sulfonamide, carbamate and urea series of FLT3 inhibitors.  Previous studies showed that the sulfonamide and carbamate series were potent and selective FLT3 inhibitors with good in vivo efficacy.  Herein, the authors describe the urea series, which the authors found to be potent inhibitors of FLT3 and VEGFR2.  Some inhibited growth of FLT3-mutated MOLM-13 cells more strongly than the FLT3 inhibitors sorafenib and ABT-869.  In preliminary in vivo toxicity studies of the four most active compds., N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide was found to be the least toxic.  A further in vivo efficacy study demonstrated that N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide achieved complete tumor regression in a higher proportion of MOLM-13 xenograft.  These results show that compd. N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide possesses improved pharmacol. and selectivity profiles and could be more effective than previously disclosed FLT3 inhibitors in the treatment of acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8nbO4pzTXbrVg90H21EOLACvtfcHk0lijczGK9H_lvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D&md5=3b4f4323360170e8a7fbe763b79d3128</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.083%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DHsieh%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DYen%26aufirst%3DS.-C.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChou%26aufirst%3DL.-H.%26aulast%3DYang%26aufirst%3DY.-N.%26aulast%3DChiu%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DTseng%26aufirst%3DY.-J.%26aulast%3DYen%26aufirst%3DK.-J.%26aulast%3DYeh%26aufirst%3DC.-F.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DJiaang%26aufirst%3DW.-T.%26atitle%3DDiscovery%2520of%25203-phenyl-1H-5-pyrazolylamine%2520derivatives%2520containing%2520a%2520urea%2520pharmacophore%2520as%2520potent%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2856%26epage%3D2867%26doi%3D10.1016%2Fj.bmc.2013.03.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3906</span>– <span class="NLM_lpage">3919</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3906-3919&author=C.-H.+Tuauthor=W.-H.+Linauthor=Y.-H.+Pengauthor=T.+Hsuauthor=J.-S.+Wuauthor=C.-Y.+Changauthor=C.-T.+Luauthor=P.-C.+Lyuauthor=C.+Shihauthor=W.-T.+Jiaangauthor=S.-Y.+Wu&title=Pyrazolylamine+derivatives+reveal+the+conformational+switching+between+type+I+and+type+II+binding+modes+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Tu, Chih-Hsiang; Lin, Wen-Hsing; Peng, Yi-Hui; Hsu, Tsu; Wu, Jian-Sung; Chang, Chun-Yu; Lu, Cheng-Tai; Lyu, Ping-Chiang; Shih, Chuan; Jiaang, Weir-Torn; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3906-3919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available.  Herein, the authors present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type II binding mode.  It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK.  A structure-activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK.  To the best of the authors' knowledge, this is the first structural biol. study to directly observe how changes in the structure of a small mol. can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX2IoqRzkgK7Vg90H21EOLACvtfcHk0lhVQ9z7c5RXyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D&md5=732cbe2ef77a84f50de49aeef838895d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00106%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DLyu%26aufirst%3DP.-C.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DJiaang%26aufirst%3DW.-T.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DPyrazolylamine%2520derivatives%2520reveal%2520the%2520conformational%2520switching%2520between%2520type%2520I%2520and%2520type%2520II%2520binding%2520modes%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3906%26epage%3D3919%26doi%3D10.1021%2Facs.jmedchem.6b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino-Enriquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donsky, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1770</span>– <span class="NLM_lpage">1780</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1158%2F1535-7163.MCT-12-0223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22665524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1770-1780&author=M.+C.+Heinrichauthor=A.+Marino-Enriquezauthor=A.+Presnellauthor=R.+S.+Donskyauthor=D.+J.+Griffithauthor=A.+McKinleyauthor=J.+Pattersonauthor=T.+Taguchiauthor=C.-W.+Liangauthor=J.+A.+Fletcher&title=Sorafenib+inhibits+many+kinase+mutations+associated+with+drug-resistant+gastrointestinal+stromal+tumors&doi=10.1158%2F1535-7163.MCT-12-0223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Marino-Enriquez, Adrian; Presnell, Ajia; Donsky, Rachel S.; Griffith, Diana J.; McKinley, Arin; Patterson, Janice; Taguchi, Takahiro; Liang, Cher-Wei; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1770-1780</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Sorafenib has substantial clin. activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST).  Because sorafenib targets both angiogenesis-related kinases (VEGFR) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the mol. basis for sorafenib efficacy in this setting remains unknown.  We sought to det. the spectrum of activity of sorafenib against different mutant kinases assocd. with drug-sensitive and drug-resistant GIST.  We compared the activity of imatinib and sorafenib against transiently expressed mutant forms of KIT and PDGFRA, including various secondary mutations that have been identified in imatinib-resistant or sunitinib-resistant GISTs.  We also examd. these drugs against four GIST cell lines, three of which are imatinib resistant.  In our in vitro studies, we detd. that sorafenib inhibited imatinib-resistant mutations in exons encoding the ATP/drug-binding pocket and in exons encoding the activation loop, with the exception of substitutions at KIT codon D816 and PDGFRA codon 842.  Notably our data indicate that sorafenib is more effective than imatinib or sunitinib for inhibiting the kinase activity of drug-resistant KIT mutants (as assessed by biochem. IC50).  We hypothesize that a major determinant of the efficacy of sorafenib for treatment of advanced GIST is the activity of this agent against KIT or PDGFRA-mutant kinases.  These results have implications for the further development of treatments for drug-resistant GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCww61mOGw3rVg90H21EOLACvtfcHk0lhVQ9z7c5RXyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrO&md5=b3027bfa716c41e6cb594e37200d05b8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0223%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMarino-Enriquez%26aufirst%3DA.%26aulast%3DPresnell%26aufirst%3DA.%26aulast%3DDonsky%26aufirst%3DR.%2BS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DMcKinley%26aufirst%3DA.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DC.-W.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DSorafenib%2520inhibits%2520many%2520kinase%2520mutations%2520associated%2520with%2520drug-resistant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1770%26epage%3D1780%26doi%3D10.1158%2F1535-7163.MCT-12-0223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Gao</span>, <span class="hlFld-ContribAuthor ">Mingming  Wei</span>, <span class="hlFld-ContribAuthor ">Yonghui  Li</span>, <span class="hlFld-ContribAuthor ">Guang  Yang</span>, <span class="hlFld-ContribAuthor ">Cheng  Yang</span>, <span class="hlFld-ContribAuthor ">Li  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis. </span><span class="cited-content_cbyCitation_journal-name">Clinical Science</span><span> <strong>2021,</strong> <em>135 </em>
                                    (14)
                                     , 1751-1765. <a href="https://doi.org/10.1042/CS20210571" title="DOI URL">https://doi.org/10.1042/CS20210571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/CS20210571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FCS20210571%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Science%26atitle%3DA%252Bnovel%252Bepigenetic%252Bdrug%252Bconjugating%252Bflavonoid%252Band%252BHDAC%252Binhibitor%252Bconfer%252Bsuppression%252Bof%252Bacute%252Bmyeloid%252Bleukemogenesis%26aulast%3DZhang%26aufirst%3DJuan%26date%3D2021%26date%3D2021%26volume%3D135%26issue%3D14%26spage%3D1751%26epage%3D1765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of c-KIT and FLT3 inhibitors in the clinic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Identification of 5- pyridine-thiazol-2-ylamine derivatives as TKIs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) TEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (b) 3-chloropyridine, 4-chloropyridine, or 5-chloropyrimidine, KOAc, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMAc, 150 °C, or 2-chloropyridine, CsF, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMSO, 160 °C; (c) 12 N HCl, H<sub>2</sub>O, 110 °C; (d) NaHCO<sub>3</sub>, H<sub>2</sub>O, rt to 50 °C; (e) 4,6-dichloropyrimidine or 4,6-dichloro-2-methylpyrimidine, NaH, NMP, 0 °C; (f) 2° amines, DMSO, 100 °C, or 4-(2-hydroxyethyl)morpholine, KOH, diglyme, 160 °C for <b>15f</b>; (g) 6 N HCl/CH<sub>3</sub>OH, 0 °C; (h) pyridine, 0 °C to rt.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Overall structures of c-KIT in complex with <b>15a</b> (PDB code: 6KLA). (B) The interactions of c-KIT with <b>15a</b>. The juxtamembrane (JM) domain and activation loop are shown in magenta and yellow, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>15a</b> effectively suppressed c-KIT phosphorylation and its downstream signaling pathways in GIST cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. HEK293T cells expressing FLT3-WT, FLT3-ITD, FLT3-D835Y, or FLT3-ITD/D835Y were analyzed. FLT3-transfected HEK293T cells were treated with compound <b>15a</b> at various concentrations for 1 h. Compound <b>15a</b> potently inhibits the FLT3-WT, FLT3-ITD, and FLT3-D835Y signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/medium/jm9b01229_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>15a</b> inhibits the growth of GIST and AML xenografts. (A) A pharmacodynamics study was conducted in the GIST430 xenograft model separately from the efficacy study. Levels of phosphorylated c-KIT (c-KIT-Tyr703) and AKT (AKT-Ser473) were determined by immunoblot. GIST430 xenografts were treated with <b>15a</b> (10, 20, and 40 mg/kg) or vehicle for 16 h. Tumors were then harvested, and protein lysates were subjected to immunoblotting for p-c-KIT, total c-KIT, p-AKT, total AKT, and β-actin. (B–F) Antitumor activity of <b>15a</b> was evaluated against (B) GIST430 xenografts, <i>n</i> = 5/group, (C) c-KIT exon 11 (delW557K558)/exon 17 (Y823D) GIST PDX, <i>n</i> = 6/group, (D) c-KIT exon 13 (K642E)/exon 17 (N822K) GIST PDX, <i>n</i> = 6/group, (E) c-KIT mutated Kasumi-1 AML xenografts, <i>n</i> = 8/group, (F) FLT3-ITD-mutated MOLM-13 AML xenografts, <i>n</i> = 4/group. Mice were treated with <b>15a</b> and reference compounds using the dosing levels indicated. The gray bars indicate the dosing schedule for <b>15a</b> and reference compounds. The tumor size is expressed as the mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01229/20191219/images/large/jm9b01229_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01229&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">983</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)60106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2FS0140-6736%2813%2960106-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23623056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=973-983&author=H.+Joensuuauthor=P.+Hohenbergerauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2FS0140-6736%2813%2960106-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu, Heikki; Hohenberger, Peter; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">9896</span>),
    <span class="NLM_cas:pages">973-983</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that arise in the gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in the abdomen.  They can occur at any age, the median age being 60-65 years, and typically cause bleeding, anemia, and pain.  GISTs have variable malignant potential, ranging from small lesions with a benign behavior to fatal sarcomas.  Most tumors stain pos. for the mast/stem cell growth factor receptor KIT and anoctamin 1 and harbor a kinase-activating mutation in either KIT or PDGFRA.  Tumors without such mutations could have alterations in genes of the succinate dehydrogenase complex or in BRAF, or rarely RAS family genes.  About 60% of patients are cured by surgery.  Adjuvant treatment with imatinib is recommended for patients with a substantial risk of recurrence, if the tumor has an imatinib-sensitive mutation.  Tyrosine kinase inhibitors substantially improve survival in advanced disease, but secondary drug resistance is common.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUnoEP2zf4WbVg90H21EOLACvtfcHk0lgVTrpHg9T--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFCmu74%253D&md5=11113c24bdb425aac4341372dea2e9bc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2960106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252960106-3%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26spage%3D973%26epage%3D983%26doi%3D10.1016%2FS0140-6736%2813%2960106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miettinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasota, J.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span>. <i>Virchows Arch.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>438</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1007/s004280000338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1007%2Fs004280000338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=11213830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2001&pages=1-12&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%E2%80%93definition%2C+clinical%2C+histological%2C+immunohistochemical%2C+and+molecular+genetic+features+and+differential+diagnosis&doi=10.1007%2Fs004280000338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span></div><div class="casAuthors">Miettinen, Markku; Lasota, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 81 refs.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.  They are defined here as KIT (CD117, stem cell factor receptor)-pos. mesenchymal spindle cell or epithelioid neoplasms primary in the GI tract, omentum, and mesentery.  GISTs typically present in older individuals and are most common in the stomach (60-70%), followed by small intestine (20-25%), colon and rectum (5%), and esophagus (<5%).  Benign tumors outnumber the malignant ones by a wide margin.  Approx. 70% of GISTs are pos. for CD34, 20-30% are pos. for smooth muscle actin (SMA), 10% are pos. for S100 protein and <5% are pos. for desmin.  The expression of CD34 and SMA is often reciprocal.  GISTs commonly have activating mutations in exon 11 (or rarely exon 9 and exon 13) of the KIT gene that encodes a tyrosine kinase receptor for the growth factor named stem cell factor or mast cell growth factor.  Ligand-independent activation of KIT appears to be a strong candidate for mol. pathogenesis of GISTs, and it may be a target for future treatment for such tumors.  Other genetic changes in GISTs discovered using comparative genomic hybridization include losses in 14q and 22q in both benign and malignant GISTs and occurrence in various gains predominantly in malignant GISTs.  GISTs have phenotypic similarities with the interstitial cells of Cajal and, therefore, a histogenetic origin from these cells has been suggested.  An alternative possibility, origin of pluripotential stem cells, is also possible; this is supported by the same origin of Cajal cells and smooth muscle and by the common SMA expression in GISTs.  GISTs differ clin. and pathogenetically from true leiomyosarcomas (very rare in the GI tract) and leiomyomas.  The latter occur in the GI tract, predominantly in the esophagus (intramural tumors) and the colon and rectum (muscularis mucosae tumors).  They also differ from schwannomas that are benign S100-pos. spindle cell tumors usually presenting in the stomach.  GI autonomic nerve tumors (GANTs) are probably a subset of GIST.  Other mesenchymal tumors that have to be sepd. from GISTs include inflammatory myofibroblastic tumors in children, desmoid, and dedifferentiated liposarcoma.  Angiosarcomas and metastatic melanomas, both of which are often KIT-pos., should not be confused with GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeixqNq3cd-7Vg90H21EOLACvtfcHk0lgVTrpHg9T--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D&md5=d2600b6aa118b36339ace603c1c9b87f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs004280000338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004280000338%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%25E2%2580%2593definition%252C%2520clinical%252C%2520histological%252C%2520immunohistochemical%252C%2520and%2520molecular%2520genetic%2520features%2520and%2520differential%2520diagnosis%26jtitle%3DVirchows%2520Arch.%26date%3D2001%26volume%3D438%26spage%3D1%26epage%3D12%26doi%3D10.1007%2Fs004280000338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad
Tunio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad%0ATunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lgvwoz6G8B4gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarlomo-Rikala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tervahartiala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1056</span>, <span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+kinase+inhibitor+STI571+in+a+patient+with+a+metastatic+gastrointestinal+stromal+tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2eYtrebVHFMALLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poveda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Muro, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Guerrero, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubedo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valverde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Broto, J.</span></span> <span> </span><span class="NLM_article-title">GEIS guidelines for gastrointestinal sarcomas (GIST)</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.ctrv.2016.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=28351781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A280%3ADC%252BC1cvitVKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2017&pages=107-119&author=A.+Povedaauthor=X.+G.+Del+Muroauthor=J.+A.+L%C3%B3pez-Guerreroauthor=R.+Cubedoauthor=V.+Mart%C3%ADnezauthor=I.+Romeroauthor=C.+Serranoauthor=C.+Valverdeauthor=J.+Mart%C3%ADn-Broto&title=GEIS+guidelines+for+gastrointestinal+sarcomas+%28GIST%29&doi=10.1016%2Fj.ctrv.2016.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">GEIS guidelines for gastrointestinal sarcomas (GIST)</span></div><div class="casAuthors">Poveda Andres; Garcia Del Muro Xavier; Lopez-Guerrero Jose Antonio; Cubedo Ricardo; Martinez Virginia; Romero Ignacio; Serrano Cesar; Valverde Claudia; Martin-Broto Javier</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-119</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract.  They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes(1).  On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum.  GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists...) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours.  Following its introduction, median survival of patients with advanced or metastatic GIST increased from 18 to more than 60months.  Sunitinib and Regorafenib are two targeted agents with worldwide approval for second- and third-line treatment, respectively, in metastatic GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMuzx4_Tbipsjl5L8hwNX0fW6udTcc2eYtrebVHFMALLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvitVKrtg%253D%253D&md5=aed94085e7bdbb5c0d5b69039d49e8e2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DPoveda%26aufirst%3DA.%26aulast%3DDel%2BMuro%26aufirst%3DX.%2BG.%26aulast%3DL%25C3%25B3pez-Guerrero%26aufirst%3DJ.%2BA.%26aulast%3DCubedo%26aufirst%3DR.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DV.%26aulast%3DRomero%26aufirst%3DI.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DValverde%26aufirst%3DC.%26aulast%3DMart%25C3%25ADn-Broto%26aufirst%3DJ.%26atitle%3DGEIS%2520guidelines%2520for%2520gastrointestinal%2520sarcomas%2520%2528GIST%2529%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2017%26volume%3D55%26spage%3D107%26epage%3D119%26doi%3D10.1016%2Fj.ctrv.2016.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den%0AAbbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+M.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors&doi=10.1056%2FNEJMoa020461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0lg-IUWTTyXfpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480%26doi%3D10.1056%2FNEJMoa020461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span> <span> </span><span class="NLM_article-title">Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.13.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2007.13.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18235121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=620-625&author=C.+D.+Blankeauthor=G.+D.+Demetriauthor=M.+von+Mehrenauthor=M.+C.+Heinrichauthor=B.+Eisenbergauthor=J.+A.+Fletcherauthor=C.+L.+Corlessauthor=C.+D.+M.+Fletcherauthor=P.+J.+Robertsauthor=D.+Heinzauthor=E.+Wehreauthor=Z.+Nikolovaauthor=H.+Joensuu&title=Long-term+results+from+a+randomized+phase+II+trial+of+standard-versus+higher-dose+imatinib+mesylate+for+patients+with+unresectable+or+metastatic+gastrointestinal+stromal+tumors+expressing+KIT&doi=10.1200%2FJCO.2007.13.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT</span></div><div class="casAuthors">Blanke, Charles D.; Demetri, George D.; von Mehren, Margaret; Heinrich, Michael C.; Eisenberg, Burton; Fletcher, Jonathan A.; Corless, Christopher I.; Fletcher, Christopher D. M.; Roberts, Peter J.; Heinz, Daniela; Wehre, Elisabeth; Nikolova, Zariana; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown.  A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels.  We conducted a long-term anal. of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status.  Patients and Methods: Patients with advanced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to receive imatinib 400 vs. 600 mg/d.  Data were prospectively collected on KIT mutational status, total tumor area, and other potential prognostic factors.  Patients were followed for a median of 63 mo.  Results: One hundred forty-seven patients were enrolled: 73 were in arm A (imatinib 400 mg/d), and 74 were in arm B (imatinib 600 mg/d).  Response rates, median progression-free survival, and median overall survival were essentially identical on both arms, and median survival was 57 mo for all patients.  Forty-one patients overall (28%) remained on the drug long-term.  Female sex, the presence of an exon 11 mutation, and normal albumin and neutrophil levels were independently assocd. with better survival.  Conclusion: Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyVblFUfMWELVg90H21EOLACvtfcHk0lg-IUWTTyXfpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1alsL0%253D&md5=c46d47e909e201a380a236246a2af159</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.4403%26sid%3Dliteratum%253Aachs%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinz%26aufirst%3DD.%26aulast%3DWehre%26aufirst%3DE.%26aulast%3DNikolova%26aufirst%3DZ.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DLong-term%2520results%2520from%2520a%2520randomized%2520phase%2520II%2520trial%2520of%2520standard-versus%2520higher-dose%2520imatinib%2520mesylate%2520for%2520patients%2520with%2520unresectable%2520or%2520metastatic%2520gastrointestinal%2520stromal%2520tumors%2520expressing%2520KIT%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D620%26epage%3D625%26doi%3D10.1200%2FJCO.2007.13.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramwell, V. H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, E. C.</span></span> <span> </span><span class="NLM_article-title">Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.13.4452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2007.13.4452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18235122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1alsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=626-632&author=C.+D.+Blankeauthor=C.+Rankinauthor=G.+D.+Demetriauthor=C.+W.+Ryanauthor=M.+von+Mehrenauthor=R.+S.+Benjaminauthor=A.+K.+Raymondauthor=V.+H.+C.+Bramwellauthor=L.+H.+Bakerauthor=R.+G.+Makiauthor=M.+Tanakaauthor=J.+R.+Hechtauthor=M.+C.+Heinrichauthor=C.+D.+M.+Fletcherauthor=J.+J.+Crowleyauthor=E.+C.+Borden&title=Phase+III+Randomized%2C+Intergroup+Trial+Assessing+Imatinib+Mesylate+At+Two+Dose+Levels+in+Patients+With+Unresectable+or+Metastatic+Gastrointestinal+Stromal+Tumors+Expressing+the+Kit+Receptor+Tyrosine+Kinase%3A+S0033&doi=10.1200%2FJCO.2007.13.4452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033</span></div><div class="casAuthors">Blanke, Charles D.; Rankin, Cathryn; Demetri, George D.; Ryan, Christopher W.; von Mehren, Margaret; Benjamin, Robert S.; Raymond, A. Kevin; Bramwell, Vivien H. C.; Baker, Laurence H.; Maki, Robert G.; Tanaka, Michael; Hecht, J. Randolph; Heinrich, Michael C.; Fletcher, Christopher D. M.; Crowley, John J.; Borden, Ernest C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">626-632</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a std. dose (400 mg daily) vs. a high dose (400 mg twice daily).  Patients and Methods: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clin. trial.  At registration, patients were randomly assigned to either std. or high-dose imatinib, with close interval follow-up.  If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the std.-dose arm could reregister to the trial and receive the high-dose imatinib regimen.  Results: Seven hundred forty-six patients with advanced GIST from-148 centers across the United States and Canada were enrolled onto this trial in 9 mo.  With a median follow-up of 4.5 years, median progression-free survival was 18 mo for patients on the std.-dose arm, and 20 mo for those receiving high-dose imatinib.  Median overall survival was 55 and 51 mo, resp.  There were no statistically significant differences in objective response rates, progression-free survival, or overall survival.  After progression on std.-dose imatinib, 33% of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease.  There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm.  Conclusion: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment.  It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6phAEmNKA7Vg90H21EOLACvtfcHk0ljPcdVEr45cmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1alsLs%253D&md5=ab64d4536338ce48e613ff17290f9f14</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.4452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.4452%26sid%3Dliteratum%253Aachs%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DRankin%26aufirst%3DC.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DRaymond%26aufirst%3DA.%2BK.%26aulast%3DBramwell%26aufirst%3DV.%2BH.%2BC.%26aulast%3DBaker%26aufirst%3DL.%2BH.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DHecht%26aufirst%3DJ.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DCrowley%26aufirst%3DJ.%2BJ.%26aulast%3DBorden%26aufirst%3DE.%2BC.%26atitle%3DPhase%2520III%2520Randomized%252C%2520Intergroup%2520Trial%2520Assessing%2520Imatinib%2520Mesylate%2520At%2520Two%2520Dose%2520Levels%2520in%2520Patients%2520With%2520Unresectable%2520or%2520Metastatic%2520Gastrointestinal%2520Stromal%2520Tumors%2520Expressing%2520the%2520Kit%2520Receptor%2520Tyrosine%2520Kinase%253A%2520S0033%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D626%26epage%3D632%26doi%3D10.1200%2FJCO.2007.13.4452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gounder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1007/s00280-010-1526-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1007%2Fs00280-010-1526-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1aisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=25-43&author=M.+M.+Gounderauthor=R.+G.+Maki&title=Molecular+basis+for+primary+and+secondary+tyrosine+kinase+inhibitor+resistance+in+gastrointestinal+stromal+tumor&doi=10.1007%2Fs00280-010-1526-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor</span></div><div class="casAuthors">Gounder, Mrinal M.; Maki, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">25-43</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Small mol. kinase inhibitors have irrevocably altered cancer treatment.  March 2010 marks the 10th anniversary of using imatinib in gastrointestinal stromal tumors (GIST), a cardinal example of the utility of such targeted therapy in a solid tumor.  Before imatinib, metastatic GIST was frustrating to treat due to its resistance to std. cytotoxic chemotherapy.  Median survival for patients with metastatic GIST improved from 19 to 60 mo with imatinib.  In treating patients with GIST, two patterns of tyrosine kinase inhibitor resistance have been obsd.  In the first, ∼9-14% of patients have progression within 3 mo of starting imatinib.  These patients are classified as having primary or early resistance.  Median progression-free survival (PFS) on imatinib is approx. 24 mo; patients with later progression are classified as having secondary or acquired resistance.  Primary studies and a meta-anal. of studies of imatinib in GIST patients have identified prognostic features that contribute to treatment failure.  One of the strongest predictors for success of therapy is KIT or PDGFRA mutational status.  Patients with KIT exon 11 mutant GIST have better response rates, PFS, and overall survival compared to other mutations.  A great deal has been learned in the last decade about sensitivity and resistance of GIST to imatinib; however, many unanswered questions remain about secondary resistance mechanisms and clin. management in the third- and fourth-line setting.  This review will discuss the role of dose effects, and early and late resistance to imatinib and their clin. implications.  Patients intolerant to imatinib (5%) and those who progress on imatinib are treated with sunitinib.  The mechanism of resistance to sunitinib is unknown at this time but is also appears related to growth of clones with secondary mutations in KIT.  Third- and fourth-line treatments of GIST and with future treatment strategies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCg0Z0wMSrHLVg90H21EOLACvtfcHk0ljPcdVEr45cmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1aisg%253D%253D&md5=cacc77383bbbca1c503a03074f1ac5e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1526-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1526-3%26sid%3Dliteratum%253Aachs%26aulast%3DGounder%26aufirst%3DM.%2BM.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26atitle%3DMolecular%2520basis%2520for%2520primary%2520and%2520secondary%2520tyrosine%2520kinase%2520inhibitor%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D25%26epage%3D43%26doi%3D10.1007%2Fs00280-010-1526-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumours: origin and molecular oncology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1038/nrc3143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fnrc3143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22089421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=865-878&author=C.+L.+Corlessauthor=C.+M.+Barnettauthor=M.+C.+Heinrich&title=Gastrointestinal+stromal+tumours%3A+origin+and+molecular+oncology&doi=10.1038%2Fnrc3143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumours: origin and molecular oncology</span></div><div class="casAuthors">Corless, Christopher L.; Barnett, Christine M.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">865-878</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are a paradigm for the development of personalized treatment for cancer patients.  The nearly simultaneous discovery of a biomarker that is reflective of their origin and the presence of gain-of-function kinase mutations in these tumors set the stage for more accurate diagnosis and the development of kinase inhibitor therapy.  Subsequent studies of genotype and phenotype have led to a mol. classification of GIST and to treatment optimization on the basis of mol. subtype.  The study of drug-resistant tumors has advanced our understanding of kinase biol., enabling the development of novel kinase inhibitors.  Further improvements in GIST treatment may require targeting GIST stem cell populations and/or addnl. genomic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY7ze-9Y_FbVg90H21EOLACvtfcHk0lgaPZMB4pQU_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOisb3I&md5=345c2287f7cdf8775b2a05114ccf5563</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3143%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBarnett%26aufirst%3DC.%2BM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DGastrointestinal%2520stromal%2520tumours%253A%2520origin%2520and%2520molecular%2520oncology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D865%26epage%3D878%26doi%3D10.1038%2Fnrc3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Call, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walentas, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherzer, N.</span></span> <span> </span><span class="NLM_article-title">Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">90</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-12-90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1186%2F1471-2407-12-90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22429770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos12msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=90&author=J.+Callauthor=C.+D.+Walentasauthor=J.+C.+Eickhoffauthor=N.+Scherzer&title=Survival+of+gastrointestinal+stromal+tumor+patients+in+the+imatinib+era%3A+life+raft+group+observational+registry&doi=10.1186%2F1471-2407-12-90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry</span></div><div class="casAuthors">Call, Jerry; Walentas, Christopher D.; Eickhoff, Jens C.; Scherzer, Norman</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Gastrointestinal stromal tumors (GIST), one of the most common mesenchymal tumors of the gastrointestinal tract, prior to routine immunohistochem. staining and the introduction of tyrosine kinase inhibitors, were often mistaken for neoplasms of smooth muscle origin such as leiomyomas, leiomyosarcomas or leiomyoblastomas.  Since the advent of imatinib, GIST has been further delineated into adult- (KIT or PDGFRα mutations) and pediatric- (typified by wild-type GIST/succinate dehydrogenase deficiencies) types.  Using varying gender ratios at age of diagnosis we sought to elucidate prognostic factors for each sub-type and their impact on overall survival.  Methods: This is a long-term retrospective anal. of a large observational study of an international open cohort of patients from a GIST research and patient advocacy's lifetime registry.  Demog. and disease-specific data were voluntarily supplied by its members from May 2000-Oct. 2010; the primary outcome was overall survival.  Assocns. between survival and prognostic factors were evaluated by univariate Cox proportional hazard analyses, with backward selection at P < 0.05 used to identify independent factors.  Results: Inflections in gender ratios by age at diagnosis in years delineated two distinct groups: above and below age 35 at diagnosis.  Closer anal. confirmed the above 35 age group as previously reported for adult-type GIST, typified by mixed primary tumor sites and gender, KIT or PDGFRα mutations and shorter survival times.  The pediatric group (< age 18 at diagnosis) was also as previously reported with predominantly stomach tumors, females, wild-type GIST or SDH mutations, and extended survival.  "Young adults" however formed a third group aged 18-35 at diagnosis and were a clear mix of these two previously reported distinct sub-types.  Conclusions: Pediatric- and adult-type GIST have been previously characterized in clin. settings and these observations confirm significant prognostic factors for each from a diverse real-world cohort.  Addnl., these findings suggest that extra diligence be taken with "young adults" (aged 18-35 at diagnosis) as pediatric-type GIST may present well beyond adolescence, particularly as these distinct sub-types have different causes, and consequently respond differently to treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKjgXc16iy87Vg90H21EOLACvtfcHk0lgaPZMB4pQU_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos12msbc%253D&md5=1b11f5d1caa2c42ee2c1c5767c3ddc58</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-12-90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-12-90%26sid%3Dliteratum%253Aachs%26aulast%3DCall%26aufirst%3DJ.%26aulast%3DWalentas%26aufirst%3DC.%2BD.%26aulast%3DEickhoff%26aufirst%3DJ.%2BC.%26aulast%3DScherzer%26aufirst%3DN.%26atitle%3DSurvival%2520of%2520gastrointestinal%2520stromal%2520tumor%2520patients%2520in%2520the%2520imatinib%2520era%253A%2520life%2520raft%2520group%2520observational%2520registry%26jtitle%3DBMC%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D90%26doi%3D10.1186%2F1471-2407-12-90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owzar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramwell, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertagnolli, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5360</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.17.4284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2008.17.4284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18955451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5360-5367&author=M.+C.+Heinrichauthor=K.+Owzarauthor=C.+L.+Corlessauthor=D.+Hollisauthor=E.+C.+Bordenauthor=C.+D.+M.+Fletcherauthor=C.+W.+Ryanauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=C.+Rankinauthor=R.+S.+Benjaminauthor=V.+H.+Bramwellauthor=G.+D.+Demetriauthor=M.+M.+Bertagnolliauthor=J.+A.+Fletcher&title=Correlation+of+Kinase+Genotype+and+Clinical+Outcome+in+the+North+American+Intergroup+Phase+III+Trial+of+Imatinib+Mesylate+for+Treatment+of+Advanced+Gastrointestinal+Stromal+Tumor%3A+CALGB+150105+Study+by+Cancer+and+Leukemia+Group+B+and+Southwest+Oncology+Group&doi=10.1200%2FJCO.2008.17.4284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group</span></div><div class="casAuthors">Heinrich, Michael C.; Owzar, Kouros; Corless, Christopher L.; Hollis, Donna; Borden, Ernest C.; Fletcher, Christopher D. M.; Ryan, Christopher W.; von Mehren, Margaret; Blanke, Charles D.; Rankin, Cathryn; Benjamin, Robert S.; Bramwell, Vivien H.; Demetri, George D.; Bertagnolli, Monica M.; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5360-5367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Imatinib mesylate is std. treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally.  In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing.  We examd. the relationship between kinase genotype and treatment outcome for 428 patients enrolled on the North American phase III study SWOG S0033/CALGB 150105 and treated with either 400 mg or 800 mg daily doses of imatinib.  The presence of KIT exon 11-mutant genotype (n = 283) correlated with improved treatment outcome when compared with KIT exon 9-mutant (n = 32) and wild-type (WT; n = 67) genotypes for objective response (complete response [CR]/partial response [PR], 71.7% v 44.4% [P = .007]; and 44.6% [P = .0002], resp.); time to tumor progression (TTP; median 24.7 mo v 16.7 and 12.8 mo, resp.); and overall survival (OS; median 60.0 mo v 38.4 and 49.0 mo, resp.).  The survival outcomes for patients with exon 9-mutant, exon 11-mutant or WT GIST were not affected by imatinib dose.  However, there was evidence of improved response rates for patients with exon 9-mutant tumors treated with imatinib 800 mg vs. 400 mg (CR/PR, 67% v 17%; P = .02).  Patients who had CD117-neg. GIST had similar TTP but inferior OS compared with patients who had CD117-pos. disease, which suggests that patients who have CD117-neg. GIST may benefit from imatinib treatment.  In addn., we identified novel but rare mutations of the KIT extracellular domain (exons 8 and 9).  We confirmed the favorable impact of KIT exon 11 genotype when compared with KIT exon 9 and wild-type genotype for patients with advanced GIST who are treated with imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEsXG_BaegR7Vg90H21EOLACvtfcHk0lgaPZMB4pQU_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmug%253D%253D&md5=e172b60b8246817b8dd79fa23794f2fc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.4284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.4284%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DOwzar%26aufirst%3DK.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHollis%26aufirst%3DD.%26aulast%3DBorden%26aufirst%3DE.%2BC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DRankin%26aufirst%3DC.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DBramwell%26aufirst%3DV.%2BH.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBertagnolli%26aufirst%3DM.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DCorrelation%2520of%2520Kinase%2520Genotype%2520and%2520Clinical%2520Outcome%2520in%2520the%2520North%2520American%2520Intergroup%2520Phase%2520III%2520Trial%2520of%2520Imatinib%2520Mesylate%2520for%2520Treatment%2520of%2520Advanced%2520Gastrointestinal%2520Stromal%2520Tumor%253A%2520CALGB%2520150105%2520Study%2520by%2520Cancer%2520and%2520Leukemia%2520Group%2520B%2520and%2520Southwest%2520Oncology%2520Group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5360%26epage%3D5367%26doi%3D10.1200%2FJCO.2008.17.4284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreevey, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4342</span>– <span class="NLM_lpage">4349</span>, <span class="refDoi"> DOI: 10.1200/JCO.2003.04.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.-J.+Chenauthor=A.+D.+Van+den%0AAbbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor&doi=10.1200%2FJCO.2003.04.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0ljHBqqwkI1BRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.-J.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349%26doi%3D10.1200%2FJCO.2003.04.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Gastrointestinal
Stromal Tumor Meta-Analysis Group (MetaGIST)</span> <span> </span><span class="NLM_article-title">Comparison of Two Doses of Imatinib for the Treatment
of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis
of 1,640 Patients</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.1200/JCO.2009.24.2099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2009.24.2099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=20124181" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1247-1253&author=Gastrointestinal%0AStromal+Tumor+Meta-Analysis+Group+%28MetaGIST%29&title=Comparison+of+Two+Doses+of+Imatinib+for+the+Treatment%0Aof+Unresectable+or+Metastatic+Gastrointestinal+Stromal+Tumors%3A+A+Meta-Analysis%0Aof+1%2C640+Patients&doi=10.1200%2FJCO.2009.24.2099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.24.2099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.24.2099%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DComparison%2520of%2520Two%2520Doses%2520of%2520Imatinib%2520for%2520the%2520Treatment%250Aof%2520Unresectable%2520or%2520Metastatic%2520Gastrointestinal%2520Stromal%2520Tumors%253A%2520A%2520Meta-Analysis%250Aof%25201%252C640%2520Patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1247%26epage%3D1253%26doi%3D10.1200%2FJCO.2009.24.2099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koryotowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leversha, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMatteo, R. P.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4190</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0ljHBqqwkI1BRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5352</span>– <span class="NLM_lpage">5359</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.15.7461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1200%2FJCO.2007.15.7461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18955458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5352-5359&author=M.+C.+Heinrichauthor=R.+G.+Makiauthor=C.+L.+Corlessauthor=C.+R.+Antonescuauthor=A.+Harlowauthor=D.+Griffithauthor=A.+Townauthor=A.+McKinleyauthor=W.+B.+Ouauthor=J.+A.+Fletcherauthor=C.+D.+M.+Fletcherauthor=X.+Huangauthor=D.+P.+Cohenauthor=C.+M.+Baumauthor=G.+D.+Demetri&title=Primary+and+secondary+kinase+genotypes+correlate+with+the+biological+and+clinical+activity+of+sunitinib+in+imatinib-resistant+gastrointestinal+stromal+tumor&doi=10.1200%2FJCO.2007.15.7461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Maki, Robert G.; Corless, Christopher L.; Antonescu, Cristina R.; Harlow, Amy; Griffith, Diana; Town, Ajia; McKinley, Arin; Ou, Wen-Bin; Fletcher, Jonathan A.; Fletcher, Christopher D. M.; Huang, Xin; Cohen, Darrel P.; Baum, Charles M.; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5352-5359</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor α (PDGFRA) kinases, which are imatinib targets.  Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with GIST after they experience imatinib failure.  We evaluated the impact of primary and secondary kinase genotype on sunitinib activity.  Tumor responses were assessed radiol. in a phase I/II trial of sunitinib in 97 patients with metastatic, imatinib-resistant/intolerant GIST.  KIT/PDGFRA mutational status was detd. for 78 patients by using tumor specimens obtained before and after prior imatinib therapy.  Kinase mutants were biochem. profiled for sunitinib and imatinib sensitivity.  Clin. benefit (partial response or stable disease for ≥ 6 mo) with sunitinib was obsd. for the three most common primary GIST genotypes: KIT exon 9 (58%), KIT exon 11 (34%), and wild-type KIT/PDGFRA (56%).  Progression-free survival (PFS) was significantly longer for patients with primary KIT exon 9 mutations (P = .0005) or with a wild-type genotype (P = .0356) than for those with KIT exon 11 mutations.  The same pattern was obsd. for overall survival (OS).  PFS and OS were longer for patients with secondary KIT exon 13 or 14 mutations (which involve the KIT-ATP binding pocket) than for those with exon 17 or 18 mutations (which involve the KIT activation loop).  Biochem. profiling studies confirmed the clin. results.  The clin. activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-Yvw1bbDYrVg90H21EOLACvtfcHk0lhB41hdnxmkhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D&md5=b84e19da0589f0ba6b12d8ed6b0da2c6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.15.7461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.15.7461%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DHarlow%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DMcKinley%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCohen%26aufirst%3DD.%2BP.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DPrimary%2520and%2520secondary%2520kinase%2520genotypes%2520correlate%2520with%2520the%2520biological%2520and%2520clinical%2520activity%2520of%2520sunitinib%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5352%26epage%3D5359%26doi%3D10.1200%2FJCO.2007.15.7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterom, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackstein, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69446-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2FS0140-6736%2806%2969446-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=17046465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Efficacy+and+safety+of+sunitinib+in+patients+with+advanced+gastrointestinal+stromal+tumour+after+failure+of+imatinib%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2806%2969446-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span></div><div class="casAuthors">Demetri, George D.; van Oosterom, Allan T.; Garrett, Christopher R.; Blackstein, Martin E.; Shah, Manisha H.; Verweij, Jaap; McArthur, Grant; Judson, Ian R.; Heinrich, Michael C.; Morgan, Jeffrey A.; Desai, Jayesh; Fletcher, Christopher D.; George, Suzanne; Bello, Carlo L.; Huang, Xin; Baum, Charles M.; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9544</span>),
    <span class="NLM_cas:pages">1329-1338</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumor are available.  We did a randomized, double-blind, placebo-controlled, multicenter, international trial to assess tolerability and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients with advanced gastrointestinal stromal tumor who were resistant to or intolerant of previous treatment with imatinib.  Blinded sunitinib or placebo was given orally once daily at a 50-mg starting dose in 6-wk cycles with 4 wk on and 2 wk off treatment.  The primary endpoint was time to tumor progression.  Intention-to-treat, modified intention-to-treat, and per-protocol analyses were done.  This study is registered at ClinicalTrials.gov, no. NCT00075218.  Three hundred and twelve patients were randomized in a 2:1 ratio to receive sunitinib (n = 207) or placebo (n=105); the trial was unblinded early when a planned interim anal. showed significantly longer time to tumor progression with sunitinib.  Median time to tumor progression was 27.3 wk (95% CI 16.0-32.1) in patients receiving sunitinib and 6.4 wk (4.4-10.0) in those on placebo (hazard ratio 0.33; p < 0.0001).  Therapy was reasonably well tolerated; the most common treatment-related adverse events were fatigue, diarrhea, skin discoloration, and nausea.  We noted significant clin. benefit, including disease control and superior survival, with sunitinib compared with placebo in patients with advanced gastrointestinal stromal tumor after failure and discontinuation of imatinib.  Tolerability was acceptable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6YRQ18H894LVg90H21EOLACvtfcHk0lhB41hdnxmkhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOrtL%252FL&md5=b21e01faede44c98f645be945c2638c0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969446-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969446-4%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2806%2969446-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badalamenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappeler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuss, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group">GRID study investigators</span> <span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23177515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Sch%C3%B6ffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casaliauthor=GRID+study+investigators&title=Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28GRID%29%3A+an+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Demetri, George D.; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, Piotr; Gelderblom, Hans; Hohenberger, Peter; Leahy, Michael; von Mehren, Margaret; Joensuu, Heikki; Badalamenti, Giuseppe; Blackstein, Martin; Le Cesne, Axel; Schoffski, Patrick; Maki, Robert G.; Bauer, Sebastian; Nguyen, Binh Bui; Xu, Jianming; Nishida, Toshirou; Chung, John; Kappeler, Christian; Kuss, Iris; Laurent, Dirk; Casali, Paolo G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9863</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Until now, only imatinib and sunitinib have proven clin. benefit in patients with gastrointestinal stromal tumors (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression.  We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.We did this phase 3 trial at 57 hospitals in 17 countries.  Patients with histol. confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geog. region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 wk of each 4 wk cycle.  The study sponsor, participants, and investigators were masked to treatment assignment.  The primary endpoint was progression-free survival (PFS).  At disease progression, patients assigned placebo could crossover to open-label regorafenib.  Analyses were by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT01271712.From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66).  Data cutoff was Jan 26, 2012.  Median PFS per independent blinded central review was 4·8 mo (IQR 1·4-9·2) for regorafenib and 0·9 mo (0·9-1·8) for placebo (hazard ratio [HR] 0·27, 95% CI 0·19-0·39; p<0·0001).  After progression, 56 patients (85%) assigned placebo crossed over to regorafenib.  Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned placebo.  The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%).The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on std. treatments.  As far as we are aware, this is the first clin. trial to show benefit from a kinase inhibitor in this highly refractory population of patients.Bayer HealthCare Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2GIfYXBPyLVg90H21EOLACvtfcHk0ljz7q71agvmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslarsLvL&md5=f8ee42424a9b3bd7558b1a2f1461af33</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528GRID%2529%253A%2520an%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, J. M.</span></span> <span> </span><span class="NLM_article-title">Drug therapy for acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-01-0178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2005-01-0178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15870183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVejsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=1154-1163&author=M.+S.+Tallmanauthor=D.+G.+Gillilandauthor=J.+M.+Rowe&title=Drug+therapy+for+acute+myeloid+leukemia&doi=10.1182%2Fblood-2005-01-0178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Drug therapy for acute myeloid leukemia</span></div><div class="casAuthors">Tallman, Martin S.; Gilliland, D. Gary; Rowe, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1154-1163</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Although improvement in outcomes has occurred in younger adults with acute myeloid leukemia (AML) during the past 4 decades, progress in older adults has been much less conspicuous, if at all.  Approx. 50% to 75% of adults with AML achieve complete remission (CR) with cytarabine and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.  However, only approx. 20% to 30% of the patients enjoy long-term disease survival.  Various post-remission strategies have been explored to eliminate minimal residual disease.  The optimal dose, schedule, and no. of cycles of post-remission chemotherapy for most patients are not known.  A variety of prognostic factors can predict outcome and include the karyotype of the leukemic cells and the presence of transmembrane transporter proteins, which extrude certain chemotherapy agents from the cell and confer multidrug resistance and mutations in or over expressions of specific genes such as WT1, CEBPA, BAX and the ratio of BCL2 to BAX, BAALC, EVI1, KIT, and FLT3.  Most recently, insights into the mol. pathogenesis of AML have led to the development of more specific targeted agents and have ushered in an exciting new era of antileukemia therapy.  Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors, farnesyl transferase inhibitors, histone deacetylase and proteasome inhibitors, antiangiogenesis agents, Fms-like tyrosine kinase 3 (FLT3) inhibitors, and apoptosis inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzCcZj26mc7Vg90H21EOLACvtfcHk0ljz7q71agvmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVejsLg%253D&md5=47612c984ffbba03ddbb344d59e9a7f9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-01-0178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-01-0178%26sid%3Dliteratum%253Aachs%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26atitle%3DDrug%2520therapy%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D1154%26epage%3D1163%26doi%3D10.1182%2Fblood-2005-01-0178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0ljz7q71agvmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0ljz7q71agvmvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitruck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreitmeier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4372</span>– <span class="NLM_lpage">4380</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-05-1440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2002-05-1440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=12393388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsFCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=4372-4380&author=S.+Fr%C3%B6hlingauthor=R.+F.+Schlenkauthor=J.+Breitruckauthor=A.+Bennerauthor=S.+Kreitmeierauthor=K.+Tobisauthor=H.+D%C3%B6hnerauthor=K.+D%C3%B6hner&title=Prognostic+significance+of+activating+FLT3+mutations+in+younger+adults+%2816+to+60+years%29+with+acute+myeloid+leukemia+and+normal+cytogenetics%3A+a+study+of+the+AML+Study+Group+Ulm&doi=10.1182%2Fblood-2002-05-1440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group Ulm</span></div><div class="casAuthors">Frohling, Stefan; Schlenk, Richard F.; Breitruck, Jochen; Benner, Axel; Kreitmeier, Sylvia; Tobis, Karen; Dohner, Hartmut; Dohner, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4372-4380</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To assess the prognostic relevance of activating mutations of the FLT3 gene in homogeneously treated adults 16 to 60 yr of age with acute myeloid leukemia (AML) and normal cytogenetics, pretreatment samples from 224 patients entered into 2 consecutive multicenter treatment trials were analyzed for FLT3 internal tandem duplications (ITDs) and Asp835 mutations.  Treatment included intensive double-induction therapy and postremission therapy with high cumulative doses of high-dose cytarabine.  ITDs were detected in 32% of the patients and were related to de novo AML and to high white blood cell (WBC) counts, percentages of peripheral blood (PB) and bone marrow (BM) blasts, and serum lactate dehydrogenase levels.  Asp835 mutations were present in 14% of the patients and were assocd. with WBC counts and percentages of PB and BM blasts that were higher than those of patients without FLT3 mutations.  With a median follow-up of 34 mo, remission duration and overall survival (OS) were significantly shorter for patients with Asp835 mutations or an ITD than for those without FLT3 mutations.  These results were attributable mainly to the neg. prognostic effect of FLT3 ITDs.  On multivariate anal., mutant FLT3 was an independent marker affecting remission duration and OS (hazard ratio, 2.35 and 2.11, resp.).  Fluorescence in situ hybridization did not detect monoallelic FLT3 deletions in ITD-pos. patients.  FLT3 mutations identify a subset of young AML patients with normal cytogenetics who do not benefit from intensive chemotherapy, including double-induction and postremission therapy with high-dose cytarabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5OxLOop4i7rVg90H21EOLACvtfcHk0lh-HkesxwnD5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsFCqsL4%253D&md5=5720f6a42a67b4481b331219ad8e30ca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-05-1440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-05-1440%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DBreitruck%26aufirst%3DJ.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DKreitmeier%26aufirst%3DS.%26aulast%3DTobis%26aufirst%3DK.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26atitle%3DPrognostic%2520significance%2520of%2520activating%2520FLT3%2520mutations%2520in%2520younger%2520adults%2520%252816%2520to%252060%2520years%2529%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520normal%2520cytogenetics%253A%2520a%2520study%2520of%2520the%2520AML%2520Study%2520Group%2520Ulm%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D4372%26epage%3D4380%26doi%3D10.1182%2Fblood-2002-05-1440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kikushige, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niiro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagafuji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, K.</span></span> <span> </span><span class="NLM_article-title">Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">7358</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.180.11.7358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.4049%2Fjimmunol.180.11.7358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=18490735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=7358-7367&author=Y.+Kikushigeauthor=G.+Yoshimotoauthor=T.+Miyamotoauthor=T.+Iinoauthor=Y.+Moriauthor=H.+Iwasakiauthor=H.+Niiroauthor=K.+Takenakaauthor=K.+Nagafujiauthor=M.+Haradaauthor=F.+Ishikawaauthor=K.+Akashi&title=Human+Flt3+is+expressed+at+the+hematopoietic+stem+cell+and+the+granulocyte%2Fmacrophage+progenitor+stages+to+maintain+cell+survival&doi=10.4049%2Fjimmunol.180.11.7358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival</span></div><div class="casAuthors">Kikushige, Yoshikane; Yoshimoto, Goichi; Miyamoto, Toshihiro; Iino, Tadafumi; Mori, Yasuo; Iwasaki, Hiromi; Niiro, Hiroaki; Takenaka, Katsuto; Nagafuji, Koji; Harada, Mine; Ishikawa, Fumihiko; Akashi, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7358-7367</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">FLT3/FLK2, a member of the receptor tyrosine kinase family, plays a crit. role in maintenance of hematopoietic homeostasis, and the constitutively active form of the FLT3 mutation is one of the most common genetic abnormalities in acute myelogenous leukemia.  In murine hematopoiesis, Flt3 is not expressed in self-renewing hematopoietic stem cells, but its expression is restricted to the multipotent and the lymphoid progenitor stages at which cells are incapable of self-renewal.  The authors extensively analyzed the expression of Flt3 in human (h) hematopoiesis.  Strikingly, in both the bone marrow and the cord blood, the human hematopoietic stem cell population capable of long-term reconstitution in xenogeneic hosts uniformly expressed Flt3.  Furthermore, human Flt3 is expressed not only in early lymphoid progenitors, but also in progenitors continuously along the granulocyte/macrophage pathway, including the common myeloid progenitor and the granulocyte/macrophage progenitor.  The authors further found that human Flt3 signaling prevents stem and progenitors from spontaneous apoptotic cell death at least through up-regulating Mcl-1, an indispensable survival factor for hematopoiesis.  Thus, the distribution of Flt3 expression is considerably different in human and mouse hematopoiesis, and human FLT3 signaling might play an important role in cell survival, esp. at stem and progenitor cells that are crit. cellular targets for acute myelogenous leukemia transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKXcrR-KQExrVg90H21EOLACvtfcHk0lh-HkesxwnD5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D&md5=3ff9bbe7a42c4ce0a87017014f7c3c2b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.180.11.7358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.180.11.7358%26sid%3Dliteratum%253Aachs%26aulast%3DKikushige%26aufirst%3DY.%26aulast%3DYoshimoto%26aufirst%3DG.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DIino%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DTakenaka%26aufirst%3DK.%26aulast%3DNagafuji%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DF.%26aulast%3DAkashi%26aufirst%3DK.%26atitle%3DHuman%2520Flt3%2520is%2520expressed%2520at%2520the%2520hematopoietic%2520stem%2520cell%2520and%2520the%2520granulocyte%252Fmacrophage%2520progenitor%2520stages%2520to%2520maintain%2520cell%2520survival%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D7358%26epage%3D7367%26doi%3D10.4049%2Fjimmunol.180.11.7358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Duhier, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodeve, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Care, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peake, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. T.</span></span> <span> </span><span class="NLM_article-title">Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2141.2001.02850.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1046%2Fj.1365-2141.2001.02850.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=11442493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2001&pages=983-988&author=F.+M.+Abu-Duhierauthor=A.+C.+Goodeveauthor=G.+A.+Wilsonauthor=R.+S.+Careauthor=I.+R.+Peakeauthor=J.+T.+Reilly&title=Identification+of+novel+FLT-3+Asp835+mutations+in+adult+acute+myeloid+leukaemia&doi=10.1046%2Fj.1365-2141.2001.02850.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia</span></div><div class="casAuthors">Abu-Duhier, F. M.; Goodeve, A. C.; Wilson, G. A.; Care, R. S.; Peake, I. R.; Reilly, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">983-988</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Genomic DNA from 97 cases of adult de novo acute myeloid leukemia (AML) was screened using polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) for FLT3 exon 20 mutations.  Initial sequencing of four cases, representing the spectrum of CSGE abnormalities, revealed changes affecting codon Asp835 in three cases and also an intron 20 A to G change.  In order to identify all possible Asp835 alterations, as well as the frequency of the intronic change nucleotide 2541+57 A→G, the patient PCR products were digested with EcoRV and NlaIII resp.  Seven cases (7.2%) possessed a mutation affecting Asp835; these were identified, following DNA sequencing, as Asp835Tyr (n = 5), Asp835His (n = 1) and Asp835del (n = 1).  Alterations affecting Asp835 were not found in 80 normal control DNA samples.  In contrast, the nucleotide 2541+57 A→G change was shown to be a polymorphism, with an allelic frequency of 0.24 for the G and 0.76 for the A allele.  This study reports, for the first time, point mutations in the human FLT3 gene that, because of their homol. with other class III receptor tyrosine kinase mutations, probably result in constitutive activation of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyMMv-RBFxCbVg90H21EOLACvtfcHk0lh-HkesxwnD5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D&md5=7989d20d19f76954dbeaf2fde89d8add</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2141.2001.02850.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2141.2001.02850.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Duhier%26aufirst%3DF.%2BM.%26aulast%3DGoodeve%26aufirst%3DA.%2BC.%26aulast%3DWilson%26aufirst%3DG.%2BA.%26aulast%3DCare%26aufirst%3DR.%2BS.%26aulast%3DPeake%26aufirst%3DI.%2BR.%26aulast%3DReilly%26aufirst%3DJ.%2BT.%26atitle%3DIdentification%2520of%2520novel%2520FLT-3%2520Asp835%2520mutations%2520in%2520adult%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2001%26volume%3D113%26spage%3D983%26epage%3D988%26doi%3D10.1046%2Fj.1365-2141.2001.02850.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boissel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brethon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvrignon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesnel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruchel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preudhomme, C.</span></span> <span> </span><span class="NLM_article-title">Acute Leukemia French Association (ALFA) and the Leucémies Aiguës Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">965</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fsj.leu.2404188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=16598313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVymtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=965-970&author=N.+Boisselauthor=H.+Leroyauthor=B.+Brethonauthor=N.+Philippeauthor=S.+de+Bottonauthor=A.+Auvrignonauthor=E.+Raffouxauthor=T.+Leblancauthor=X.+Thomasauthor=O.+Hermineauthor=B.+Quesnelauthor=A.+Baruchelauthor=G.+Levergerauthor=H.+Dombretauthor=C.+Preudhomme&title=Acute+Leukemia+French+Association+%28ALFA%29+and+the+Leuc%C3%A9mies+Aigu%C3%ABs+My%C3%A9loblastiques+de+l%E2%80%99Enfant+%28LAME%29+Cooperative+Groups.+Incidence+and+prognostic+impact+of+c-kit%2C+FLT3%2C+and+Ras+gene+mutations+in+core+binding+factor+acute+myeloid+leukemia+%28CBF-AML%29&doi=10.1038%2Fsj.leu.2404188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)</span></div><div class="casAuthors">Boissel, N.; Leroy, H.; Brethon, B.; Philippe, N.; de Botton, S.; Auvrignon, A.; Raffoux, E.; Leblanc, T.; Thomas, X.; Hermine, O.; Quesnel, B.; Baruchel, A.; Leverger, G.; Dombret, H.; Preudhomme, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">965-970</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In core binding factors (CBF) acute myeloid leukemia (AML), the disruption of CBFα/β genes impairs normal hematopoietic differentiation and is supposed to cooperate with addnl. mutations promoting proliferation.  The incidence and the prognosis of receptor tyrosine kinase (RTK) c-Kit and FLT3 mutations and Ras mutations were evaluated in 103 pediatric and adult patients with CBF-AML. c-Kit mutations were present in 17% patients. c-Kit exon 8 mutations were more frequent in inv(16) than in t(8;21) subset (20 vs. 6%).  Only one patient had FLT3-ITD but FLT3-D835 was as frequent as reported in AML population (7%).  Ras mutations were significantly more frequent in inv(16) than in t(8;21) subset (36 vs. 8%, P=0.001).  RTK mutations were assocd. with a higher white blood cell count (WBC) (36 vs. 21 G/L, P=0.05).  FLT3 mutations were significantly assocd. with a shorter EFS and survival (P<0.0001 and P=0.0002) owing to an excess of early events. c-Kit mutations were assocd. with a shorter EFS and RFS (P=0.002 and P=0.003) in t(8;21) but not inv(16) patients.  As previously obsd., Ras mutations did not affect prognosis.  Screening for RTK mutations may help to identify patients with a more adverse outcome and thus susceptible to benefit from intensified protocols or RTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS1ibFNaWpL7Vg90H21EOLACvtfcHk0li37rWL9NI2Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVymtL8%253D&md5=3157803f6302d4f4fcca7c3d0ceda228</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404188%26sid%3Dliteratum%253Aachs%26aulast%3DBoissel%26aufirst%3DN.%26aulast%3DLeroy%26aufirst%3DH.%26aulast%3DBrethon%26aufirst%3DB.%26aulast%3DPhilippe%26aufirst%3DN.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DAuvrignon%26aufirst%3DA.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DLeblanc%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DQuesnel%26aufirst%3DB.%26aulast%3DBaruchel%26aufirst%3DA.%26aulast%3DLeverger%26aufirst%3DG.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DPreudhomme%26aufirst%3DC.%26atitle%3DAcute%2520Leukemia%2520French%2520Association%2520%2528ALFA%2529%2520and%2520the%2520Leuc%25C3%25A9mies%2520Aigu%25C3%25ABs%2520My%25C3%25A9loblastiques%2520de%2520l%25E2%2580%2599Enfant%2520%2528LAME%2529%2520Cooperative%2520Groups.%2520Incidence%2520and%2520prognostic%2520impact%2520of%2520c-kit%252C%2520FLT3%252C%2520and%2520Ras%2520gene%2520mutations%2520in%2520core%2520binding%2520factor%2520acute%2520myeloid%2520leukemia%2520%2528CBF-AML%2529%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D965%26epage%3D970%26doi%3D10.1038%2Fsj.leu.2404188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzaniga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colapietro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elice, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadali, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larizza, L.</span></span> <span> </span><span class="NLM_article-title">KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15339674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2jsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2004&pages=920-925&author=A.+Beghiniauthor=C.+B.+Ripamontiauthor=R.+Cairoliauthor=G.+Cazzanigaauthor=P.+Colapietroauthor=F.+Eliceauthor=G.+Nadaliauthor=G.+Grilloauthor=O.+A.+Haasauthor=A.+Biondiauthor=E.+Morraauthor=L.+Larizza&title=KIT+activating+mutations%3A+incidence+in+adult+and+pediatric+acute+myeloid+leukemia%2C+and+identification+of+an+internal+tandem+duplication"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication</span></div><div class="casAuthors">Beghini, Alessandro; Ripamonti, Carla B.; Cairoli, Roberto; Cazzaniga, Giovanni; Colapietro, Patrizia; Elice, Francesca; Nadali, Gianpaolo; Grillo, Giovanni; Haas, Oskar A.; Biondi, Andrea; Morra, Enrica; Larizza, Lidia</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">920-925</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Mutations of KIT receptor tyrosine kinase are involved in the constitutive activation and development of human hematol. malignancies.  Gain-of-function mutations in the second intracellular kinase domain (TK2) and in the juxtamembrane domain are described in patients with core binding factor acute myeloid leukemia (CBFL) and are assocd. with leukocytosis.  We evaluated the incidence of KIT mutation in 52 adult patients with de novo CBFL and in 49 FLT3/ITD-neg. childhood patients with de novo acute myeloid leukemia (AML), excluding cases of acute promyelocytic leukemia.  In order to analyze the role of KIT in CBFL we examd. the KIT mutations in 52 adult CBFL, including 15 previously reported patients, and in 49 non-APL childhood AML patients using sensitive detection methods.  We correlated our findings with the presence of trisomy 4 and investigated the relationship of the extra chromosome 4 with KIT mutations.  Several kinds of gain-of-function KIT mutations were found in 24 of the 52 (46.1%) adult CBFL cases and 6 of the 49 (12.2%) non-APL childhood AML patients.  KIT mutations were detected in 4 of the 8 adult patients and one childhood AML case bearing trisomy of chromosome 4 as either the sole cytogenetic aberration or a karyotypic aberration addnl. to t(8;21).  In three of the trisomy 4 cases we demonstrated that trisomy 4 leads to duplication of the KIT mutated allele.  These results underline that the KIT gene is activated in AML characterized by distinct cytogenetic and mol. genetic patterns and represents the most frequently mutated target in adult CBFL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ-Z_ofoCbQ7Vg90H21EOLACvtfcHk0li37rWL9NI2Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2jsLo%253D&md5=822eece5386084d15bbcf57c37a0575e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DRipamonti%26aufirst%3DC.%2BB.%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DCazzaniga%26aufirst%3DG.%26aulast%3DColapietro%26aufirst%3DP.%26aulast%3DElice%26aufirst%3DF.%26aulast%3DNadali%26aufirst%3DG.%26aulast%3DGrillo%26aufirst%3DG.%26aulast%3DHaas%26aufirst%3DO.%2BA.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DMorra%26aufirst%3DE.%26aulast%3DLarizza%26aufirst%3DL.%26atitle%3DKIT%2520activating%2520mutations%253A%2520incidence%2520in%2520adult%2520and%2520pediatric%2520acute%2520myeloid%2520leukemia%252C%2520and%2520identification%2520of%2520an%2520internal%2520tandem%2520duplication%26jtitle%3DHaematologica%26date%3D2004%26volume%3D89%26spage%3D920%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span> <span> </span><span class="NLM_article-title">Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">5593</span>– <span class="NLM_lpage">5603</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-03-343988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2011-03-343988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=21881046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=5593-5603&author=Y.+Shenauthor=Y.-M.+Zhuauthor=X.+Fanauthor=J.-Y.+Shiauthor=Q.-R.+Wangauthor=X.-J.+Yanauthor=Z.-H.+Guauthor=Y.-Y.+Wangauthor=B.+Chenauthor=C.-L.+Jiangauthor=H.+Yanauthor=F.-F.+Chenauthor=H.-M.+Chenauthor=Z.+Chenauthor=J.+Jinauthor=S.-J.+Chen&title=Gene+mutation+patterns+and+their+prognostic+impact+in+a+cohort+of+1185+patients+with+acute+myeloid+leukemia&doi=10.1182%2Fblood-2011-03-343988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia</span></div><div class="casAuthors">Shen, Yang; Zhu, Yong-Mei; Fan, Xing; Shi, Jing-Yi; Wang, Win-Rong; Yan, Xiao-Jing; Gu, Zhao-Hui; Wang, Yan-Yan; Chen, Bing; Jiang, Chun-Lei; Yan, Han; Chen, Fei-Fei; Chen, Hai-Min; Chen, Zhu; Jin, Jie; Chen, Sai-Juan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5593-5603</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML) patients, we examd. the gene status for both fusion products such as AML1 (CBFα)-ETO, CBFβ-MYH11, PML-RARα, and MLL rearrangement as a result of chromosomal translocations and mutations in genes including FLT3, C-KIT, N-RAS, NPM1, CEBPA, WT1, ASXL1, DNMT3A, MLL, IDH1, IDH2, and TET2 in 1185 AML patients.  Clin. anal. was mainly carried out among 605 cases without recognizable karyotype abnormalities except for 11q23.  Of these 605 patients, 452 (74.7%) were found to have at least 1 mutation, and the relationship of gene mutations with clin. outcome was investigated.  We revealed a correlation pattern among NPM1, DNMT3A, FLT3, IDH1, IDH2, CEBPA, and TET2 mutations.  Multivariate anal. identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event-free survival (EFS), whereas biallelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in both the whole group and among younger patients < 60 years of age.  The use of mol. markers allowed us to subdivide the series of 605 patients into distinct prognostic groups with potential clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUMhCyQzG2g7Vg90H21EOLACvtfcHk0lh4Jmbx2vRqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqtrzO&md5=bb8076c36e63b1d63a3fba3fe42894c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-03-343988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-03-343988%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.-M.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.-Y.%26aulast%3DWang%26aufirst%3DQ.-R.%26aulast%3DYan%26aufirst%3DX.-J.%26aulast%3DGu%26aufirst%3DZ.-H.%26aulast%3DWang%26aufirst%3DY.-Y.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DC.-L.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DF.-F.%26aulast%3DChen%26aufirst%3DH.-M.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.-J.%26atitle%3DGene%2520mutation%2520patterns%2520and%2520their%2520prognostic%2520impact%2520in%2520a%2520cohort%2520of%25201185%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D5593%26epage%3D5603%26doi%3D10.1182%2Fblood-2011-03-343988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadali, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elice, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colapietro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichelatti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunghi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuneo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodeghiero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzolo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larizza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span> <span> </span><span class="NLM_article-title">Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3463</span>– <span class="NLM_lpage">3468</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-09-3640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2005-09-3640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=16384925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Git7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3463-3468&author=R.+Cairoliauthor=A.+Beghiniauthor=G.+Grilloauthor=G.+Nadaliauthor=F.+Eliceauthor=C.+B.+Ripamontiauthor=P.+Colapietroauthor=M.+Nichelattiauthor=L.+Pezzettiauthor=M.+Lunghiauthor=A.+Cuneoauthor=A.+Violaauthor=F.+Ferraraauthor=M.+Lazzarinoauthor=F.+Rodeghieroauthor=G.+Pizzoloauthor=L.+Larizzaauthor=E.+Morra&title=Prognostic+impact+of+c-KIT+mutations+in+core+binding+factor+leukemias%3A+an+Italian+retrospective+study&doi=10.1182%2Fblood-2005-09-3640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study</span></div><div class="casAuthors">Cairoli, Roberto; Beghini, Alessandro; Grillo, Giovanni; Nadali, Gianpaolo; Elice, Francesca; Ripamonti, Carla Barbara; Colapietro, Patrizia; Nichelatti, Michele; Pezzetti, Laura; Lunghi, Monia; Cuneo, Antonio; Viola, Assunta; Ferrara, Felicetto; Lazzarino, Mario; Rodeghiero, Francesco; Pizzolo, Giovanni; Larizza, Lidia; Morra, Enrica</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3463-3468</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain, exon 8, and internal tandem duplication (ITD) mutations of c-KIT, were obsd. in about 46% of core binding factor leukemia (CBFL) patients.  To evaluate their prognostic significance, 67 adult patients with CBFL were analyzed to ascertain the c-KIT mutation status.  In acute myeloid leukemia (AML) with t(8;21), the presence of c-KIT TKD mutation at codon 816 (TKD816) was assocd. with a high white blood cell count at diagnosis (median, 29.60 × 109/L) and a higher incidence (33%) of extramedullary leukemia (EML) during the course of the disease.  Data also showed that the TKD816 mutated patients (n = 12) had a significantly higher incidence of relapse and a lower overall survival (OS) at 24 mo, compared with the 17 c-KIT unmutated (c-KIT-) patients (90% vs 35.3%, P = .002; 25% vs 76.5%, P = .006, resp.).  No difference in relapse incidence (P = .126) and OS (P = .474) was obsd. between the c-KIT mutated other than TKD816 (n = 7) and the c-KIT patients.  These findings indicate that c-KIT TKD816 mutation has a neg. impact on the outcome of AML with t(8;21).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-PTedhnPNrVg90H21EOLACvtfcHk0lh4Jmbx2vRqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Git7Y%253D&md5=8ebedd57cca52e77db305f45d6eab23a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-09-3640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-09-3640%26sid%3Dliteratum%253Aachs%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DGrillo%26aufirst%3DG.%26aulast%3DNadali%26aufirst%3DG.%26aulast%3DElice%26aufirst%3DF.%26aulast%3DRipamonti%26aufirst%3DC.%2BB.%26aulast%3DColapietro%26aufirst%3DP.%26aulast%3DNichelatti%26aufirst%3DM.%26aulast%3DPezzetti%26aufirst%3DL.%26aulast%3DLunghi%26aufirst%3DM.%26aulast%3DCuneo%26aufirst%3DA.%26aulast%3DViola%26aufirst%3DA.%26aulast%3DFerrara%26aufirst%3DF.%26aulast%3DLazzarino%26aufirst%3DM.%26aulast%3DRodeghiero%26aufirst%3DF.%26aulast%3DPizzolo%26aufirst%3DG.%26aulast%3DLarizza%26aufirst%3DL.%26aulast%3DMorra%26aufirst%3DE.%26atitle%3DPrognostic%2520impact%2520of%2520c-KIT%2520mutations%2520in%2520core%2520binding%2520factor%2520leukemias%253A%2520an%2520Italian%2520retrospective%2520study%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3463%26epage%3D3468%26doi%3D10.1182%2Fblood-2005-09-3640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H. D.</span></span> <span> </span><span class="NLM_article-title">KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1007/s00277-012-1580-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1007%2Fs00277-012-1580-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23053179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2013&pages=163-171&author=H.-J.+Kimauthor=H.+K.+Ahnauthor=C.+W.+Jungauthor=J.+H.+Moonauthor=C.-H.+Parkauthor=K.-O.+Leeauthor=S.-H.+Kimauthor=Y.-K.+Kimauthor=H.-J.+Kimauthor=S.+K.+Sohnauthor=S.+H.+Kimauthor=W.+S.+Leeauthor=K.+H.+Kimauthor=Y.-C.+Munauthor=H.+Kimauthor=J.+Parkauthor=W.+S.+Minauthor=H.-J.+Kimauthor=D.+H.+D.+Kim&title=KIT+D816+mutation+associates+with+adverse+outcomes+in+core+binding+factor+acute+myeloid+leukemia%2C+especially+in+the+subgroup+with+RUNX1%2FRUNX1T1+rearrangement&doi=10.1007%2Fs00277-012-1580-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement</span></div><div class="casAuthors">Kim, Hee-Jin; Ahn, Hee Kyung; Jung, Chul Won; Moon, Joon Ho; Park, Chang-Hun; Lee, Ki-O.; Kim, Sun-Hee; Kim, Yeo-Kyeoung; Kim, Hyeoung-Joon; Sohn, Sang Kyun; Kim, Sung Hyun; Lee, Won Sik; Kim, Kyoung Ha; Mun, Yeung-Chul; Kim, Hawk; Park, Jinny; Min, Woo-Sung; Kim, Hee-Je; Kim, Dong Hwan Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-171</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Core binding factor (CBF)-pos. acute myeloid leukemia (AML) presents a favorable prognosis, except for patients with KIT mutation, esp. D816 mutation.  The current retrospective study attempted to validate a prognostic role of KIT mutation in 121 Korean patients with CBF AML.  The study patients consisted of 121 patients with CBF AML (82 patients with RUNX1/RUNX1T1 [67.8 %] and 39 patients with CBFB/MYH11 [32.2 %]) recruited from eight institutions in Korea.  All patients received idarubicin plus cytarabine or behenoyl cytosine arabinoside 3 + 7 induction chemotherapy.  The KIT gene mutation status was detd. by direct sequencing analyses.  A KIT mutation was detected in 32 cases (26.4 %) in our series of patients.  The KIT mutation was most frequent in exon 17 (n = 18, 14.9 %; n = 16 with D816 mutation), followed by exon 8 (n = 10, 8.3 %).  The presence of KIT D816 mutation was assocd. with adverse outcomes for the event-free survival (p = 0.03) and for the overall survival (p = 0.02).  The unfavorable impact of D816 mutation was more prominent when the anal. was confined to the RUNX1/RUNX1T1 subtype.  The KIT mutation was detected in 26.4 % of Korean patients with CBF AML.  The KIT D816 mutation demonstrated an unfavorable prognostic implication, particularly in the RUNX1/RUNX1T1 subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj8NJvDprBILVg90H21EOLACvtfcHk0lh4Jmbx2vRqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslyksQ%253D%253D&md5=d7f9c9f6672d6e1d9c3851366ae793df</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs00277-012-1580-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-012-1580-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DAhn%26aufirst%3DH.%2BK.%26aulast%3DJung%26aufirst%3DC.%2BW.%26aulast%3DMoon%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DC.-H.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DY.-K.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DSohn%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DMun%26aufirst%3DY.-C.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DMin%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DD.%2BH.%2BD.%26atitle%3DKIT%2520D816%2520mutation%2520associates%2520with%2520adverse%2520outcomes%2520in%2520core%2520binding%2520factor%2520acute%2520myeloid%2520leukemia%252C%2520especially%2520in%2520the%2520subgroup%2520with%2520RUNX1%252FRUNX1T1%2520rearrangement%26jtitle%3DAnn.%2520Hematol.%26date%3D2013%26volume%3D92%26spage%3D163%26epage%3D171%26doi%3D10.1007%2Fs00277-012-1580-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span> <span> </span><span class="NLM_article-title">BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT–driven myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2323</span>– <span class="NLM_lpage">2333</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-1006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1158%2F1535-7163.MCT-15-1006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=27512117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2323-2333&author=L.-T.+Chenauthor=C.-T.+Chenauthor=W.-T.+Jiaangauthor=T.-Y.+Chenauthor=J.-H.+Butterfieldauthor=N.-Y.+Shihauthor=J.+T.-A.+Hsuauthor=H.-Y.+Linauthor=S.-F.+Linauthor=H.-J.+Tsai&title=BPR1J373%2C+an+oral+multiple+tyrosine+kinase+inhibitor%2C+targets+c-KIT+for+the+treatment+of+c-KIT%E2%80%93driven+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-15-1006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia</span></div><div class="casAuthors">Chen, Li-Tzong; Chen, Chiung-Tong; Jiaang, Weir-Torn; Chen, Tsai-Yun; Butterfield, Joseph H.; Shih, Neng-Yao; Hsu, John Tsu-An; Lin, Hui-You; Lin, Sheng-Fung; Tsai, Hui-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2323-2333</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myelogenous leukemia (AML) carrying t(8;21)(q22;q22) or inv(16)/t(16;16)(p13;q22) is classified as core binding factor (CBF)-AML and accounts for approx. 15% of AML.  C-KIT mutation can be detected in 17%∼46% of CBF-AML and is assocd. with poor prognosis.  C-KIT mutation is a crucial hit and cooperates with AML1-ETO resulting from t(8;21)(q22;q22) to cause overt AML.  Tyrosine kinase inhibitors (TKI) targeting c-KIT, such as imatinib, has been used successfully to treat c-KIT driven gastrointestinal stromal tumors.  However, the effect of TKI on c-KIT-driven leukemia, including CBF-AML and systemic mastocytosis (SM), has not been satisfactory.  BPR1J373 is a 5-phenylthiazol-2-ylamine-pyriminide deriv. targeting multiple tyrosine kinases.  It was shown to inhibit cell proliferation and induce apoptosis in AML cells with constitutively activated c-KIT via inhibiting c-KIT phosphorylation and its downstream signals.  The compd. induced apoptosis by the mitochondrial intrinsic pathway through upregulation of proapoptotic proteins Bax and Bak and caspase 8 and 9 activation in c-KIT mutant Kasumi-1 cells.  Furthermore, it induced cell-cycle arrest via targeting aurora kinase B in c-KIT wild-type KG-1 cells.  The antitumor response of BPR1J373 was also shown in s.c. grafted SCID mice.  BPR1J373 was shown to effectively suppress c-KIT phosphorylation of D816V mutation by treating c-KIT-null COS-1 cells transfected with c-KIT D816V mutant plasmid.  In conclusion, BPR1J373 inhibits cell proliferation of c-KIT-driven AML cells via induction of apoptosis and cell-cycle arrest.  It is also effective for multiple drug-resistant c-KIT D816V mutation.  BPR1J373 deserves further development for clin. use in c-KIT-driven myeloid leukemia.  Mol Cancer Ther; 15(10); 2323-33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4zD_iK24M3rVg90H21EOLACvtfcHk0lhbtpN7yxX7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbvF&md5=6cdc91f7966670a03c7d9aedf0443a75</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-1006%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.-T.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DJiaang%26aufirst%3DW.-T.%26aulast%3DChen%26aufirst%3DT.-Y.%26aulast%3DButterfield%26aufirst%3DJ.-H.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLin%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DS.-F.%26aulast%3DTsai%26aufirst%3DH.-J.%26atitle%3DBPR1J373%252C%2520an%2520oral%2520multiple%2520tyrosine%2520kinase%2520inhibitor%252C%2520targets%2520c-KIT%2520for%2520the%2520treatment%2520of%2520c-KIT%25E2%2580%2593driven%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2323%26epage%3D2333%26doi%3D10.1158%2F1535-7163.MCT-15-1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span> <span> </span><span class="NLM_article-title">Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes</span>. <i>Arch. Iran. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=20039765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2isr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=21-25&author=F.+Zakerauthor=M.+Mohammadzadehauthor=M.+Mohammadi&title=Detection+of+KIT+and+FLT3+mutations+in+acute+myeloid+leukemia+with+different+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes</span></div><div class="casAuthors">Zaker, Farhad; Mohammadzadeh, Mohammad; Mohammadi, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Iranian Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-25</span>CODEN:
                <span class="NLM_cas:coden">AIMRD2</span>;
        ISSN:<span class="NLM_cas:issn">1029-2977</span>.
    
            (<span class="NLM_cas:orgname">Academy of Medical Sciences of the I. R. Iran</span>)
        </div><div class="casAbstract">Background: Mutations in KIT and fms-like tyrosine kinase 3 genes lead to uncontrolled proliferation of leukemic cells with a poor prognosis.  Since, data concerning the incidence and assocns. with patients characteristics vary amongst different studies, the aim of the present study is to identify and quantify the frequency of mutations in Iranian patients suffering from acute myeloid leukemia.  Methods: Internal tandem duplication and D835 mutations in the fms-like tyrosine kinase 3 gene of acute myeloid leukemia patients were studied through polymerase chain reaction and polymerase chain reaction-RFLP anal.  Amplified products for a point mutation in D816 for KIT have also been identified through the polymerase chain reaction-RFLP technique.  The mutations in exon 8 of KIT were detected by using the PCR and the Conformational Sensitive Gel Electrophoresis techniques, and amplified products have been confirmed by sequencing techniques.  Results: Internal tandem duplication and D835 mutations in the fms-like tyrosine kinase 3 gene occurred in 18% and 6% of AML patients, resp.  Frequencies of mutation were 1.4% and 4.7% in exon 8 and D816 of the KIT gene in acute myeloid leukemia patients.  These results were substantially different for various subclasses of French-American-British classification.  Conclusion: This study revealed that approx. 30% of acute myeloid leukemia patients have either KIT or fms-like tyrosine kinase 3 genetic mutations.  The presence of fms-like tyrosine kinase 3 was significantly assocd. with M3 morphol. and mutations of KIT were significantly assocd. with M2 and M4 subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEOqJdH-gspLVg90H21EOLACvtfcHk0lhbtpN7yxX7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2isr%252FO&md5=26d1cbeb3a8b12d53ab621e2586914a3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaker%26aufirst%3DF.%26aulast%3DMohammadzadeh%26aufirst%3DM.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DDetection%2520of%2520KIT%2520and%2520FLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520with%2520different%2520subtypes%26jtitle%3DArch.%2520Iran.%2520Med.%26date%3D2010%26volume%3D13%26spage%3D21%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrekar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiede, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Coco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandwein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederwieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span> <span> </span><span class="NLM_article-title">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1614359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJMoa1614359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=28644114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=454-464&author=R.+M.+Stoneauthor=S.+J.+Mandrekarauthor=B.+L.+Sanfordauthor=K.+Laumannauthor=S.+Geyerauthor=C.+D.+Bloomfieldauthor=C.+L.+Thiedeauthor=T.+W.+Priorauthor=K.+D%C3%B6hnerauthor=G.+Marcucciauthor=F.+Lo-Cocoauthor=R.+B.+Klisovicauthor=A.+Weiauthor=J.+Sierraauthor=M.+A.+Sanzauthor=J.+M.+Brandweinauthor=T.+de+Witteauthor=D.+Niederwieserauthor=F.+R.+Appelbaumauthor=B.+C.+Medeirosauthor=M.+S.+Tallmanauthor=J.+Krauterauthor=R.+F.+Schlenkauthor=A.+Ganserauthor=H.+Serveauthor=G.+Ehningerauthor=S.+Amadoriauthor=R.+A.+Larsonauthor=H.+D%C3%B6hner&title=Midostaurin+plus+chemotherapy+for+acute+myeloid+leukemia+with+a+FLT3+mutation&doi=10.1056%2FNEJMoa1614359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span></div><div class="casAuthors">Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S.; Bloomfield, C. D.; Thiede, C.; Prior, T. W.; Dohner, K.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; Wei, A.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T.; Niederwieser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Krauter, J.; Schlenk, R. F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R. A.; Dohner, H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-464</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes.  We conducted a phase 3 trial to det. whether the addn. of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to std. chemotherapy would prolong overall survival in this population.  Methods: We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 mutations.  Patients were randomly assigned to receive std. chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or placebo.  Randomization was stratified according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal tandem duplication (ITD) mutation with either a high ratio (>0.7) or a low ratio (0.05 to 0.7) of mutant to wild-type alleles (ITD [high] and ITD [low], resp.).  Allogeneic transplantation was allowed.  The primary end point was overall survival.  Results: A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 357 to the placebo group.  The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, and TKD in 162 patients.  The treatment groups were well balanced with respect to age, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin group vs. 59.4% in the placebo group were women, P = 0.04).  Overall survival was significantly longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P = 0.009), as was event-free survival (hazard ratio for event or death, 0.78; one-sided P = 0.002).  In both the primary anal. and an anal. in which data for patients who underwent transplantation were censored, the benefit of midostaurin was consistent across all FLT3 subtypes.  The rate of severe adverse events was similar in the two groups.  Conclusions: The addn. of the multitargeted kinase inhibitor midostaurin to std. chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IT8JULCk7bVg90H21EOLACvtfcHk0lhbtpN7yxX7kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK&md5=9b0b003122a307b4d92f05826745cb8c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1614359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1614359%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DMandrekar%26aufirst%3DS.%2BJ.%26aulast%3DSanford%26aufirst%3DB.%2BL.%26aulast%3DLaumann%26aufirst%3DK.%26aulast%3DGeyer%26aufirst%3DS.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DThiede%26aufirst%3DC.%2BL.%26aulast%3DPrior%26aufirst%3DT.%2BW.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DSierra%26aufirst%3DJ.%26aulast%3DSanz%26aufirst%3DM.%2BA.%26aulast%3DBrandwein%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26atitle%3DMidostaurin%2520plus%2520chemotherapy%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520a%2520FLT3%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D454%26epage%3D464%26doi%3D10.1056%2FNEJMoa1614359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbiano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podoltsev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosono, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasabou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1728</span>– <span class="NLM_lpage">1740</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1902688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1056%2FNEJMoa1902688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=31665578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1728-1740&author=A.+E.+Perlauthor=G.+Martinelliauthor=J.+E.+Cortesauthor=A.+Neubauerauthor=E.+Bermanauthor=S.+Paoliniauthor=P.+Montesinosauthor=M.+R.+Baerauthor=R.+A.+Larsonauthor=C.+Ustunauthor=F.+Fabbianoauthor=H.+P.+Erbaauthor=A.+Di+Stasiauthor=R.+Stuartauthor=R.+Olinauthor=M.+Kasnerauthor=F.+Ciceriauthor=W.+C.+Chouauthor=N.+Podoltsevauthor=C.+Recherauthor=H.+Yokoyamaauthor=N.+Hosonoauthor=S.+S.+Yoonauthor=J.+H.+Leeauthor=T.+Pardeeauthor=A.+T.+Fathiauthor=C.+Liuauthor=N.+Hasabouauthor=X.+Liuauthor=E.+Bahceciauthor=M.+J.+Levis&title=Gilteritinib+or+Chemotherapy+for+Relapsed+or+Refractory+FLT3-Mutated+AML&doi=10.1056%2FNEJMoa1902688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML</span></div><div class="casAuthors">Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; Fabbiano, F.; Erba, H. P.; Stasi, A. Di; Stuart, R.; Olin, R.; Kasner, M.; Ciceri, F.; Chou, W.-C.; Podoltsev, N.; Recher, C.; Yokoyama, H.; Hosono, N.; Yoon, S.-S.; Lee, J.-H.; Pardee, T.; Fathi, A. T.; Liu, C.; Hasabou, N.; Liu, X.; Bahceci, E.; Levis, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1728-1740</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy.  Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refractory FLT3-mutated AML. methods In a phase 3 trial, we randomly assigned adults with relapsed or refractory FLT3-mutated AML in a 2:1 ratio to receive either gilteritinib (at a dose of 120 mg per day) or salvage chemotherapy.  The two primary end points were overall survival and the percentage of patients who had complete remission with full or partial hematol. recovery.  Secondary end points included event-free survival (freedom from treatment failure [i.e., relapse or lack of remission] or death) and the percentage of patients who had complete remission. results Of 371 eligible patients, 247 were randomly assigned to the gilteritinib group and 124 to the salvage chemotherapy group.  The median overall survival in the gilteritinib group was significantly longer than that in the chemotherapy group (9.3 mo vs. 5.6 mo; hazard ratio for death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P<0.001).  The median event-free survival was 2.8 mo in the gilteritinib group and 0.7 mo in the chemotherapy group (hazard ratio for treatment failure or death, 0.79; 95% CI, 0.58 to 1.09).  The percentage of patients who had complete remission with full or partial hematol. recovery was 34.0% in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, resp. (risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4).  In an anal. that was adjusted for therapy duration, adverse events of grade 3 or higher and serious adverse events occurred less frequently in the gilteritinib group than in the chemotherapy group; the most common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia (45.9%), anemia (40.7%), and thrombocytopenia (22.8%). conclusions Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrkmbPcDc_2rVg90H21EOLACvtfcHk0lhrWyiLQFi3GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktr3J&md5=6ea458f41ee4d275f423bf9749d920ce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1902688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1902688%26sid%3Dliteratum%253Aachs%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DBerman%26aufirst%3DE.%26aulast%3DPaolini%26aufirst%3DS.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DUstun%26aufirst%3DC.%26aulast%3DFabbiano%26aufirst%3DF.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDi%2BStasi%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DR.%26aulast%3DOlin%26aufirst%3DR.%26aulast%3DKasner%26aufirst%3DM.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DChou%26aufirst%3DW.%2BC.%26aulast%3DPodoltsev%26aufirst%3DN.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DYokoyama%26aufirst%3DH.%26aulast%3DHosono%26aufirst%3DN.%26aulast%3DYoon%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DPardee%26aufirst%3DT.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DHasabou%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DGilteritinib%2520or%2520Chemotherapy%2520for%2520Relapsed%2520or%2520Refractory%2520FLT3-Mutated%2520AML%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D1728%26epage%3D1740%26doi%3D10.1056%2FNEJMoa1902688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashman, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of c-KIT in cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1517/13543784.2013.740010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1517%2F13543784.2013.740010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23127174" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=103-115&author=L.+K.+Ashmanauthor=R.+Griffith&title=Therapeutic+targeting+of+c-KIT+in+cancer&doi=10.1517%2F13543784.2013.740010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.740010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.740010%26sid%3Dliteratum%253Aachs%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DGriffith%26aufirst%3DR.%26atitle%3DTherapeutic%2520targeting%2520of%2520c-KIT%2520in%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D22%26spage%3D103%26epage%3D115%26doi%3D10.1517%2F13543784.2013.740010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cammenga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergholz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocking, C.</span></span> <span> </span><span class="NLM_article-title">Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3961</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-02-0583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1182%2Fblood-2005-02-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=16081693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12ktr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3958-3961&author=J.+Cammengaauthor=S.+Hornauthor=U.+Bergholzauthor=G.+Sommerauthor=G.+Sommerauthor=P.+Besmerauthor=W.+Fiedlerauthor=C.+Stocking&title=Extracellular+KIT+receptor+mutants%2C+commonly+found+in+core+binding+factor+AML%2C+are+constitutively+active+and+respond+to+imatinib+mesylate&doi=10.1182%2Fblood-2005-02-0583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate</span></div><div class="casAuthors">Cammenga, Joerg; Horn, Stefan; Bergholz, Ulla; Sommer, Gunhild; Besmer, Peter; Fiedler, Walter; Stocking, Carol</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3958-3961</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Multiple genetic alterations are required to induce acute myelogenous leukemia (AML).  Mutations in the extracellular domain of the KIT receptor are almost exclusively found in patients with AML carrying translocations or inversions affecting members of the core binding factor (CBF) gene family and correlate with a high risk of relapse.  We demonstrate that these complex insertion and deletion mutations lead to constitutive activation of the KIT receptor, which induces factor-independent growth of interleukin-3 (IL-3)-dependent cells.  Mutation of the evolutionary conserved amino acid D419 within the extracellular domain was sufficient to constitutively activate the KIT receptor, although high expression levels were required.  Dose-dependent growth inhibition and apoptosis were obsd. using either the protein tyrosine kinase inhibitor imatinib mesylate (STI571, Gleevec) or by blocking the phosphoinositide-3-kinase (PI3K)-AKT pathway.  Our data show that the addn. of kinase inhibitors to conventional chemotherapy might be a new therapeutic option for CBF-AML expressing mutant KIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMvzuHAcCqt7Vg90H21EOLACvtfcHk0lhrWyiLQFi3GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12ktr3N&md5=d326a7e9c09e5345a09b4acbd12bc862</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0583%26sid%3Dliteratum%253Aachs%26aulast%3DCammenga%26aufirst%3DJ.%26aulast%3DHorn%26aufirst%3DS.%26aulast%3DBergholz%26aufirst%3DU.%26aulast%3DSommer%26aufirst%3DG.%26aulast%3DSommer%26aufirst%3DG.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DStocking%26aufirst%3DC.%26atitle%3DExtracellular%2520KIT%2520receptor%2520mutants%252C%2520commonly%2520found%2520in%2520core%2520binding%2520factor%2520AML%252C%2520are%2520constitutively%2520active%2520and%2520respond%2520to%2520imatinib%2520mesylate%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3958%26epage%3D3961%26doi%3D10.1182%2Fblood-2005-02-0583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mpakou, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontsioti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papageorgiou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottaridi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girkas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakitsos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitriadis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dervenoulas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappa, V.</span></span> <span> </span><span class="NLM_article-title">Dasatinib inhibits proliferation and induces apoptosis in the Kasumi-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2012.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.leukres.2012.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23149070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GksLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=175-182&author=V.+E.+Mpakouauthor=F.+Kontsiotiauthor=S.+Papageorgiouauthor=A.+Spathisauthor=C.+Kottaridiauthor=K.+Girkasauthor=P.+Karakitsosauthor=G.+Dimitriadisauthor=I.+Dervenoulasauthor=V.+Pappa&title=Dasatinib+inhibits+proliferation+and+induces+apoptosis+in+the+Kasumi-1+cell+line+bearing+the+t%288%3B21%29%28q22%3Bq22%29+and+the+N822K+c-kit+mutation&doi=10.1016%2Fj.leukres.2012.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation</span></div><div class="casAuthors">Mpakou, Vassiliki E.; Kontsioti, Frieda; Papageorgiou, Sotiris; Spathis, Aris; Kottaridi, Christine; Girkas, Kostas; Karakitsos, Petros; Dimitriadis, George; Dervenoulas, Ioannis; Pappa, Vasiliki</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating mutations of the c-kit gene are frequently found in CBF (core binding factor) leukemias.  We evaluated the effect of tyrosine kinase inhibitor dasatinib in leukemic cell lines bearing or not c-kit mutations.  Our data demonstrate that in the AML Kasumi-1 cell line, bearing the N822K c-kit mutation, dasatinib is a potent suppressor of c-kit and Src kinase activity and inhibits the phosphorylation of their downstream target AKT, possibly through the Src-mediated VEGF/VEGFR receptor type 2 pathway.  Dasatinib also effectively blocks proliferation and induces apoptosis through caspase-3 activation in Kasumi-1 cells.  These data further encourage the integration of dasatinib in the treatment of CBF AML with c-kit mutations in the context of clin. trials, which are eagerly anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWv_FEismgWbVg90H21EOLACvtfcHk0lh9PNNdPQb4Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GksLvE&md5=397f482ae8e13bda68734eb99112e582</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DMpakou%26aufirst%3DV.%2BE.%26aulast%3DKontsioti%26aufirst%3DF.%26aulast%3DPapageorgiou%26aufirst%3DS.%26aulast%3DSpathis%26aufirst%3DA.%26aulast%3DKottaridi%26aufirst%3DC.%26aulast%3DGirkas%26aufirst%3DK.%26aulast%3DKarakitsos%26aufirst%3DP.%26aulast%3DDimitriadis%26aufirst%3DG.%26aulast%3DDervenoulas%26aufirst%3DI.%26aulast%3DPappa%26aufirst%3DV.%26atitle%3DDasatinib%2520inhibits%2520proliferation%2520and%2520induces%2520apoptosis%2520in%2520the%2520Kasumi-1%2520cell%2520line%2520bearing%2520the%2520t%25288%253B21%2529%2528q22%253Bq22%2529%2520and%2520the%2520N822K%2520c-kit%2520mutation%26jtitle%3DLeuk.%2520Res.%26date%3D2013%26volume%3D37%26spage%3D175%26epage%3D182%26doi%3D10.1016%2Fj.leukres.2012.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larizza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, E.</span></span> <span> </span><span class="NLM_article-title">Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations a report of three cases</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2004.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.leukres.2004.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=15725473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslWlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2005&pages=397-400&author=R.+Cairoliauthor=A.+Beghiniauthor=E.+Morelloauthor=G.+Grilloauthor=M.+Montilloauthor=L.+Larizzaauthor=E.+Morra&title=Imatinib+mesylate+in+the+treatment+of+core+binding+factor+leukemias+with+KIT+mutations+a+report+of+three+cases&doi=10.1016%2Fj.leukres.2004.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases</span></div><div class="casAuthors">Cairoli, Roberto; Beghini, Alessandro; Morello, Enrico; Grillo, Giovanni; Montillo, Marco; Larizza, Lidia; Morra, Enrica</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-400</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aim of this study is to investigate the capability of Imatinib to induce an anti-leukemic effect in Core Binding Factor (CBF)-leukemia patients presenting either with extracellular juxtamembrane or kinase KIT mutations.  On the basis of a screening anal. for KIT mutations, two patients with a kinase mutation and one with extracellular juxtamembrane mutation, in first or subsequent leukemic relapse, received 400 mg Imatinib twice daily for 30 days.  After Imatinib discontinuation, bone marrow cells were re-tested to assess the KIT mutational status and the chromosomal set.  In our experience, none of the treated patients had a response by std. criteria; in particular, we did not observe any activity against acute myeloid leukemia (AML) assocd. with KIT kinase mutations.  However, in the patient with extracellular juxtamembrane mutation, Imatinib seems to have some clin. beneficial effect and, most important, is able to abrogate the leukemic subclone carrying the mutation.  Whether Imatinib, in combination with other agents, may play a role in the treatment of AML with more sensitive extracellular juxtamembrane KIT mutation remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXbvOZfx-WF7Vg90H21EOLACvtfcHk0lh9PNNdPQb4Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslWlsrk%253D&md5=2cd30e11361aa06b7c2499fd950b5fb4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2004.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2004.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DMorello%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DG.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DLarizza%26aufirst%3DL.%26aulast%3DMorra%26aufirst%3DE.%26atitle%3DImatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520core%2520binding%2520factor%2520leukemias%2520with%2520KIT%2520mutations%2520a%2520report%2520of%2520three%2520cases%26jtitle%3DLeuk.%2520Res.%26date%3D2005%26volume%3D29%26spage%3D397%26epage%3D400%26doi%3D10.1016%2Fj.leukres.2004.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kündgen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwänen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfreundschuh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringhoffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girschikofsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinicke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göhring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span> <span> </span><span class="NLM_article-title">Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1621</span>– <span class="NLM_lpage">1630</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0129-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fs41375-018-0129-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=29720733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOnu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1621-1630&author=P.+Paschkaauthor=R.+F.+Schlenkauthor=D.+Weberauthor=A.+Bennerauthor=L.+Bullingerauthor=M.+Heuserauthor=V.+I.+Gaidzikauthor=F.+Tholauthor=M.+Agrawalauthor=V.+Teleanuauthor=M.+L%C3%BCbbertauthor=W.+Fiedlerauthor=M.+Radsakauthor=J.+Krauterauthor=H.+A.+Horstauthor=R.+Greilauthor=K.+Mayerauthor=A.+K%C3%BCndgenauthor=U.+Martensauthor=G.+Heilauthor=H.+R.+Salihauthor=B.+Hertensteinauthor=C.+Schw%C3%A4nenauthor=G.+Wulfauthor=E.+Langeauthor=M.+Pfreundschuhauthor=M.+Ringhofferauthor=M.+Girschikofskyauthor=T.+Heinickeauthor=D.+Kraemerauthor=G.+G%C3%B6hringauthor=A.+Ganserauthor=K.+D%C3%B6hnerauthor=H.+D%C3%B6hner&title=Adding+dasatinib+to+intensive+treatment+in+core-binding+factor+acute+myeloid+leukemia-results+of+the+AMLSG+11-08+trial&doi=10.1038%2Fs41375-018-0129-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial</span></div><div class="casAuthors">Paschka, Peter; Schlenk, Richard F.; Weber, Daniela; Benner, Axel; Bullinger, Lars; Heuser, Michael; Gaidzik, Verena I.; Thol, Felicitas; Agrawal, Mridul; Teleanu, Veronica; Luebbert, Michael; Fiedler, Walter; Radsak, Markus; Krauter, Juergen; Horst, Heinz-A.; Greil, Richard; Mayer, Karin; Kuendgen, Andrea; Martens, Uwe; Heil, Gerhard; Salih, Helmut R.; Hertenstein, Bernd; Schwaenen, Carsten; Wulf, Gerald; Lange, Elisabeth; Pfreundschuh, Michael; Ringhoffer, Mark; Girschikofsky, Michael; Heinicke, Thomas; Kraemer, Doris; Goehring, Gudrun; Ganser, Arnold; Doehner, Konstanze; Doehner, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1621-1630</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation chemotherapy and administered as single agent for 1-yr maintenance in first-line treatment of adult patients with core-binding factor (CBF) acute myeloid leukemia (AML).  The primary combined end point in this study was safety and feasibility, and included the rates of early (ED) and hypoplastic (HD) deaths, pleural/pericardial effusion 3°/4° and liver toxicity 3°/4°, and the rate of refractory disease.  Secondary end points were cumulative incidence of relapse (CIR) and death in complete remission (CID), and overall survival (OS).  Eighty-nine pts [median age 49.5 years, range: 19-73 years; t(8;21), n = 37; inv (16), n = 52] were included.  No unexpected excess in toxicity was obsd.  The rates of ED/HD and CR/CRi were 4.5% (4/89) and 94% (84/89), resp.  The 4-yr estd. CIR, CID, and OS were 33.1% [95%-CI (confidence interval), 22.7-43.4%], 6.0% (95% CI, 0.9-11.2%), and 74.7% (95% CI, 66.1-84.5%), resp.  On the basis of the acceptable toxicity profile and favorable outcome in the AMLSG 11-08 trial, a confirmatory randomized phase III trial with dasatinib in adults with CBF-AML is ongoing (ClinicalTrials.gov Identifier: NCT02013648).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXBMxJwo61LVg90H21EOLACvtfcHk0lh9PNNdPQb4Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOnu7fL&md5=54051eb915d0ff0257f9958ba04c1c23</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0129-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0129-6%26sid%3Dliteratum%253Aachs%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DWeber%26aufirst%3DD.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DM.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DMayer%26aufirst%3DK.%26aulast%3DK%25C3%25BCndgen%26aufirst%3DA.%26aulast%3DMartens%26aufirst%3DU.%26aulast%3DHeil%26aufirst%3DG.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DHertenstein%26aufirst%3DB.%26aulast%3DSchw%25C3%25A4nen%26aufirst%3DC.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DLange%26aufirst%3DE.%26aulast%3DPfreundschuh%26aufirst%3DM.%26aulast%3DRinghoffer%26aufirst%3DM.%26aulast%3DGirschikofsky%26aufirst%3DM.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DKraemer%26aufirst%3DD.%26aulast%3DG%25C3%25B6hring%26aufirst%3DG.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26atitle%3DAdding%2520dasatinib%2520to%2520intensive%2520treatment%2520in%2520core-binding%2520factor%2520acute%2520myeloid%2520leukemia-results%2520of%2520the%2520AMLSG%252011-08%2520trial%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1621%26epage%3D1630%26doi%3D10.1038%2Fs41375-018-0129-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.ejmech.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=26081023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=151-161&author=C.-T.+Chenauthor=J.+T.-A.+Hsuauthor=W.-H.+Linauthor=C.-T.+Luauthor=S.-C.+Yenauthor=T.+Hsuauthor=Y.-L.+Huangauthor=J.-S.+Songauthor=C.-H.+Chenauthor=L.-H.+Chouauthor=K.-J.+Yenauthor=C.-P.+Chenauthor=P.-C.+Kuoauthor=C.-L.+Huangauthor=H.-E.+Liuauthor=Y.-S.+Chaoauthor=T.-K.+Yehauthor=W.-T.+Jiaang&title=Identification+of+a+potent+5-phenyl-thiazol-2-ylamine-based+inhibitor+of+FLT3+with+activity+against+drug+resistance-conferring+point+mutations&doi=10.1016%2Fj.ejmech.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations</span></div><div class="casAuthors">Chen, Chiung-Tong; Hsu, John T.-A.; Lin, Wen-Hsing; Lu, Cheng-Tai; Yen, Shih-Chieh; Hsu, Tsu; Huang, Yu-Ling; Song, Jen-Shin; Chen, Chun-Hwa; Chou, Ling-Hui; Yen, Kuei-Jung; Chen, Ching-Ping; Kuo, Po-Chu; Huang, Chen-Lung; Liu, H. Eugene; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML).  However, clin. data have been not encouraging due to incomplete inhibition of FLT3 or the emergence of resistant mutations treated with these older agents.  The authors previously developed a series of 3-phenyl-1H-5-pyrazolylamine derivs. as highly potent and selective FLT3 inhibitors with good in vivo efficacy using an i.v. (IV) route.  However, the poor bioavailability of these pyrazole compds. limits the development of these promising antileukemic compds. for clin. use.  Herein, the authors describe a novel class of 5-phenyl-thiazol-2-ylamine compds. that are multitargeted FLT3 inhibitors.  From this class of compds., compd. I was very potent against AML cell lines and exhibited excellent oral efficacy in AML xenograft models.  In addn., further studies demonstrated that compd. I exhibited potent in vitro and in vivo activities against clin. relevant AC220 (3)-resistant kinase domain mutants of FLT3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KrlNgs-LL7Vg90H21EOLACvtfcHk0lirnID6eUy6Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eltLjI&md5=d51f2152965d841a378c3c38dbcde6c7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DYen%26aufirst%3DS.-C.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.-L.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChou%26aufirst%3DL.-H.%26aulast%3DYen%26aufirst%3DK.-J.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DKuo%26aufirst%3DP.-C.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DLiu%26aufirst%3DH.-E.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DJiaang%26aufirst%3DW.-T.%26atitle%3DIdentification%2520of%2520a%2520potent%25205-phenyl-thiazol-2-ylamine-based%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520drug%2520resistance-conferring%2520point%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D100%26spage%3D151%26epage%3D161%26doi%3D10.1016%2Fj.ejmech.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lirnID6eUy6Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broekman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: Multi-targeted or single-targeted?</span>. <i>World J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.5306/wjco.v2.i2.80</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.5306%2Fwjco.v2.i2.80" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=21603317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=80-93&author=F.+Broekmanauthor=E.+Giovannettiauthor=G.+J.+Peters&title=Tyrosine+kinase+inhibitors%3A+Multi-targeted+or+single-targeted%3F&doi=10.5306%2Fwjco.v2.i2.80"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: Multi-targeted or single-targeted?</span></div><div class="casAuthors">Broekman Fleur; Giovannetti Elisa; Peters Godefridus J</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since in most tumors multiple signaling pathways are involved, many of the inhibitors in clinical development are designed to affect a wide range of targeted kinases.  The most important tyrosine kinase families in the development of tyrosine kinase inhibitors are the ABL, SCR, platelet derived growth factor, vascular endothelial growth factor receptor and epidermal growth factor receptor families.  Both multi-kinase inhibitors and single-kinase inhibitors have advantages and disadvantages, which are related to potential resistance mechanisms, pharmacokinetics, selectivity and tumor environment.  In different malignancies various tyrosine kinases are mutated or overexpressed and several resistance mechanisms exist.  Pharmacokinetics is influenced by interindividual differences and differs for two single targeted inhibitors or between patients treated by the same tyrosine kinase inhibitor.  Different tyrosine kinase inhibitors have various mechanisms to achieve selectivity, while differences in gene expression exist between tumor and stromal cells.  Considering these aspects, one type of inhibitor can generally not be preferred above the other, but will depend on the specific genetic constitution of the patient and the tumor, allowing personalized therapy.  The most effective way of cancer treatment by using tyrosine kinase inhibitors is to consider each patient/tumor individually and to determine the strategy that specifically targets the consequences of altered (epi)genetics of the tumor.  This strategy might result in treatment by a single multi kinase inhibitor for one patient, but in treatment by a couple of single kinase inhibitors for other patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUsa5qqJaBY_csfMJQC1ZdfW6udTcc2eaexWwQRRZoRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mrkt1arsw%253D%253D&md5=683eaad679244b5efc5813d1ffaaaf57</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v2.i2.80&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v2.i2.80%26sid%3Dliteratum%253Aachs%26aulast%3DBroekman%26aufirst%3DF.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520Multi-targeted%2520or%2520single-targeted%253F%26jtitle%3DWorld%2520J.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D2%26spage%3D80%26epage%3D93%26doi%3D10.5306%2Fwjco.v2.i2.80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettati, M.</span>; <span class="NLM_string-name">Churcher, I.</span>; <span class="NLM_string-name">Hunt, P. A.</span>; <span class="NLM_string-name">Steadman, V. A.</span></span> <span> </span><span class="NLM_article-title">Aminothiazole Derivatives as Inhibitors of MARK</span>. Patent WO <span class="NLM_patent">2007141571</span>, December 13, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Bettati&author=I.+Churcher&author=P.+A.+Hunt&author=V.+A.+Steadman&title=Aminothiazole+Derivatives+as+Inhibitors+of+MARK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBettati%26aufirst%3DM.%26atitle%3DAminothiazole%2520Derivatives%2520as%2520Inhibitors%2520of%2520MARK%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mjambili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizrahi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.bmcl.2013.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=24373723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=560-564&author=F.+Mjambiliauthor=M.+Njorogeauthor=K.+Naranauthor=C.+De+Kockauthor=P.+J.+Smithauthor=V.+Mizrahiauthor=D.+Warnerauthor=K.+Chibale&title=Synthesis+and+biological+evaluation+of+2-aminothiazole+derivatives+as+antimycobacterial+and+antiplasmodial+agents&doi=10.1016%2Fj.bmcl.2013.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents</span></div><div class="casAuthors">Mjambili, Faith; Njoroge, Mathew; Naran, Krupa; De Kock, Carmen; Smith, Peter J.; Mizrahi, Valerie; Warner, Digby; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">560-564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of compds. I [R = 4-O2NC6H4, 4-ClC6H4, 2-thienyl, etc.] derived from the 2-amino-4-(2-pyridyl)thiazole scaffold was synthesized and tested for in vitro antimycobacterial activity against the Mycobacterium tuberculosis H37Rv strain, antiplasmodial activity against the chloroquine sensitive NF54 Plasmodium falciparum strain and cytotoxicity on a mammalian cell line.  Optimal antimycobacterial activity was found with compds. with a 2-pyridyl ring at position 4 of the thiazole scaffold, a substituted Ph ring at the 2-amino position, and an amide linker between the scaffold and the substituted Ph.  The antiplasmodial activity was best with compds. that had the Ph ring substituted with hydrophobic electron withdrawing groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9Hw3LGvVwi7Vg90H21EOLACvtfcHk0liiPrZx_Vm-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSn&md5=85051bd02817d8033f0c23fb6c9d59f9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DMjambili%26aufirst%3DF.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DNaran%26aufirst%3DK.%26aulast%3DDe%2BKock%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3DMizrahi%26aufirst%3DV.%26aulast%3DWarner%26aufirst%3DD.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-aminothiazole%2520derivatives%2520as%2520antimycobacterial%2520and%2520antiplasmodial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D560%26epage%3D564%26doi%3D10.1016%2Fj.bmcl.2013.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artusi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennuni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calgani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Identification of aminoimidazole and aminothiazole derivatives as Src family kinase inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2027</span>– <span class="NLM_lpage">2041</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1002%2Fcmdc.201500428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=26514807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCksrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2027-2041&author=C.+M.+Franciniauthor=A.+L.+Fallacaraauthor=R.+Artusiauthor=L.+Mennuniauthor=A.+Calganiauthor=A.+Angelucciauthor=S.+Schenoneauthor=M.+Botta&title=Identification+of+aminoimidazole+and+aminothiazole+derivatives+as+Src+family+kinase+inhibitors&doi=10.1002%2Fcmdc.201500428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors</span></div><div class="casAuthors">Francini, Cinzia Maria; Fallacara, Anna Lucia; Artusi, Roberto; Mennuni, Laura; Calgani, Alessia; Angelucci, Adriano; Schenone, Silvia; Botta, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2027-2041</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Src family kinases (SFKs) are a family of non-receptor tyrosine kinases (TKs) implicated in the regulation of many cellular processes.  The aberrant activity of these TKs has been assocd. with the growth and progression of cancer.  In particular, c-Src is overexpressed or hyperactivated in a variety of solid tumors and is most likely a strong promoting factor for the development of metastasis.  Herein, the synthesis of new 4-aminoimidazole and 2-aminothiazole derivs. and their in vitro biol. evaluation are described for their potential use as SFK inhibitors.  Initially, 2-aminothiazole analogs of dasatinib and 4-aminoimidazole derivs. were synthesized and tested against the SFKs Src, Fyn, Lyn, and Yes.  Five hits were identified as the most promising compds., with Ki values in the range of 90-480 nM.  A combination of mol. docking, homol. modeling, and mol. dynamics were then used to investigate the possible binding mode of such compds. within the ATP binding site of the SFKs.  Finally, the antiproliferative activities of the best candidates were evaluated against SH-SY5Y and K562 cell lines.  Compd. 3 b [2-(4-{2-methyl-6-[(5-phenylthiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)ethanol] was found to be the most active inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd1goyBW68MbVg90H21EOLACvtfcHk0liiPrZx_Vm-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCksrbP&md5=0e48b0e39f0796f0598776baf60b1421</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500428%26sid%3Dliteratum%253Aachs%26aulast%3DFrancini%26aufirst%3DC.%2BM.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DArtusi%26aufirst%3DR.%26aulast%3DMennuni%26aufirst%3DL.%26aulast%3DCalgani%26aufirst%3DA.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520aminoimidazole%2520and%2520aminothiazole%2520derivatives%2520as%2520Src%2520family%2520kinase%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D2027%26epage%3D2041%26doi%3D10.1002%2Fcmdc.201500428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, F.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of conformational control inhibitors switching off the activated c-KIT and targeting a broad range of clinically relevant c-KIT mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3940</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01845</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01845" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=3940-3957&author=T.-S.+Wuauthor=W.-H.+Linauthor=H.-J.+Tsaiauthor=C.-C.+Hsuehauthor=T.+Hsuauthor=P.-C.+Wangauthor=H.-Y.+Linauthor=Y.-H.+Pengauthor=C.-T.+Luauthor=L.-C.+Leeauthor=C.-H.+Tuauthor=F.-C.+Kungauthor=H.-Y.+Shiaoauthor=T.-K.+Yehauthor=J.-S.+Songauthor=J.-Y.+Changauthor=Y.-C.+Suauthor=L.-T.+Chenauthor=C.-T.+Chenauthor=W.-T.+Jiaangauthor=S.-Y.+Wu&title=Discovery+of+conformational+control+inhibitors+switching+off+the+activated+c-KIT+and+targeting+a+broad+range+of+clinically+relevant+c-KIT+mutants&doi=10.1021%2Facs.jmedchem.8b01845"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01845%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.-S.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DHsueh%26aufirst%3DC.-C.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.-C.%26aulast%3DLin%26aufirst%3DH.-Y.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DLee%26aufirst%3DL.-C.%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DKung%26aufirst%3DF.-C.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DSu%26aufirst%3DY.-C.%26aulast%3DChen%26aufirst%3DL.-T.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DJiaang%26aufirst%3DW.-T.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DDiscovery%2520of%2520conformational%2520control%2520inhibitors%2520switching%2520off%2520the%2520activated%2520c-KIT%2520and%2520targeting%2520a%2520broad%2520range%2520of%2520clinically%2520relevant%2520c-KIT%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D62%26spage%3D3940%26epage%3D3957%26doi%3D10.1021%2Facs.jmedchem.8b01845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2856</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1016%2Fj.bmc.2013.03.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=23618709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2856-2867&author=W.-H.+Linauthor=J.+T.-A.+Hsuauthor=S.-Y.+Hsiehauthor=C.-T.+Chenauthor=J.-S.+Songauthor=S.-C.+Yenauthor=T.+Hsuauthor=C.-T.+Luauthor=C.-H.+Chenauthor=L.-H.+Chouauthor=Y.-N.+Yangauthor=C.-H.+Chiuauthor=C.-P.+Chenauthor=Y.-J.+Tsengauthor=K.-J.+Yenauthor=C.-F.+Yehauthor=Y.-S.+Chaoauthor=T.-K.+Yehauthor=W.-T.+Jiaang&title=Discovery+of+3-phenyl-1H-5-pyrazolylamine+derivatives+containing+a+urea+pharmacophore+as+potent+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmc.2013.03.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Lin, Wen-Hsing; Hsu, John T.-A.; Hsieh, Shu-Yi; Chen, Chiung-Tong; Song, Jen-Shin; Yen, Shih-Chieh; Hsu, Tsu; Lu, Cheng-Tai; Chen, Chun-Hwa; Chou, Ling-Hui; Yang, Yung-Ning; Chiu, Ching-Hui; Chen, Ching-Ping; Tseng, Ya-Ju; Yen, Kuei-Jung; Yeh, Ching-Fang; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2856-2867</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preclin. investigations and early clin. trials suggest that FLT3 inhibitors are a viable therapy for acute myeloid leukemia.  However, early clin. data have been underwhelming due to incomplete inhibition of FLT3.  The authors have developed 3-phenyl-1H-5-pyrazolylamine as an efficient template for kinase inhibitors.  Structure-activity relationships led to the discovery of sulfonamide, carbamate and urea series of FLT3 inhibitors.  Previous studies showed that the sulfonamide and carbamate series were potent and selective FLT3 inhibitors with good in vivo efficacy.  Herein, the authors describe the urea series, which the authors found to be potent inhibitors of FLT3 and VEGFR2.  Some inhibited growth of FLT3-mutated MOLM-13 cells more strongly than the FLT3 inhibitors sorafenib and ABT-869.  In preliminary in vivo toxicity studies of the four most active compds., N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide was found to be the least toxic.  A further in vivo efficacy study demonstrated that N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide achieved complete tumor regression in a higher proportion of MOLM-13 xenograft.  These results show that compd. N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide possesses improved pharmacol. and selectivity profiles and could be more effective than previously disclosed FLT3 inhibitors in the treatment of acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8nbO4pzTXbrVg90H21EOLACvtfcHk0lis-0t2OZhVig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D&md5=3b4f4323360170e8a7fbe763b79d3128</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.083%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DHsieh%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DYen%26aufirst%3DS.-C.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChou%26aufirst%3DL.-H.%26aulast%3DYang%26aufirst%3DY.-N.%26aulast%3DChiu%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DTseng%26aufirst%3DY.-J.%26aulast%3DYen%26aufirst%3DK.-J.%26aulast%3DYeh%26aufirst%3DC.-F.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DJiaang%26aufirst%3DW.-T.%26atitle%3DDiscovery%2520of%25203-phenyl-1H-5-pyrazolylamine%2520derivatives%2520containing%2520a%2520urea%2520pharmacophore%2520as%2520potent%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2856%26epage%3D2867%26doi%3D10.1016%2Fj.bmc.2013.03.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.-Y.</span></span> <span> </span><span class="NLM_article-title">Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3906</span>– <span class="NLM_lpage">3919</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3906-3919&author=C.-H.+Tuauthor=W.-H.+Linauthor=Y.-H.+Pengauthor=T.+Hsuauthor=J.-S.+Wuauthor=C.-Y.+Changauthor=C.-T.+Luauthor=P.-C.+Lyuauthor=C.+Shihauthor=W.-T.+Jiaangauthor=S.-Y.+Wu&title=Pyrazolylamine+derivatives+reveal+the+conformational+switching+between+type+I+and+type+II+binding+modes+of+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Tu, Chih-Hsiang; Lin, Wen-Hsing; Peng, Yi-Hui; Hsu, Tsu; Wu, Jian-Sung; Chang, Chun-Yu; Lu, Cheng-Tai; Lyu, Ping-Chiang; Shih, Chuan; Jiaang, Weir-Torn; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3906-3919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available.  Herein, the authors present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type II binding mode.  It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK.  A structure-activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK.  To the best of the authors' knowledge, this is the first structural biol. study to directly observe how changes in the structure of a small mol. can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX2IoqRzkgK7Vg90H21EOLACvtfcHk0lis-0t2OZhVig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1GjsLk%253D&md5=732cbe2ef77a84f50de49aeef838895d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00106%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DC.-H.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLu%26aufirst%3DC.-T.%26aulast%3DLyu%26aufirst%3DP.-C.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DJiaang%26aufirst%3DW.-T.%26aulast%3DWu%26aufirst%3DS.-Y.%26atitle%3DPyrazolylamine%2520derivatives%2520reveal%2520the%2520conformational%2520switching%2520between%2520type%2520I%2520and%2520type%2520II%2520binding%2520modes%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3906%26epage%3D3919%26doi%3D10.1021%2Facs.jmedchem.6b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino-Enriquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donsky, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1770</span>– <span class="NLM_lpage">1780</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=10.1158%2F1535-7163.MCT-12-0223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=22665524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1770-1780&author=M.+C.+Heinrichauthor=A.+Marino-Enriquezauthor=A.+Presnellauthor=R.+S.+Donskyauthor=D.+J.+Griffithauthor=A.+McKinleyauthor=J.+Pattersonauthor=T.+Taguchiauthor=C.-W.+Liangauthor=J.+A.+Fletcher&title=Sorafenib+inhibits+many+kinase+mutations+associated+with+drug-resistant+gastrointestinal+stromal+tumors&doi=10.1158%2F1535-7163.MCT-12-0223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Marino-Enriquez, Adrian; Presnell, Ajia; Donsky, Rachel S.; Griffith, Diana J.; McKinley, Arin; Patterson, Janice; Taguchi, Takahiro; Liang, Cher-Wei; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1770-1780</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Sorafenib has substantial clin. activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST).  Because sorafenib targets both angiogenesis-related kinases (VEGFR) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the mol. basis for sorafenib efficacy in this setting remains unknown.  We sought to det. the spectrum of activity of sorafenib against different mutant kinases assocd. with drug-sensitive and drug-resistant GIST.  We compared the activity of imatinib and sorafenib against transiently expressed mutant forms of KIT and PDGFRA, including various secondary mutations that have been identified in imatinib-resistant or sunitinib-resistant GISTs.  We also examd. these drugs against four GIST cell lines, three of which are imatinib resistant.  In our in vitro studies, we detd. that sorafenib inhibited imatinib-resistant mutations in exons encoding the ATP/drug-binding pocket and in exons encoding the activation loop, with the exception of substitutions at KIT codon D816 and PDGFRA codon 842.  Notably our data indicate that sorafenib is more effective than imatinib or sunitinib for inhibiting the kinase activity of drug-resistant KIT mutants (as assessed by biochem. IC50).  We hypothesize that a major determinant of the efficacy of sorafenib for treatment of advanced GIST is the activity of this agent against KIT or PDGFRA-mutant kinases.  These results have implications for the further development of treatments for drug-resistant GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCww61mOGw3rVg90H21EOLACvtfcHk0lgAXClOzq7SKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOisLrO&md5=b3027bfa716c41e6cb594e37200d05b8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0223%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMarino-Enriquez%26aufirst%3DA.%26aulast%3DPresnell%26aufirst%3DA.%26aulast%3DDonsky%26aufirst%3DR.%2BS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DMcKinley%26aufirst%3DA.%26aulast%3DPatterson%26aufirst%3DJ.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DC.-W.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DSorafenib%2520inhibits%2520many%2520kinase%2520mutations%2520associated%2520with%2520drug-resistant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1770%26epage%3D1780%26doi%3D10.1158%2F1535-7163.MCT-12-0223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i56"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01229">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_84583"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01229?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01229</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Material and methods of HotSpot kinase profiling assays and antiproliferation assays; Figure S1, the TREEspot interaction maps and selectivity score of <b>15a</b>; Table S1, kinase inhibition profile of compound <b>15a</b>; Table S2, statistics of X-ray diffraction data and structure refinement for the c-KIT complex; Table S3, cell viability of cancer cell lines and normal cell line treated with <b>15a</b>; Figure S2, comparison of the antitumor effect of <b>15a</b> (15 mg/kg) and <b>2</b> (40 mg/kg) on GIST430 xenograft mouse model; <sup>1</sup>H and <sup>13</sup>C NMR spectrum of <b>15a</b> and HPLC reports for the purity check of compounds <b>15a</b>–<b>g</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Additional information for <b>14a</b>, <b>14b</b>, and <b>15a</b>–<b>5g</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_001.pdf">jm9b01229_si_001.pdf (1.79 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01229/suppl_file/jm9b01229_si_002.csv">jm9b01229_si_002.csv (3.47 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">6KLA (c-KIT/<b>15a</b>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01229&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01229" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01229" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679962d368e632cd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
